US20080153820A1 - Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists - Google Patents

Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists Download PDF

Info

Publication number
US20080153820A1
US20080153820A1 US12/071,577 US7157708A US2008153820A1 US 20080153820 A1 US20080153820 A1 US 20080153820A1 US 7157708 A US7157708 A US 7157708A US 2008153820 A1 US2008153820 A1 US 2008153820A1
Authority
US
United States
Prior art keywords
pyrimidine
thieno
group
alkyl
conr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/071,577
Inventor
Roger John Gillespie
Joanne Lerpiniere
Claire Elizabeth Dawson
Suneel Gaur
Robert Mark Pratt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Research Ltd
Original Assignee
Vernalis Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Research Ltd filed Critical Vernalis Research Ltd
Priority to US12/071,577 priority Critical patent/US20080153820A1/en
Publication of US20080153820A1 publication Critical patent/US20080153820A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Definitions

  • the present invention relates to thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use in therapy.
  • the present invention relates to the treatment of disorders in which the reduction of purinergic neurotransmission could be beneficial.
  • the invention relates in particular to blockade of adenosine receptors and particularly adenosine A 2A receptors, and to the treatment of movement disorders such as Parkinson's disease.
  • Movement disorders constitute a serious health problem, especially amongst the elderly sector of the population. These movement disorders are often the result of brain lesions. Disorders involving the basal ganglia which result in movement disorders include Parkinson's disease, Huntington's chorea and Wilson's disease. Furthermore, dyskinesias often arise as sequelae of cerebral ischaemia and other neurological disorders.
  • Parkinson's disease There are four classic symptoms of Parkinson's disease: tremor, rigidity, akinesia and postural changes. The disease is also commonly associated with depression, dementia and overall cognitive decline. Parkinson's disease has a prevalence of 1 per 1,000 of the total population. The incidence increases to 1 per 100 for those aged over 60 years. Degeneration of dopaminergic neurones in the substantia nigra and the subsequent reductions in interstitial concentrations of dopamine in the striatum are critical to the development of Parkinson's disease. Some 80% of cells from the substantia nigra need to be destroyed before the clinical symptoms of Parkinson's disease are manifested.
  • L-dihydroxyphenylacetic acid L-DOPA
  • L-DOPA L-dihydroxyphenylacetic acid
  • Deprenyl® monoamine oxidase
  • dopamine receptor agonists e.g. bromocriptine and apomorphine
  • anticholinergics e.g. benztrophine, orphenadrine
  • Transmitter replacement therapy in particular does not provide consistent clinical benefit, especially after prolonged treatment when “on-off” symptoms develop, and this treatment has also been associated with involuntary movements of athetosis and chorea, nausea and vomiting. Additionally current therapies do not treat the underlying neurodegenerative disorder resulting in a continuing cognitive decline in patients.
  • Blockade of A 2 adenosine receptors has recently been implicated in the treatment of movement disorders such as Parkinson's disease (Richardson, P. J. et al., Trends Pharmacol. Sci. 1997, 18, 338-344) and in the treatment of cerebral ischaemia (Gao, Y. and Phillis, J. W., Life Sci. 1994, 55, 61-65).
  • the potential utility of adenosine A 2A receptor antagonists in the treatment of movement disorders such as Parkinson's Disease has recently been reviewed (Mally, J. and Stone, T. W., CNS Drugs, 1998, 10, 311-320).
  • Adenosine is a naturally occurring purine nucleoside which has a wide variety of well-documented regulatory functions and physiological effects.
  • the central nervous system (CNS) effects of this endogenous nucleoside have attracted particular attention in drug discovery, owing to the therapeutic potential of purinergic agents in CNS disorders (Jacobson, K. A. et al., J. Med. Chem. 1992, 35, 407-422).
  • This therapeutic potential has resulted in considerable recent research endeavour within the field of adenosine receptor agonists and antagonists (Bhagwhat, S. S.; Williams, M. Exp. Opin. Ther. Patents 1995, 5, 547-558).
  • Adenosine receptors represent a subclass (P 1 ) of the group of purine nucleotide and nucleoside receptors known as purinoreceptors.
  • the main pharmacologically distinct adenosine receptor subtypes are known as A 1 , A 2A , A 2B (of high and low affinity) and A 3 (Fredholm, B. B., et al., Pharmacol. Rev. 1994, 46, 143-156).
  • the adenosine receptors are present in the CNS (Fredholm, B. B., News Physiol. Sci., 1995, 10, 122-128).
  • P 1 receptor-mediated agents The design of P 1 receptor-mediated agents has been reviewed (Jacobson, K. A., Suzuki, F., Drug Dev. Res., 1997, 39, 289-300; Baraldi, P. G. et al., Curr. Med. Chem. 1995, 2, 707-722), and such compounds are claimed to be useful in the treatment of cerebral ischemia or neurodegenerative disorders, such as Parkinson's disease (Williams, M. and Burnstock, G. Purinergic Approaches Exp. Ther . (1997), 3-26. Editor: Jacobson, Kenneth A.; Jarvis, Michael F. Publisher: Wiley-Liss, New York, N.Y.)
  • xanthine derivatives such as caffeine may offer a form of treatment for attention-deficit hyperactivity disorder (ADHD).
  • ADHD attention-deficit hyperactivity disorder
  • Antagonism of adenosine receptors is thought to account for the majority of the behavioural effects of caffeine in humans and thus blockade of adenosine A 2A receptors may account for the observed effects of caffeine in ADHD patients. Therefore a selective A 2A receptor antagonist may provide an effective treatment for ADHD but without the unwanted side-effects associated with current therapy.
  • Adenosine receptors have been recognised to play an important role in regulation of sleep patterns, and indeed adenosine antagonists such as caffeine exert potent stimulant effects and can be used to prolong wakefulness (Porkka-Heiskanen, T. et al., Science, 1997, 276, 1265-1268). Recent evidence suggests that a substantial part of the actions of adenosine in regulating sleep is mediated through the adenosine A 2A receptor (Satoh, S., et al., Proc. Natl. Acad. Sci., USA, 1996). Thus, a selective A 2A receptor antagonist may be of benefit in counteracting excessive sleepiness in sleep disorders such as hypersomnia or narcolepsy.
  • a 2A receptor antagonists may offer a novel therapy for the treatment of major depression and other affective disorders in patients.
  • adenosine A 2A receptors The pharmacology of adenosine A 2A receptors has been reviewed (Ongini, E.; Fredholm, B. B. Trends Pharmacol. Sci. 1996, 17(10), 364-372).
  • One potential underlying mechanism in the aforementioned treatment of movement disorders by the blockade of A 2 adenosine receptors is the evidence of a functional link between adenosine A 2A receptors to dopamine D 2 receptors in the CNS.
  • Some of the early studies e.g. Ferre, S. et al., Stimulation of high-affinity adenosine A 2 receptors decreases the affinity of dopamine D 2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci.
  • adenosine A 2A antagonist therapy is that the underlying neurodegenerative disorder may also be treated.
  • the neuroprotective effect of adenosine A 2A antagonists has been reviewed (Ongini, E.; Adami, M.; Ferri, C.; Bertorelli, R., Ann. N.Y. Acad. Sci. 1997, 825 (Neuroprotective Agents), 30-48).
  • blockade of A 2A receptor function confers neuroprotection against MPTP-induced neurotoxicity in mice (Chen, J-F., J. Neurosci. 2001, 21, RC143).
  • a 2A receptor antagonist may offer a novel treatment for conferring neuroprotection in neurodegenerative diseases such as Parkinson's disease.
  • Xanthine derivatives have been disclosed as adenosine A 2 receptor antagonists as useful for treating various diseases caused by hyperfunctioning of adenosine A 2 receptors, such as Parkinson's disease (see, for example, EP-A-565377).
  • CSC 8-(3-chlorostyryl)caffeine
  • Theophylline (1,3-dimethylxanthine), a bronchodilator drug which is a mixed antagonist at adenosine A 1 and A 2A receptors, has been studied clinically.
  • the patients exhibited significant improvements in mean objective disability scores and 11 reported moderate or marked subjective improvement (Mally, J., Stone, T-.W. J. Pharm. Pharmacol. 1994, 46, 515-517).
  • KF 17837 [(E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine] is a selective adenosine A 2A receptor antagonist which on oral administration significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A 2A receptor agonist, CGS 21680. KF 17837 also reduced the catalepsy induced by haloperidol and reserpine.
  • KF 17837 potentiated the anticataleptic effects of a subthreshold dose of L-DOPA plus benserazide, suggesting that KF 17837 is a centrally active adenosine A 2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A 2A receptor antagonists (Kanda, T. et al., Eur. J. Pharmacol. 1994, 256, 263-268).
  • SAR structure activity relationship
  • New non-xanthine structures sharing these pharmacological properties include SCH 58261 and its derivatives (Baraldi, P. G. et al., Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives: Potent and Selective A 2A Adenosine Antagonists. J. Med. Chem. 1996, 39, 1164-71).
  • SCH 58261 (7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine) is reported as effective in the treatment of movement disorders (Ongini, E. Drug Dev. Res. 1997, 42(2), 63-70) and has been followed up by a later series of compounds (Baraldi, P. G. et al., J. Med. Chem. 1998, 41(12), 2126-2133).
  • thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines which are structurally unrelated to known adenosine receptor antagonists, exhibit unexpected antagonist binding affinity at adenosine (P 1 ) receptors, and in particular at the adenosine A 2A receptor.
  • Such compounds may therefore be useful for the treatment of disorders in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A 2A receptors, may be beneficial.
  • such compounds may be suitable for the treatment of movement disorders, such as disorders of the basal ganglia which result in dyskinesias.
  • Disorders of particular interest include Parkinson's disease, Alzheimer's disease, spasticity, Huntington's chorea and Wilson's disease.
  • Such compounds may also be particularly suitable for the treatment of depression, cognitive or memory impairment including Alzheimer's disease, acute or chronic pain, ADHD, narcolepsy or for neuroprotection.
  • X is S or O
  • R 1 is selected from H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, COR 5 , CO 2 R 5 , CONR 6 R 7 , CONR 5 NR 6 R 7 , NR 6 R 7 , NR 5 CONR 6 R 7 , NR 5 COR 6 , NR 5 CO 2 R 8 , and NR 5 SO 2 R 8 ;
  • R 2 is selected from aryl attached via an unsaturated carbon atom;
  • R 3 is selected from H, alkyl, hydroxy, alkoxy, halogen, CN and NO 2 ;
  • R 4 is selected from H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, NO 2 , COR 5 , CO 2 R 5 , CONR 6 R 7 , CONR 5 NR 6 R 7 , NR 6
  • alkyl means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl)hydrocarbyl radical which may be substituted or unsubstituted.
  • the alkyl group is preferably C 3 to C 12 , more preferably C 5 to C 10 , more preferably C 5 , C 6 or C 7 .
  • the alkyl group is preferably C 1 to C 10 , more preferably C 1 to C 6 , more preferably methyl, ethyl, propyl (n-propyl or isopropyl), butyl (n-butyl, isobutyl or tertiary-butyl) or pentyl (including n-pentyl and iso-pentyl), more preferably methyl.
  • alkyl as used herein includes alkyl (branched or unbranched), alkenyl (branched or unbranched), alkynyl (branched or unbranched), cycloalkyl, cycloalkenyl and cycloalkynyl.
  • lower alkyl means methyl, ethyl, propyl (n-propyl or isopropyl) or butyl (n-butyl, isobutyl or tertiary-butyl).
  • aryl means an aromatic group, such as phenyl or naphthyl (preferably phenyl), or a heteroaromatic group containing one or more heteroatom(s) preferably selected from N, O and S, such as pyridyl, pyrrolyl, quinolinyl, furanyl, thienyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, imidazolyl or pyrimidinyl.
  • heteroaryl means an aromatic group containing one or more heteroatom(s) preferably selected from N, O and S, such as pyridyl, pyrrolyl, quinolinyl, furanyl, thienyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, imidazolyl or pyrimidinyl.
  • alkoxy means alkyl-O—.
  • aryloxy means aryl-O—.
  • halogen means a fluorine, chlorine, bromine or iodine radical.
  • ortho,ortho-disubstituted aryl groups refers to aryl groups which are substituted in both ortho positions of the aryl group relative to the point of attachment of the aryl group to the pyrimidine ring.
  • prodrug means any pharmaceutically acceptable prodrug of a compound of the present invention.
  • R 1 to R 13 is selected from alkyl, alkoxy and thioalkyl, in accordance with formula (I) as defined above, then that alkyl group, or the alkyl group of the alkoxy or thioalkyl group, may be substituted or unsubstituted.
  • alkyl group, or the alkyl group of the alkoxy or thioalkyl group may be substituted or unsubstituted.
  • R 1 to R 13 are selected from aryl, aryloxy and thioaryl, in accordance with formula (I) as defined above, then said aryl group, or the aryl group of the aryloxy or thioaryl group, may be substituted or unsubstituted.
  • heterocyclic group may be substituted or unsubstituted. Where substituted, there will generally be 1 to 3 substituents present, preferably 1 substituent. Substituents may include:
  • any of R 1 to R 13 is directly substituted by an alkyl substituent group, or by an alkyl-containing substituent group (such as alkoxy, alkoxyalkyl or alkylcarbonylamino for example), then the alkyl moiety of the substituent group directly attached to any of R 1 to R 13 may be further substituted by the substituent groups hereinbefore described and particularly by halogen, hydroxy, alkoxy, CN, amines (including amino, mono- and di-alkyl amino) and aryl.
  • an alkyl substituent group such as alkoxy, alkoxyalkyl or alkylcarbonylamino for example
  • any of R 1 to R 13 is directly substituted by an aryl substitutent group, or by an aryl-containing substituent group (such as aryloxy or arylaminocarbonylamino for example), then the aryl moiety of the substituent group directly attached to any of R 1 to R 13 may be further substituted by the substituent groups hereinbefore described and particularly by halogen, alkyl (including CF 3 ), hydroxy, alkoxy, CN, amines (including amino, mono- and di-alkyl amino) and NO 2 .
  • R 1 is selected from H, alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, and cyclic and acyclic alkyl), aryl (including heteroaryl), hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, COR 5 , CO 2 R 5 , CONR 6 R 7 , CONR 5 NR 6 R 7 , NR 6 R 7 (including NH 2 , monoalkyl amino and dialkylamino), NR 5 CONR 6 R 7 , NR 5 COR 6 , NR 5 CO 2 R 8 and NR 5 SO 2 R 8 .
  • R 1 is selected from alkyl, alkoxy, thioalkyl, NR 6 R 7 and NR 5 COR 6 , and preferably from alkyl and NR 6 R 7 . In one embodiment, R 1 is selected from NH 2 .
  • R 1 is selected from alkyl, alkoxy and alkylthio
  • said alkyl group or the alkyl group of the alkoxy or alkylthio is preferably selected from C 1-6 alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, and cyclic and acyclic alkyl), preferably saturated C 1-6 alkyl, and more preferably lower alkyl.
  • R 1 is selected from substituted alkyl, particularly haloalkyl (including CF 3 ) and arylalkyl (including heteroarylalkyl).
  • R 1 is selected from CONR 5 NR 6 R 7 , NR 5 CONR 6 R 7 , NR 5 COR 6 , NR 5 CO 2 R 8 and NR 5 SO 2 R 8 , and R 5 is H or alkyl, and preferably H.
  • R 1 is selected from NR 6 R 7 wherein R 6 is preferably selected from H and alkyl (preferably H), and R 7 is a substituted alkyl group represented by (CR 9 R 10 ) n R 11 , wherein R 9 and R 10 are independently selected from H, alkyl and aryl (preferably from H and alkyl, and more preferably from H), n is selected from 1 to 6 (preferably from 2 to 4, more preferably 2), and R 11 is selected from aryl (including heteroaryl), COR 5 , CO 2 R 5 , CONR 12 R 13 , CONR 5 NR 12 R 13 , NR 12 R 13 (including NH 2 , monoalkyl amino and dialkylamino), NR 5 CONR 12 R 13 , NR 5 COR 12 , NR 5 CO 2 R 8 and NR 5 SO 2 R 8 (and preferably from aryl (including heteroaryl), NR 12 R 13 (including NH 2 , monoalkyl amino and dialkylamino), NR 5
  • R 2 is substituted or unsubstituted aryl (including heteroaryl) attached via an unsaturated carbon atom.
  • the aryl group is a 5- or 6-membered monocyclic aryl group.
  • R 2 is a heteroaryl group, and preferably a heteroaryl group which is attached to the pyrimidine ring of formula (I) such that a heteroatom is adjacent to the unsaturated carbon atom attached to said pyrimidine ring.
  • R 2 is an N, O or S-containing heteroaryl group.
  • R 2 may contain one or more heteroatom(s) selected from N, O and S.
  • the aryl (including heteroaryl) group of R 2 is not ortho,ortho-disubstituted.
  • the aryl (including heteroaryl) group of R 2 is not substituted at either ortho position.
  • reference to ortho-substitution of the R 2 group means the ortho positions of the R 2 group relative to the point of attachment of R 2 to the pyrimidine moiety of formula (I).
  • R 2 is selected from furyl (including 2-furyl), thienyl (including 2-thienyl), pyridyl (including 2-pyridyl), thiazolyl (including 2- and 5-thiazolyl), pyrazolyl (including 3-pyrazolyl), triazolyl (including 4-triazolyl), pyrrolyl (including 2-pyrrolyl) and oxazolyl (including 5-oxazolyl).
  • R 2 is selected from 2-furyl, 2-thienyl, 2-thiazolyl, 2-pyridyl, 3-pyrazolyl, 2-pyrrolyl, 4-triazolyl and 5-oxazolyl.
  • R 2 is selected from furyl, thienyl, pyridyl and thiazolyl, and preferably from 2-furyl, 2-thienyl, 2-thiazolyl and 2-pyridyl.
  • R 2 is selected from 2-thiazolyl, optionally substituted, particularly by methyl.
  • R 3 is selected from H, alkyl (including haloalkyl (particularly CF 3 )), hydroxy, alkoxy (including OCF 3 ), halogen, CN and NO 2 .
  • R 3 is selected from H, CF 3 , hydroxy, alkoxy, halogen, CN and NO 2 , and preferably R 3 is H.
  • said alkyl group or the alkyl group of said alkoxy is preferably C 1-6 alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, and cyclic and acyclic alkyl), preferably saturated C 1-6 alkyl, and more preferably lower alkyl.
  • R 3 is haloalkyl (particularly CF 3 ).
  • R 4 is selected from H, alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, and cyclic and acyclic alkyl), aryl (including heteroaryl), hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, NO 2 , COR 5 , CO 2 R 5 , CONR 6 R 7 , CONR 5 NR 6 R 7 , NR 6 R 7 (including NH 2 ), NR 5 CONR 6 R 7 , NR 5 COR 6 , NR 5 CO 2 R 8 and NR 5 SO 2 R 8 .
  • R 4 is selected from alkyl, preferably R 4 is C 1-6 alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, and cyclic and acyclic alkyl), preferably saturated C 1-6 alkyl, and more preferably lower alkyl.
  • R 4 is selected from substituted alkyl, wherein the substituent groups are selected from halogen, substituted and unsubstituted aryl (including heteroaryl), cycloalkyl, non-aromatic heterocyclyl, CO 2 R 5 , CONR 6 R 7 , CONR 5 NR 6 R 7 and C( ⁇ NR 5 )NR 6 R 7 , preferably aryl (including heteroaryl) and CONR 6 R 7 , more preferably aryl (including heteroaryl).
  • R 4 is selected from substituted alkyl, particularly haloalkyl (including CF 3 ) and arylalkyl (including heteroarylalkyl).
  • R 4 is selected from unsubstituted C 1-6 alkyl (preferably saturated C 1-6 alkyl).
  • R 4 is selected from H, alkyl (including arylalkyl (including heteroarylalkyl)), halogen, COR 5 , CO 2 R 5 , CONR 6 R 7 and CONR 5 NR 6 R 7 , preferably from H, alkyl (including arylalkyl (including heteroarylalkyl)) and halogen, and preferably from H.
  • R 5 , R 6 and R 7 are independently selected from H, alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, cyclic and acyclic alkyl) and aryl (including heteroaryl), or where R 6 and R 7 are in any NR 6 R 7 group R 6 and R 7 may be linked to form a heterocyclic group, or where R 5 , R 6 and R 7 are in a CONR 5 NR 6 R 7 group, R 5 and R 6 may be linked to form a heterocyclic group.
  • R 12 and R 13 are independently selected from H, alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, cyclic and acyclic alkyl) and aryl (including heteroaryl), or where R 12 and R 13 are in any NR 12 R 13 group R 12 and R 13 may be linked to form a heterocyclic group, or where R 5 , R 12 and R 13 are in a CONR 5 NR 12 R 13 group, R 5 and R 12 may be linked to form a heterocyclic group.
  • R 8 is selected from alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, cyclic and acyclic alkyl) and aryl (including heteroaryl).
  • R 5 to R 10 , R 12 and R 13 are independently selected from alkyl, preferably R 5 to R 10 , R 12 and R 13 are independently selected from C 1-6 alkyl, preferably C 1-6 saturated alkyl and more preferably from lower alkyl.
  • heterocyclic ring may be saturated, partially unsaturated or aromatic, and is preferably saturated.
  • Said heterocyclic ring is preferably a 5, 6 or 7-membered ring, preferably a 5 or 6-membered ring, and may contain one or more further heteroatom(s) preferably selected from N, O and S.
  • the compounds of the present invention are selected from:
  • the present invention may be employed in respect of a human or animal subject, more preferably a mammal, more preferably a human subject.
  • the disorders of particular interest are those in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A 2A receptors, may be beneficial. These may include movement disorders such as Parkinson's disease, drug-induced Parkinsonism, post-encephalitic Parkinsonism, Parkinsonism induced by poisoning (for example MPTP, manganese, carbon monoxide) and post-traumatic Parkinson's disease (punch-drunk syndrome).
  • movement disorders such as Parkinson's disease, drug-induced Parkinsonism, post-encephalitic Parkinsonism, Parkinsonism induced by poisoning (for example MPTP, manganese, carbon monoxide) and post-traumatic Parkinson's disease (punch-drunk syndrome).
  • Other movement disorders in which the blocking of purine receptors, may be of benefit include progressive supernuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity or other disorders of the basal ganglia which result in abnormal movement or posture.
  • the present invention may also be effective in treating Parkinson's with on-off phenomena; Parkinson's with freezing (end of dose deterioration); and Parkinson's with prominent dyskinesias.
  • the compounds of formula (I) may be used or administered in combination with one or more additional drugs useful in the treatment of movement disorders, such as L-DOPA or a dopamine agonist, the components being in the same formulation or in separate formulations for administration simultaneously or sequentially.
  • additional drugs useful in the treatment of movement disorders such as L-DOPA or a dopamine agonist
  • disorders in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A 2A receptors may be beneficial include acute and chronic pain; for example neuropathic pain, cancer pain, trigeminal neuralgia, migraine and other conditions associated with cephalic pain, primary and secondary hyperalgesia, inflammatory pain, nociceptive pain, tabes dorsalis, phantom limb pain, spinal cord injury pain, central pain, post-herpetic pain and HIV pain; affective disorders including mood disorders such as bipolar disorder, seasonal affective disorder, depression, manic depression, atypical depression and monodepressive disease; central and peripheral nervous system degenerative disorders including corticobasal degeneration, demyelinating disease (multiple sclerosis, disseminated sclerosis), Freidrich's ataxia, motoneurone disease (amyotrophic lateral sclerosis, progressive bulbar atrophy), multiple system atrophy, myelopathy, radiculopathy, peripheral neuropathy (dia
  • a compound of the present invention or a pharmaceutically acceptably salt or prodrug thereof in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A 2A receptors, may be beneficial.
  • a method of treating or preventing a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A 2A receptors, may be beneficial comprising administration to a subject in need of such treatment an effective dose of a compound of the present invention or a pharmaceutically acceptable salt or prodrug thereof.
  • the disorder may be caused by the hyperfunctioning of the purine receptors.
  • a compound of the present invention or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for the treatment or prevention of movement disorders in a subject.
  • a method of treating or preventing movement disorders comprising administration to a subject in need of such treatment an effective dose of a compound of the present invention or a pharmaceutically acceptable salt or prodrug thereof.
  • a method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of a compound of the present invention or a pharmaceutically acceptable salt or prodrug thereof.
  • the medicament for or method of neuroprotection may be of use in the treatment of subjects who are suffering from or at risk from a neurodegenerative disorder, such as a movement disorder.
  • aryl coupling reactions are prepared from halides of formula (2) by standard methods such as aryl coupling reactions which may be advantageously carried out in the presence of a catalyst such as a palladium catalyst.
  • the aryl coupling reaction may be carried out by reaction of a halide of formula (2) with, for example, an aryl or heteroaryl trialkyltin reagent, an aryl or heteroaryl boronic acid or boronic ester reagent or an aryl or heteroaryl zinc halide reagent according to methods described in the literature.
  • Suitable aryl or heteroaryl trialkyl tin, boronic acid, boronic ester or zinc halide reagents are either commercially available or may be prepared by standard literature methods.
  • Halides of formula (2) are either known in the literature or may be prepared from compounds of formula (3) by standard methods, for example by treatment with a chlorinating reagent such as POCl 3 .
  • Compounds of formula (3) are either known in the literature or may be prepared from compounds of formula (4) by standard methods such as treatment with an appropriate ester (R 1 CO 2 Et) in the presence of a suitable base such as NaOEt, or by treatment with an appropriate anhydride (R 1 CO) 2 O in the presence of a base such as Et 3 N followed by heating in the presence of a stronger base such as NaOH.
  • compounds of formula (3) may be prepared from compounds of formula (5) by standard methods such as treatment with an appropriate nitrile (R 1 CN) in the presence of dry HCl gas.
  • Compounds of formula (4) and formula (5) are either known in the literature or may be prepared by standard methods.
  • Compounds of formula (1) where R 1 is NR 6 R 7 may be prepared from compounds of formula (1) where R 1 is halogen by standard methods such as reaction with an appropriate amine (R 6 R 7 NH).
  • Compounds of formula (1) where R 1 is halogen may be prepared from compounds of formula (2) where R 1 is halogen as described above.
  • Compounds of formula (2) where R 1 is halogen are either known in the literature or may be prepared by methods analogous to those described in the literature.
  • R 1 is NR 5 CONR 6 R 7 , NR 5 COR 6 , NR 5 CO 2 R 8 or NR 5 SO 2 R 8 wherein R 5 is H
  • R 1 is NH 2 by standard methods for example by treatment with an appropriate isocyanate (R 6 NCO or R 7 NCO), carbamoyl chloride (R 6 R 7 NCOCl), acid chloride (R 6 COCl), chloroformate (ClCO 2 R 8 ) or sulphonyl chloride (ClSO 2 R 8 ).
  • Analogous compounds wherein R 5 is alkyl may be prepared by initial alkylation or reductive alkylation followed by reaction with the appropriate reagent as described above.
  • R 1 is NH 2
  • R 1 is halogen either by direct displacement with ammonia or by reaction with an appropriate protected amine, for example 3,4-dimethoxybenzylamine, followed by removal of the protecting group, if desired, by treatment with TFA.
  • alkyl or aryl group is substituted by an amino group it may be advantageous to protect the amino group during the synthesis by the use of a standard protecting group such as a BOC group.
  • the protecting group may then be removed at the appropriate step in the synthesis, by standard methods such as treatment with TFA.
  • Compounds of formula (1) where R 3 is halogen or NO 2 may be prepared from compounds of formula (2) where R 3 is halogen or NO 2 as described above.
  • Compounds of formula (2) where R 3 is halogen or NO 2 are either known in the literature or may be prepared from compounds of formula (2) where R 3 is H by standard literature methods such as halogenation or nitration.
  • Compounds of formula (1) where R 4 is aryl or heteroaryl may be prepared from compounds of formula (1) where R 4 is halogen by standard methods such as palladium catalysed aryl coupling reactions as described above.
  • Compounds of formula (1) where R 4 is halogen are prepared from compounds of formula (2) where R 4 is halogen as described above.
  • Compounds of formula (2) where R 4 is halogen are either known in the literature or prepared by methods analogous to those described in the literature.
  • Compounds of formula (1) where R 4 is CO 2 R 5 , CONR 6 R 7 or CONR 5 NR 6 R 7 may be prepared from compounds of formula (2) where R 4 is CO 2 R 5 , CONR 6 R 7 or CONR 5 NR 6 R 7 as described above.
  • Compounds of formula (2) where R 4 is CO 2 R 5 or CONR 6 R 7 may be prepared from compounds of formula (2) where R 4 is halogen by standard methods such as palladium catalysed carbonylation reactions in the presence of an appropriate alcohol (R 5 OH) or amine (HNR 6 R 7 ).
  • R 4 is cyano
  • R 4 is CONR 6 R 7 , wherein R 6 and R 7 are both H, by standard literature methods such as dehydration.
  • R 4 is hydroxy, alkoxy, aryloxy, thioalkyl or thioaryl
  • Such standard methods may include treatment of a compound of formula (1) where R 4 is halogen with an appropriate nucleophile.
  • compounds of formula (1) where R 4 is hydroxy or alkoxy may be prepare from a compound of formula (1) where R 4 is COR 5 by use of the Bayer Villiger reaction, followed by a hydrolysis step and followed, if desired, by an alkylation step.
  • a pharmaceutical composition comprising a compound of the present invention in combination with a pharmaceutically acceptable carrier or excipient and a method of making such a composition comprising combining a compound of the present invention with a pharmaceutically acceptable carrier or excipient.
  • compositions employed in the present invention comprise a compound of the present invention, or pharmaceutically acceptable salts or prodrugs thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients known to those skilled in the art.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic acids including inorganic acids and organic acids.
  • salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids.
  • acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, oxalic, p-toluenesulfonic and the like.
  • Particularly preferred are hydrochloric, hydrobromic, phosphoric, and sulfuric acids, and most particularly preferred is the hydrochloride salt.
  • Any suitable route of administration may be employed for providing the patient with an effective dosage of a compound of the present invention.
  • oral, rectal, parenteral (intravenous, intramuscular), transdermal, subcutaneous, and the like may be employed.
  • Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches, and the like.
  • the most suitable route in any given case will depend on the severity of the condition being treated.
  • the most preferred route of administration of the present invention is the oral route.
  • the compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • the compounds of the present invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques.
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (e.g. intravenous).
  • any of the usual pharmaceutical media may be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavouring agents, preservatives, colouring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used in the case of oral solid preparations such as, for example, powders, capsules, and tablets, with the solid oral preparations being preferred over the liquid preparations. The most preferred solid oral preparation is tablets.
  • tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or non-aqueous techniques.
  • the compounds of the present invention may also be administered by controlled release means and/or delivery devices such as those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 3,630,200; 4,008,719; 4,687,660; and 4,769,027, the disclosures of which are hereby incorporated by reference.
  • compositions employed in the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, or aerosol sprays each containing a predetermined amount of the active ingredient as a powder or granules, a solution or a suspension in an aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion.
  • Such compositions may be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
  • a tablet may be prepared by compression or moulding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, a lubricant, an inert diluent, and/or a surface active or dispersing agent.
  • Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • adenosine antagonists such as theophylline
  • dopamine antagonists such as haloperidol
  • rodents rodents
  • mice Female TO mice (25-30 g) obtained from TUCK, UK, are used for all experiments. Animals are housed in groups of 8 [cage size—40 (width) ⁇ 40 (length) ⁇ 20 (height)cm] under 12 hr light/dark cycle (lights on 08:00 hr), in a temperature (20 ⁇ 2° C.) and humidity (55 ⁇ 15%) controlled environment. Animals have free access to food and water, and are allowed at least 7 days to acclimatize after delivery before experimental use.
  • Liquid injectable haloperidol (1 ml Serenance ampoules from Baker Norton, Harlow, Essex, each containing haloperidol BP 5 mg, batch #P424) are diluted to a final concentration of 0.02 mg/ml using saline. Test compounds are typically prepared as aqueous suspensions in 8% Tween. All compounds are administered intraperitoneally in a volume of 10 ml/kg.
  • mice 1.5 hours before testing, mice are administered 0.2 mg/kg haloperidol, a dose that reduces baseline locomotor activity by at least 50%.
  • Test substances are typically administered 5-60 minutes prior to testing.
  • the animals are then placed individually into clean, clear polycarbonate cages [20 (width) ⁇ 40 (length) ⁇ 20 (height) cm, with a flat perforated, Perspex lid].
  • Horizontal locomotor activity is determined by placing the cages within a frame containing a 3 ⁇ 6 array of photocells linked to a computer, which tabulates beam breaks. Mice are left undisturbed to explore for 1 hour, and the number of beams breaks made during this period serves as a record of locomotor activity which is compared with data for control animals for statistically significant differences.
  • Parkinson's disease is a progressive neurodegenerative disorder characterised by symptoms of muscle rigidity, tremor, paucity of movement (hypokinesia), and postural instability. It has been established for some time that the primary deficit in PD is a loss of dopaminergic neurones in the substantia nigra which project to the striatum, and indeed a substantial proportion of striatal dopamine is lost (ca 80-85%) before symptoms are observed. The loss of striatal dopamine results in abnormal activity of the basal ganglia, a series of nuclei which regulate smooth and well co-ordinated movement (Blandini F. et al., Glutamate and Parkinson's Disease. Mol. Neurobiol. 1996, 12, 73-94). The neurochemical deficits seen in Parkinson's disease can be reproduced by local injection of the dopaminergic neurotoxin 6-hydroxydopamine into brain regions containing either the cell bodies or axonal fibres of the nigrostriatal neurones.
  • mice Male Sprague-Dawley rats, obtained from Charles River, are used for all experiments. Animals are housed in groups of 5 under 12 hr light/dark cycle (lights on 08:00 hr), in a temperature (20 ⁇ 2° C.) and humidity (55 ⁇ 15%) controlled environment. Animals have free access to food and water, and are allowed at least 7 days to acclimatize after delivery before experimental use.
  • 6-OHDA Ascorbic acid, desipramine, 6-OHDA and apomorphine (Sigma-Aldrich, Poole, UK).
  • 6-OHDA is freshly prepared as a solution in 0.2% ascorbate at a concentration of 4 mg/mL prior to surgery.
  • Desipramine is dissolved in warm saline, and administered in a volume of 1 ml/kg.
  • Apomorphine is dissolved in 0.02% ascorbate and administered in a volume of 2 mL/kg.
  • Test compounds are suspended in 8% Tween and injected in a volume of 2 mL/kg.
  • mice 15 minutes prior to surgery, animals are given an intraperitoneal injection of the noradrenergic uptake inhibitor desipramine (25 mg/kg) to prevent damage to non-dopamine neurones.
  • Animals are then placed in an anaesthetic chamber and anaesthetised using a mixture of oxygen and isoflurane. Once unconscious, the animals are transferred to a stereotaxic frame, where anaesthesia is maintained through a mask. The top of the animal's head is shaved and sterilised using an iodine solution. Once dry, a 2 cm long incision is made along the midline of the scalp and the skin retracted and clipped back to expose the skull. A small hole is then drilled through the skill above the injection site.
  • desipramine 25 mg/kg
  • the injection cannula is slowly lowered to position above the right medial forebrain bundle at ⁇ 3.2 mm anterior posterior, ⁇ 1.5 mm medial lateral from bregma, and to a depth of 7.2 mm below the duramater. 2 minutes after lowing the cannula, 2 ⁇ L of 6-OHDA is infused at a rate of 0.5 ⁇ L/min over 4 minutes, yielding a final dose of 8 ⁇ g. The cannula is then left in place for a further 5 minutes to facilitate diffusion before being slowly withdrawn. The skin is then sutured shut using Ethicon W501 Mersilk, and the animal removed from the stereotaxic frame and returned to its homecage. The rats are allowed 2 weeks to recover from surgery before behavioural testing.
  • Rotational behaviour is measured using an eight station rotameter system provided by Med Associates, San Diego, USA. Each station is comprised of a stainless steel bowl (45 cm diameter ⁇ 15 cm high) enclosed in a transparent Plexiglas cover running around the edge of the bowl, and extending to a height of 29 cm. To assess rotation, rats are placed in cloth jacket attached to a spring tether connected to optical rotameter positioned above the bowl, which assesses movement to the left or right either as partial (45°) or full (360°) rotations. All eight stations are interfaced to a computer that tabulated data.
  • rats are initially habituated to the apparatus for 15 minutes on four consecutive days. On the test day, rats are given an intraperitoneal injection of test compound 30 minutes prior to testing. Immediately prior to testing, animals are given a subcutaneous injection of a subthreshold dose of apomorphine, then placed in the harness and the number of rotations recorded for one hour. The total number of full contralateral rotations during the hour test period serves as an index of antiparkinsonian drug efficacy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A compound of formula (I), wherein X is S or O; R1 is selected from H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, COR5, CO2R5, CONR5R7, CONR5NR6R7, NR6R7, NR5CONR6R7, NR5COR6, NR5CO2R8, and NR5SO2R8; R2 is selected from aryl attached via an unsaturated carbon atom; R3 is selected from H, alkyl, hydroxy, alkoxy, halogen, CN and NO2; R3 is selected from H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, NO2, COR5, CO2R5, CONR6R7, CONR5NR6R7, NR6R7, NR5CONR6R7, NR5COR6, NR5CO2R8 and NR5SO2R8; R5, R6 and R7 are independently selected from H, alkyl and aryl or where R6 and R7 are in an (NR6R7) group, R6 and R7 may be linked to form a heterocyclic group, or where R5, R6 and R7 are in a (CONR5NR6R7) group, R5 and R6 may be linked to form a heterocyclic group; and R8 is selected from alkyl and aryl, or a pharmaceutically acceptable salt thereof or prodrug thereof, and the use thereof in therapy and in the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial, particularly wherein said disorder is a movement disorder such a Parkinson's disease or said disorder is depression, cognitive or memory impairment, acute or chronic pain, ADHD or narcolepsy, or wherein said medicament is for neuroprotection in a subject.
Figure US20080153820A1-20080626-C00001

Description

  • The present invention relates to thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use in therapy. In particular, the present invention relates to the treatment of disorders in which the reduction of purinergic neurotransmission could be beneficial. The invention relates in particular to blockade of adenosine receptors and particularly adenosine A2A receptors, and to the treatment of movement disorders such as Parkinson's disease.
  • Movement disorders constitute a serious health problem, especially amongst the elderly sector of the population. These movement disorders are often the result of brain lesions. Disorders involving the basal ganglia which result in movement disorders include Parkinson's disease, Huntington's chorea and Wilson's disease. Furthermore, dyskinesias often arise as sequelae of cerebral ischaemia and other neurological disorders.
  • There are four classic symptoms of Parkinson's disease: tremor, rigidity, akinesia and postural changes. The disease is also commonly associated with depression, dementia and overall cognitive decline. Parkinson's disease has a prevalence of 1 per 1,000 of the total population. The incidence increases to 1 per 100 for those aged over 60 years. Degeneration of dopaminergic neurones in the substantia nigra and the subsequent reductions in interstitial concentrations of dopamine in the striatum are critical to the development of Parkinson's disease. Some 80% of cells from the substantia nigra need to be destroyed before the clinical symptoms of Parkinson's disease are manifested.
  • Current strategies for the treatment of Parkinson's disease are based on transmitter replacement therapy (L-dihydroxyphenylacetic acid (L-DOPA)), inhibition of monoamine oxidase (e.g. Deprenyl®), dopamine receptor agonists (e.g. bromocriptine and apomorphine) and anticholinergics (e.g. benztrophine, orphenadrine). Transmitter replacement therapy in particular does not provide consistent clinical benefit, especially after prolonged treatment when “on-off” symptoms develop, and this treatment has also been associated with involuntary movements of athetosis and chorea, nausea and vomiting. Additionally current therapies do not treat the underlying neurodegenerative disorder resulting in a continuing cognitive decline in patients. Despite new drug approvals, there is still a medical need in terms of improved therapies for movement disorders, especially Parkinson's disease. In particular, effective treatments requiring less frequent dosing, effective treatments which are associated with less severe side-effects, and effective treatments which control or reverse the underlying neurodegenerative disorder, are required.
  • Blockade of A2 adenosine receptors has recently been implicated in the treatment of movement disorders such as Parkinson's disease (Richardson, P. J. et al., Trends Pharmacol. Sci. 1997, 18, 338-344) and in the treatment of cerebral ischaemia (Gao, Y. and Phillis, J. W., Life Sci. 1994, 55, 61-65). The potential utility of adenosine A2A receptor antagonists in the treatment of movement disorders such as Parkinson's Disease has recently been reviewed (Mally, J. and Stone, T. W., CNS Drugs, 1998, 10, 311-320).
  • Adenosine is a naturally occurring purine nucleoside which has a wide variety of well-documented regulatory functions and physiological effects. The central nervous system (CNS) effects of this endogenous nucleoside have attracted particular attention in drug discovery, owing to the therapeutic potential of purinergic agents in CNS disorders (Jacobson, K. A. et al., J. Med. Chem. 1992, 35, 407-422). This therapeutic potential has resulted in considerable recent research endeavour within the field of adenosine receptor agonists and antagonists (Bhagwhat, S. S.; Williams, M. Exp. Opin. Ther. Patents 1995, 5, 547-558).
  • Adenosine receptors represent a subclass (P1) of the group of purine nucleotide and nucleoside receptors known as purinoreceptors. The main pharmacologically distinct adenosine receptor subtypes are known as A1, A2A, A2B (of high and low affinity) and A3 (Fredholm, B. B., et al., Pharmacol. Rev. 1994, 46, 143-156). The adenosine receptors are present in the CNS (Fredholm, B. B., News Physiol. Sci., 1995, 10, 122-128).
  • The design of P1 receptor-mediated agents has been reviewed (Jacobson, K. A., Suzuki, F., Drug Dev. Res., 1997, 39, 289-300; Baraldi, P. G. et al., Curr. Med. Chem. 1995, 2, 707-722), and such compounds are claimed to be useful in the treatment of cerebral ischemia or neurodegenerative disorders, such as Parkinson's disease (Williams, M. and Burnstock, G. Purinergic Approaches Exp. Ther. (1997), 3-26. Editor: Jacobson, Kenneth A.; Jarvis, Michael F. Publisher: Wiley-Liss, New York, N.Y.)
  • It has been speculated that xanthine derivatives such as caffeine may offer a form of treatment for attention-deficit hyperactivity disorder (ADHD). A number of studies have demonstrated a beneficial effect of caffeine on controlling the symptoms of ADHD (Garfinkel, B. D. et al., Psychiatry, 1981, 26, 395-401). Antagonism of adenosine receptors is thought to account for the majority of the behavioural effects of caffeine in humans and thus blockade of adenosine A2A receptors may account for the observed effects of caffeine in ADHD patients. Therefore a selective A2A receptor antagonist may provide an effective treatment for ADHD but without the unwanted side-effects associated with current therapy.
  • Adenosine receptors have been recognised to play an important role in regulation of sleep patterns, and indeed adenosine antagonists such as caffeine exert potent stimulant effects and can be used to prolong wakefulness (Porkka-Heiskanen, T. et al., Science, 1997, 276, 1265-1268). Recent evidence suggests that a substantial part of the actions of adenosine in regulating sleep is mediated through the adenosine A2A receptor (Satoh, S., et al., Proc. Natl. Acad. Sci., USA, 1996). Thus, a selective A2A receptor antagonist may be of benefit in counteracting excessive sleepiness in sleep disorders such as hypersomnia or narcolepsy.
  • It has recently been observed that patients with major depression demonstrate a blunted response to adenosine agonist-induced stimulation in platelets, suggesting that a dysregulation of A2A receptor function may occur during depression (Berk, M. et al, 2001, Eur. Neuropsychopharmacol. 11, 183-186). Experimental evidence in animal models has shown that blockade of A2A receptor function confers antidepressant activity (El Yacoubi, M et al. Br. J. Pharmacol. 2001, 134, 68-77). Thus, A2A receptor antagonists may offer a novel therapy for the treatment of major depression and other affective disorders in patients.
  • The pharmacology of adenosine A2A receptors has been reviewed (Ongini, E.; Fredholm, B. B. Trends Pharmacol. Sci. 1996, 17(10), 364-372). One potential underlying mechanism in the aforementioned treatment of movement disorders by the blockade of A2 adenosine receptors is the evidence of a functional link between adenosine A2A receptors to dopamine D2 receptors in the CNS. Some of the early studies (e.g. Ferre, S. et al., Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 7238-41) have been summarised in two more recent articles (Fuxe, K. et al., Adenosine Adenine Nucleotides Mol. Biol. Integr. Physiol., [Proc. Int. Symp.], 5th (1995), 499-507. Editors: Belardinelli, Luiz; Pelleg, Amir. Publisher: Kluwer, Boston, Mass.; Ferre, S. et al., Trends Neurosci. 1997, 20, 482-487).
  • As a result of these investigations into the functional role of adenosine A2A receptors in the CNS, especially in vivo studies linking A2 receptors with catalepsy (Ferre et al., Neurosci. Lett. 1991, 130, 1624; Mandbane, S, N. et al., Eur. J. Pharmacol. 1997, 328, 135-141) investigations have been made into agents which selectively bind to adenosine A2A receptors as potentially effective treatments for Parkinson's disease.
  • While many of the potential drugs for treatment of Parkinson's disease have shown benefit in the treatment of movement disorders, an advantage of adenosine A2A antagonist therapy is that the underlying neurodegenerative disorder may also be treated. The neuroprotective effect of adenosine A2A antagonists has been reviewed (Ongini, E.; Adami, M.; Ferri, C.; Bertorelli, R., Ann. N.Y. Acad. Sci. 1997, 825 (Neuroprotective Agents), 30-48). In particular, compelling recent evidence suggests that blockade of A2A receptor function confers neuroprotection against MPTP-induced neurotoxicity in mice (Chen, J-F., J. Neurosci. 2001, 21, RC143). In addition, several recent studies have shown that consumption of dietary caffeine, a known adenosine A2A receptor antagonist, is associated with a reduced risk of Parkinson's disease in man (Ascherio, A. et al, Ann Neurol., 2001, 50, 56-63; Ross G W, et al., JAMA, 2000, 283, 2674-9). Thus, A2A receptor antagonists may offer a novel treatment for conferring neuroprotection in neurodegenerative diseases such as Parkinson's disease.
  • Xanthine derivatives have been disclosed as adenosine A2 receptor antagonists as useful for treating various diseases caused by hyperfunctioning of adenosine A2 receptors, such as Parkinson's disease (see, for example, EP-A-565377).
  • One prominent xanthine-derived adenosine A2A selective antagonist is CSC [8-(3-chlorostyryl)caffeine] (Jacobson et al., FEBS Lett., 1993, 323, 141-144).
  • Theophylline (1,3-dimethylxanthine), a bronchodilator drug which is a mixed antagonist at adenosine A1 and A2A receptors, has been studied clinically. To determine whether a formulation of this adenosine receptor antagonist would be of value in Parkinson's disease an open trial was conducted on 15 Parkinsonian patients, treated for up to 12 weeks with a slow release oral theophylline preparation (150 mg/day), yielding serum theophylline levels of 4.44 mg/L after one week. The patients exhibited significant improvements in mean objective disability scores and 11 reported moderate or marked subjective improvement (Mally, J., Stone, T-.W. J. Pharm. Pharmacol. 1994, 46, 515-517).
  • KF 17837 [(E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine] is a selective adenosine A2A receptor antagonist which on oral administration significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist, CGS 21680. KF 17837 also reduced the catalepsy induced by haloperidol and reserpine. Moreover, KF 17837 potentiated the anticataleptic effects of a subthreshold dose of L-DOPA plus benserazide, suggesting that KF 17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists (Kanda, T. et al., Eur. J. Pharmacol. 1994, 256, 263-268). The structure activity relationship (SAR) of KF 17837 has been published (Shimada, J. et al., Bioorg. Med. Chem. Lett. 1997, 7, 2349-2352). Recent data has also been provided on the A2A receptor antagonist KW-6002 (Kuwana, Y et al., Soc. Neurosci. Abstr. 1997, 23, 119.14; and Kanda, T. et al., Ann. Neurol. 1998, 43(4), 507-513).
  • New non-xanthine structures sharing these pharmacological properties include SCH 58261 and its derivatives (Baraldi, P. G. et al., Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine Derivatives: Potent and Selective A2A Adenosine Antagonists. J. Med. Chem. 1996, 39, 1164-71). SCH 58261 (7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine) is reported as effective in the treatment of movement disorders (Ongini, E. Drug Dev. Res. 1997, 42(2), 63-70) and has been followed up by a later series of compounds (Baraldi, P. G. et al., J. Med. Chem. 1998, 41(12), 2126-2133).
  • The foregoing discussion indicates that a potentially effective treatment for movement disorders in humans would comprise agents which act as antagonists at adenosine A2A receptors.
  • It has now been found that thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines, which are structurally unrelated to known adenosine receptor antagonists, exhibit unexpected antagonist binding affinity at adenosine (P1) receptors, and in particular at the adenosine A2A receptor. Such compounds may therefore be useful for the treatment of disorders in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A2A receptors, may be beneficial. In particular such compounds may be suitable for the treatment of movement disorders, such as disorders of the basal ganglia which result in dyskinesias. Disorders of particular interest include Parkinson's disease, Alzheimer's disease, spasticity, Huntington's chorea and Wilson's disease.
  • Such compounds may also be particularly suitable for the treatment of depression, cognitive or memory impairment including Alzheimer's disease, acute or chronic pain, ADHD, narcolepsy or for neuroprotection.
  • According to the present invention there is provided a compound of formula (I):
  • Figure US20080153820A1-20080626-C00002
  • wherein
    • X is S or O;
  • R1 is selected from H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, COR5, CO2R5, CONR6R7, CONR5NR6R7, NR6R7, NR5CONR6R7, NR5COR6, NR5CO2R8, and NR5SO2R8;
    R2 is selected from aryl attached via an unsaturated carbon atom;
    R3 is selected from H, alkyl, hydroxy, alkoxy, halogen, CN and NO2;
    R4 is selected from H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, NO2, COR5, CO2R5, CONR6R7, CONR5NR6R7, NR6R7, NR5CONR6R7, NR5COR6, NR5CO2R8 and NR5SO2R8;
    R5, R6 and R7 are independently selected from H, alkyl and aryl, or where R6 and R7 are in an (NR6R7) group, R6 and R7 may be linked to form a heterocyclic group, or where R5, R6 and R7 are in a (CONR5NR6R7) group, R5 and R6 may be linked to form a heterocyclic group; and
    R8 is selected from alkyl and aryl,
    or a pharmaceutically acceptable salt thereof or prodrug thereof.
  • As used herein, the term “alkyl” means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl)hydrocarbyl radical which may be substituted or unsubstituted. Where cyclic, the alkyl group is preferably C3 to C12, more preferably C5 to C10, more preferably C5, C6 or C7. Where acyclic, the alkyl group is preferably C1 to C10, more preferably C1 to C6, more preferably methyl, ethyl, propyl (n-propyl or isopropyl), butyl (n-butyl, isobutyl or tertiary-butyl) or pentyl (including n-pentyl and iso-pentyl), more preferably methyl. It will be appreciated therefore that the term “alkyl” as used herein includes alkyl (branched or unbranched), alkenyl (branched or unbranched), alkynyl (branched or unbranched), cycloalkyl, cycloalkenyl and cycloalkynyl.
  • As used herein, the term “lower alkyl” means methyl, ethyl, propyl (n-propyl or isopropyl) or butyl (n-butyl, isobutyl or tertiary-butyl).
  • As used herein, the term “aryl” means an aromatic group, such as phenyl or naphthyl (preferably phenyl), or a heteroaromatic group containing one or more heteroatom(s) preferably selected from N, O and S, such as pyridyl, pyrrolyl, quinolinyl, furanyl, thienyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, imidazolyl or pyrimidinyl.
  • As used herein, the term “heteroaryl” means an aromatic group containing one or more heteroatom(s) preferably selected from N, O and S, such as pyridyl, pyrrolyl, quinolinyl, furanyl, thienyl, oxadiazolyl, thiadiazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazolyl, triazolyl, imidazolyl or pyrimidinyl.
  • As used herein, the term “alkoxy” means alkyl-O—. As used herein, the term “aryloxy” means aryl-O—.
  • As used herein, the term “halogen” means a fluorine, chlorine, bromine or iodine radical.
  • As used herein, the term “ortho,ortho-disubstituted aryl groups” refers to aryl groups which are substituted in both ortho positions of the aryl group relative to the point of attachment of the aryl group to the pyrimidine ring.
  • As used herein, the term “prodrug” means any pharmaceutically acceptable prodrug of a compound of the present invention.
  • Where any of R1 to R13 is selected from alkyl, alkoxy and thioalkyl, in accordance with formula (I) as defined above, then that alkyl group, or the alkyl group of the alkoxy or thioalkyl group, may be substituted or unsubstituted. Where any of R1 to R13 are selected from aryl, aryloxy and thioaryl, in accordance with formula (I) as defined above, then said aryl group, or the aryl group of the aryloxy or thioaryl group, may be substituted or unsubstituted. Where R5 and R6, or R6 and R7, or R12 and R13, or R5 and R12 are linked to form a heterocyclic group, the heterocyclic group may be substituted or unsubstituted. Where substituted, there will generally be 1 to 3 substituents present, preferably 1 substituent. Substituents may include:
  • carbon-containing groups such as
      • alkyl,
      • aryl, (e.g. substituted and unsubstituted phenyl (including alkylphenyl, alkoxyphenyl and halophenyl),
      • arylalkyl; (e.g. substituted and unsubstituted benzyl);
        halogen atoms and halogen containing groups such as
      • haloalkyl (e.g. trifluoromethyl),
      • haloaryl (e.g. chlorophenyl);
        oxygen containing groups such as
      • alcohols (e.g. hydroxy, hydroxyalkyl, hydroxyaryl, (aryl)(hydroxy)alkyl),
      • ethers (e.g. alkoxy, aryloxy, alkoxyalkyl, aryloxyalkyl, alkoxyaryl, aryloxyaryl),
      • aldehydes (e.g. carboxaldehyde),
      • ketones (e.g. alkylcarbonyl, arylcarbonyl, alkylcarbonylalkyl, alkylcarbonylaryl, arylcarbonylalkyl, arylcarbonylaryl, arylalkylcarbonyl, arylalkylcarbonylalkyl, arylalkylcarbonylaryl)
      • acids (e.g. carboxy, carboxyalkyl, carboxyaryl),
      • acid derivatives such as esters
        • (e.g. alkoxycarbonyl, aryloxycarbonyl, alkoxycarbonylalkyl, aryloxycarbonylalkyl, alkoxycarbonylaryl, aryloxycarbonylaryl, alkylcarbonyloxy, alkylcarbonyloxyalkyl), amides
        • (e.g. aminocarbonyl, mono- or di-alkylaminocarbonyl, cyclicaminocarbonyl, aminocarbonylalkyl, mono- or di-alkylaminocarbonylalkyl, arylaminocarbonyl or arylalkylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino or arylalkylcarbonylamino), carbamates
        • (eg. alkoxycarbonylamino, aryloxycarbonylamino, arylalkyloxycarbonylamino, aminocarbonyloxy, mono- or di-alkylaminocarbonyloxy, arylaminocarbonyloxy or arylalkylaminocarbonyloxy)
        • and ureas
        • (eg. mono- or di-alkylaminocarbonylamino, arylaminocarbonylamino or arylalkylaminocarbonylamino);
          nitrogen containing groups such as
      • amines (e.g. amino, mono- or dialkylamino, cyclicamino, arylamino, aminoalkyl, mono- or dialkylaminoalkyl),
      • azides,
      • nitriles (e.g. cyano, cyanoalkyl),
      • nitro,
      • sulfonamides (e.g. aminosulfonyl, mono- or di-alkylaminosulfonyl, mono- or di-arylaminosulfonyl, alkyl- or aryl-sulfonylamino, alkyl- or aryl-sulfonyl(alkyl)amino, alkyl- or aryl-sulfonyl(aryl)amino);
        sulfur containing groups such as
      • thiols, thioethers, sulfoxides, and sulfones
        • (e.g. alkylthio, alkylsulfinyl, alkylsulfonyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, arylthio, arylsulfinyl, arylsulfonyl, arylthioalkyl, arylsulfinylalkyl, arylsulfonylalkyl);
          heterocyclic groups containing one or more, preferably one, heteroatom,
      • (e.g. thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiadiazolyl, aziridinyl, azetidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, pyranyl, pyronyl, pyridyl, pyrazinyl, pyridazinyl, piperidyl, hexahydroazepinyl, piperazinyl, morpholinyl, thianaphthyl, benzofuranyl, isobenzofuranyl, indolyl, oxyindolyl, isoindolyl, indazolyl, indolinyl, 7-azaindolyl, benzopyranyl, coumarinyl, isocoumarinyl, quinolinyl, isoquinolinyl, naphthridinyl, cinnolinyl, quinazolinyl, pyridopyridyl, benzoxazinyl, quinoxalinyl, chromenyl, chromanyl, isochromanyl, phthalazinyl and carbolinyl); and
        silicon-containing groups such as
      • silanes (e.g. trialkylsilyl).
  • In one embodiment, where any of R1 to R13 is directly substituted by an alkyl substituent group, or by an alkyl-containing substituent group (such as alkoxy, alkoxyalkyl or alkylcarbonylamino for example), then the alkyl moiety of the substituent group directly attached to any of R1 to R13 may be further substituted by the substituent groups hereinbefore described and particularly by halogen, hydroxy, alkoxy, CN, amines (including amino, mono- and di-alkyl amino) and aryl.
  • In a further embodiment, where any of R1 to R13 is directly substituted by an aryl substitutent group, or by an aryl-containing substituent group (such as aryloxy or arylaminocarbonylamino for example), then the aryl moiety of the substituent group directly attached to any of R1 to R13 may be further substituted by the substituent groups hereinbefore described and particularly by halogen, alkyl (including CF3), hydroxy, alkoxy, CN, amines (including amino, mono- and di-alkyl amino) and NO2.
  • The terms “directly substituted” and “directly attached”, as used herein, mean that the substituent group is bound directly to any of R1 to R13 without any intervening divalent atoms or groups.
  • In the compounds of formula (I), it is preferred that X is S.
  • In the compounds of formula (I), R1 is selected from H, alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, and cyclic and acyclic alkyl), aryl (including heteroaryl), hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, COR5, CO2R5, CONR6R7, CONR5NR6R7, NR6R7 (including NH2, monoalkyl amino and dialkylamino), NR5CONR6R7, NR5COR6, NR5CO2R8 and NR5SO2R8.
  • It is preferred that R1 is selected from alkyl, alkoxy, thioalkyl, NR6R7 and NR5COR6, and preferably from alkyl and NR6R7. In one embodiment, R1 is selected from NH2.
  • Where R1 is selected from alkyl, alkoxy and alkylthio, then said alkyl group or the alkyl group of the alkoxy or alkylthio is preferably selected from C1-6 alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, and cyclic and acyclic alkyl), preferably saturated C1-6 alkyl, and more preferably lower alkyl. In a preferred embodiment, R1 is selected from substituted alkyl, particularly haloalkyl (including CF3) and arylalkyl (including heteroarylalkyl).
  • In one embodiment, R1 is selected from CONR5NR6R7, NR5CONR6R7, NR5COR6, NR5CO2R8 and NR5SO2R8, and R5 is H or alkyl, and preferably H.
  • In one embodiment, R1 is selected from NR6R7 wherein R6 is preferably selected from H and alkyl (preferably H), and R7 is a substituted alkyl group represented by (CR9R10)nR11, wherein R9 and R10 are independently selected from H, alkyl and aryl (preferably from H and alkyl, and more preferably from H), n is selected from 1 to 6 (preferably from 2 to 4, more preferably 2), and R11 is selected from aryl (including heteroaryl), COR5, CO2R5, CONR12R13, CONR5NR12R13, NR12R13 (including NH2, monoalkyl amino and dialkylamino), NR5CONR12R13, NR5COR12, NR5CO2R8 and NR5SO2R8 (and preferably from aryl (including heteroaryl), NR12R13 (including NH2, monoalkyl amino and dialkylamino), NR5CONR12R13, NR5COR12, NR5CO2R8 and NR5SO2R9), wherein R5 and R8 are as hereinbefore defined and wherein R12 and R13 are independently selected from H, alkyl and aryl, or where R12 and R13 are in an (NR12R13) group, R12 and R13 may be linked to form a heterocyclic group, or where R5, R12 and R13 are in a (CONR5NR12R13) group, R5 and R12 may be linked to form a heterocyclic group.
  • In the compounds of formula (I), R2 is substituted or unsubstituted aryl (including heteroaryl) attached via an unsaturated carbon atom. Preferably, the aryl group is a 5- or 6-membered monocyclic aryl group.
  • Preferably, R2 is a heteroaryl group, and preferably a heteroaryl group which is attached to the pyrimidine ring of formula (I) such that a heteroatom is adjacent to the unsaturated carbon atom attached to said pyrimidine ring. Preferably, R2 is an N, O or S-containing heteroaryl group. R2 may contain one or more heteroatom(s) selected from N, O and S.
  • It is preferred that the aryl (including heteroaryl) group of R2 is not ortho,ortho-disubstituted. Preferably, the aryl (including heteroaryl) group of R2 is not substituted at either ortho position. As used herein, reference to ortho-substitution of the R2 group means the ortho positions of the R2 group relative to the point of attachment of R2 to the pyrimidine moiety of formula (I).
  • In a preferred embodiment, R2 is selected from furyl (including 2-furyl), thienyl (including 2-thienyl), pyridyl (including 2-pyridyl), thiazolyl (including 2- and 5-thiazolyl), pyrazolyl (including 3-pyrazolyl), triazolyl (including 4-triazolyl), pyrrolyl (including 2-pyrrolyl) and oxazolyl (including 5-oxazolyl). In a further embodiment, R2 is selected from 2-furyl, 2-thienyl, 2-thiazolyl, 2-pyridyl, 3-pyrazolyl, 2-pyrrolyl, 4-triazolyl and 5-oxazolyl. In a preferred embodiment, R2 is selected from furyl, thienyl, pyridyl and thiazolyl, and preferably from 2-furyl, 2-thienyl, 2-thiazolyl and 2-pyridyl.
  • In a particularly preferred embodiment, R2 is selected from 2-thiazolyl, optionally substituted, particularly by methyl.
  • In the compounds of formula (I), R3 is selected from H, alkyl (including haloalkyl (particularly CF3)), hydroxy, alkoxy (including OCF3), halogen, CN and NO2. Preferably, R3 is selected from H, CF3, hydroxy, alkoxy, halogen, CN and NO2, and preferably R3 is H.
  • In the embodiment where R3 is selected from alkyl or alkoxy, then said alkyl group or the alkyl group of said alkoxy is preferably C1-6 alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, and cyclic and acyclic alkyl), preferably saturated C1-6 alkyl, and more preferably lower alkyl. In a preferred embodiment of compounds wherein R3 is selected from alkyl, R3 is haloalkyl (particularly CF3).
  • In the compounds of formula (I), R4 is selected from H, alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, and cyclic and acyclic alkyl), aryl (including heteroaryl), hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, NO2, COR5, CO2R5, CONR6R7, CONR5NR6R7, NR6R7 (including NH2), NR5CONR6R7, NR5COR6, NR5CO2R8 and NR5SO2R8.
  • Where R4 is selected from alkyl, preferably R4 is C1-6 alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, and cyclic and acyclic alkyl), preferably saturated C1-6 alkyl, and more preferably lower alkyl. In one embodiment, R4 is selected from substituted alkyl, wherein the substituent groups are selected from halogen, substituted and unsubstituted aryl (including heteroaryl), cycloalkyl, non-aromatic heterocyclyl, CO2R5, CONR6R7, CONR5NR6R7 and C(═NR5)NR6R7, preferably aryl (including heteroaryl) and CONR6R7, more preferably aryl (including heteroaryl). In an alternative embodiment, R4 is selected from substituted alkyl, particularly haloalkyl (including CF3) and arylalkyl (including heteroarylalkyl). In an alternative embodiment, R4 is selected from unsubstituted C1-6 alkyl (preferably saturated C1-6 alkyl).
  • In one embodiment R4 is selected from H, alkyl (including arylalkyl (including heteroarylalkyl)), halogen, COR5, CO2R5, CONR6R7 and CONR5NR6R7, preferably from H, alkyl (including arylalkyl (including heteroarylalkyl)) and halogen, and preferably from H.
  • In the compounds of formula (I), R5, R6 and R7 are independently selected from H, alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, cyclic and acyclic alkyl) and aryl (including heteroaryl), or where R6 and R7 are in any NR6R7 group R6 and R7 may be linked to form a heterocyclic group, or where R5, R6 and R7 are in a CONR5NR6R7 group, R5 and R6 may be linked to form a heterocyclic group.
  • In the compounds of formula (I), R12 and R13 are independently selected from H, alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, cyclic and acyclic alkyl) and aryl (including heteroaryl), or where R12 and R13 are in any NR12R13 group R12 and R13 may be linked to form a heterocyclic group, or where R5, R12 and R13 are in a CONR5NR12R13 group, R5 and R12 may be linked to form a heterocyclic group.
  • In the compounds of formula (I), R8 is selected from alkyl (including branched and unbranched alkyl, substituted and unsubstituted alkyl, cyclic and acyclic alkyl) and aryl (including heteroaryl).
  • Where R5 to R10, R12 and R13, are independently selected from alkyl, preferably R5 to R10, R12 and R13 are independently selected from C1-6 alkyl, preferably C1-6 saturated alkyl and more preferably from lower alkyl.
  • Where R6 and R7, or R12 and R13, are linked to form a heterocyclic ring, said heterocyclic ring may be saturated, partially unsaturated or aromatic, and is preferably saturated. Said heterocyclic ring is preferably a 5, 6 or 7-membered ring, preferably a 5 or 6-membered ring, and may contain one or more further heteroatom(s) preferably selected from N, O and S.
  • Where R5 and R6, or R5 and R12, are linked to form a heterocyclic ring, said heterocyclic ring may be saturated, partially unsaturated or aromatic, and is preferably saturated. Said heterocyclic ring is preferably a 5, 6 or 7-membered ring, preferably a 5 or 6-membered ring, and may contain one or more further heteroatom(s) preferably selected from N, O and S.
  • In a particularly preferred embodiment of the invention, the compounds of the present invention are selected from:
    • 7-bromo-4-(2-furyl)-N-(2-hydroxyethyl)thieno[3,2-d]pyrimidine-2-amine;
    • N-allyl-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine;
    • 2-ethyl-4-(2-pyridyl)thieno[3,2-d]pyrimidine;
    • 2-methyl-4-(2-pyridyl)thieno[3,2-d]pyrimidine;
    • 2-n-propyl-4-(2-pyridyl)thieno[3,2-d]pyrimidine;
    • N-(2-hydroxyethyl)-4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine;
    • 2-isopropyl-4-(2-pyridyl)thieno[3,2-d]pyrimidine;
    • N-(2-methoxyethyl)-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine;
    • N,N-dimethyl-4-(4-methyl-2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine;
    • 4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine;
    • 2-ethyl-4-(4-methyl-2-thiazolyl)thieno[3,2-d]pyrimidine;
    • 2-ethyl-4-(2-thiazolyl)thieno[3,2-d]pyrimidine;
    • N,N-dimethyl-4-(5-methyl-2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine;
    • N,N-dimethyl-4-(4,5-dimethyl-2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine;
    • 4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine;
    • (2R)-2-(2-hydroxymethylpyrrolidin-1-yl)-4-(2-thiazolyl)thieno[3,2-d]pyrimidine;
    • N-allyl-4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine;
    • 2-isopropyl-4-(2-thiazolyl)thieno[3,2-d]pyrimidine;
    • N,N-dimethyl-4-(5-methyl-2-pyridyl)thieno[3,2-d]pyrimidine-2-amine;
    • 2-tert-butyl-4-(2-thiazolyl)thieno[3,2-d]pyrimidine;
    • 2-cyclopropyl-4-(2-thiazolyl)thieno[3,2-d]pyrimidine;
    • 2-ethyl-4-(6-methyl-2-pyridyl)thieno[3,2-d]pyrimidine;
    • (2S)-2-(2-hydroxymethylpyrrolidin-1-yl)-4-(2-thiazolyl)thieno[3,2-d]pyrimidine; and
    • 2-(2-chloroethyl)-4-(2-thiazolyl)thieno[3,2-d]pyrimidine.
  • Where chiral the compounds of the present invention may be in the form of a racemic mixture of pairs of enantiomers or in enantiomerically pure form.
  • According to a further aspect of the invention, there is provided for use in therapy a compound of the present invention, or a pharmaceutically acceptable salt or prodrug thereof.
  • The present invention may be employed in respect of a human or animal subject, more preferably a mammal, more preferably a human subject.
  • The disorders of particular interest are those in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A2A receptors, may be beneficial. These may include movement disorders such as Parkinson's disease, drug-induced Parkinsonism, post-encephalitic Parkinsonism, Parkinsonism induced by poisoning (for example MPTP, manganese, carbon monoxide) and post-traumatic Parkinson's disease (punch-drunk syndrome).
  • Other movement disorders in which the blocking of purine receptors, may be of benefit include progressive supernuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity or other disorders of the basal ganglia which result in abnormal movement or posture. The present invention may also be effective in treating Parkinson's with on-off phenomena; Parkinson's with freezing (end of dose deterioration); and Parkinson's with prominent dyskinesias.
  • The compounds of formula (I) may be used or administered in combination with one or more additional drugs useful in the treatment of movement disorders, such as L-DOPA or a dopamine agonist, the components being in the same formulation or in separate formulations for administration simultaneously or sequentially.
  • Other disorders in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A2A receptors may be beneficial include acute and chronic pain; for example neuropathic pain, cancer pain, trigeminal neuralgia, migraine and other conditions associated with cephalic pain, primary and secondary hyperalgesia, inflammatory pain, nociceptive pain, tabes dorsalis, phantom limb pain, spinal cord injury pain, central pain, post-herpetic pain and HIV pain; affective disorders including mood disorders such as bipolar disorder, seasonal affective disorder, depression, manic depression, atypical depression and monodepressive disease; central and peripheral nervous system degenerative disorders including corticobasal degeneration, demyelinating disease (multiple sclerosis, disseminated sclerosis), Freidrich's ataxia, motoneurone disease (amyotrophic lateral sclerosis, progressive bulbar atrophy), multiple system atrophy, myelopathy, radiculopathy, peripheral neuropathy (diabetic neuropathy, tabes dorsalis, drug-induced neuropathy, vitamin deficiency), systemic lupus erythamatosis, granulomatous disease, olivo-ponto-cerebellar atrophy, progressive pallidal atrophy, progressive supranuclear palsy, spasticity; schizophrenia and related pyshoses; cognitive disorders including dementia, Alzheimers Disease, Frontotemporal dementia, multi-infarct dementia, AIDS dementia, dementia associated with Huntingtons Disease, Lewy body dementia, senile dementia, age-related memory impairment, cognitive impairment associated with dementia, Korsakoff syndrome, dementia pugilans; attention disorders such as attention-deficit hyperactivity disorder (ADHD), attention deficit disorder, minimal brain dysfunction, brain-injured child syndrome, hyperkinetic reaction childhood, and hyperactive child syndrome; central nervous system injury including traumatic brain injury, neurosurgery (surgical trauma), neuroprotection for head injury, raised intracranial pressure, cerebral oedema, hydrocephalus, spinal cord injury; cerebral ischaemia including transient ischaemic attack, stroke (thrombotic stroke, ischaemic stroke, embolic stroke, haemorrhagic stroke, lacunar stroke) subarachnoid haemorrhage, cerebral vasospasm, neuroprotection for stroke, peri-natal asphyxia, drowning, cardiac arrest, subdural haematoma; myocardial ischaemia; muscle ischaemia; sleep disorders such as hypersomnia and narcolepsy; eye disorders such as retinal ischaemia-reperfusion injury and diabetic neuropathy; cardiovascular disorders such as claudication and hypotension; and diabetes and its complications.
  • According to a further aspect of the present invention, there is provided the use of a compound of the present invention or a pharmaceutically acceptably salt or prodrug thereof in the manufacture of a medicament for the treatment or prevention of a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly A2A receptors, may be beneficial.
  • According to a further aspect of the present invention there is provided a method of treating or preventing a disorder in which the blocking of purine receptors, particularly adenosine receptors and more particularly adenosine A2A receptors, may be beneficial, the method comprising administration to a subject in need of such treatment an effective dose of a compound of the present invention or a pharmaceutically acceptable salt or prodrug thereof.
  • The disorder may be caused by the hyperfunctioning of the purine receptors.
  • According to a further aspect of the present invention there is provided use of a compound of the present invention or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for the treatment or prevention of movement disorders in a subject.
  • According to a further aspect of the invention there is provided a method of treating or preventing movement disorders comprising administration to a subject in need of such treatment an effective dose of a compound of the present invention or a pharmaceutically acceptable salt or prodrug thereof.
  • According to a further aspect of the invention there is provided use of a compound of the present invention or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for neuroprotection in a subject.
  • According to a further aspect of the invention there is provided a method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of a compound of the present invention or a pharmaceutically acceptable salt or prodrug thereof.
  • The medicament for or method of neuroprotection may be of use in the treatment of subjects who are suffering from or at risk from a neurodegenerative disorder, such as a movement disorder.
  • According to a further aspect of the invention, there is provided a method of preparing the novel compounds of the present invention. Compounds of formula (I) may be prepared according to conventional synthetic methods, such as set out in Reaction Scheme 1.
  • Figure US20080153820A1-20080626-C00003
  • Compounds of formula (1) are prepared from halides of formula (2) by standard methods such as aryl coupling reactions which may be advantageously carried out in the presence of a catalyst such as a palladium catalyst. The aryl coupling reaction may be carried out by reaction of a halide of formula (2) with, for example, an aryl or heteroaryl trialkyltin reagent, an aryl or heteroaryl boronic acid or boronic ester reagent or an aryl or heteroaryl zinc halide reagent according to methods described in the literature. Suitable aryl or heteroaryl trialkyl tin, boronic acid, boronic ester or zinc halide reagents are either commercially available or may be prepared by standard literature methods.
  • Halides of formula (2) are either known in the literature or may be prepared from compounds of formula (3) by standard methods, for example by treatment with a chlorinating reagent such as POCl3. Compounds of formula (3) are either known in the literature or may be prepared from compounds of formula (4) by standard methods such as treatment with an appropriate ester (R1CO2Et) in the presence of a suitable base such as NaOEt, or by treatment with an appropriate anhydride (R1CO)2O in the presence of a base such as Et3N followed by heating in the presence of a stronger base such as NaOH. Alternatively compounds of formula (3) may be prepared from compounds of formula (5) by standard methods such as treatment with an appropriate nitrile (R1CN) in the presence of dry HCl gas. Compounds of formula (4) and formula (5) are either known in the literature or may be prepared by standard methods.
  • Compounds of formula (1) where R1 is NR6R7 may be prepared from compounds of formula (1) where R1 is halogen by standard methods such as reaction with an appropriate amine (R6R7NH). Compounds of formula (1) where R1 is halogen may be prepared from compounds of formula (2) where R1 is halogen as described above. Compounds of formula (2) where R1 is halogen are either known in the literature or may be prepared by methods analogous to those described in the literature.
  • Compounds of formula (1) where R1 is NR5CONR6R7, NR5COR6, NR5CO2R8 or NR5SO2R8 wherein R5 is H may be prepared from compounds of formula (1) where R1 is NH2 by standard methods for example by treatment with an appropriate isocyanate (R6NCO or R7NCO), carbamoyl chloride (R6R7NCOCl), acid chloride (R6COCl), chloroformate (ClCO2R8) or sulphonyl chloride (ClSO2R8). Analogous compounds wherein R5 is alkyl may be prepared by initial alkylation or reductive alkylation followed by reaction with the appropriate reagent as described above.
  • Compounds of formula (1) where R1 is NH2 may be prepared from compounds of formula (1) where R1 is halogen either by direct displacement with ammonia or by reaction with an appropriate protected amine, for example 3,4-dimethoxybenzylamine, followed by removal of the protecting group, if desired, by treatment with TFA.
  • Compounds of formula (1) where R1 is hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, or CN may be prepared from compounds of formula (1) where R1 is halogen by direct displacement with an appropriate nucleophile such as water, an alcohol, thiol or cyanide in the presence of a suitable base.
  • Compounds of formula (1) where R1 is CONR6R7 or CONR5NR6R7 may be prepared from compounds of formula (1) where R1 is CO2R5 by standard methods such as reaction with an appropriate amine (R6R7NH) or substituted hydrazine (HNR5NR6R7), either directly or in the presence of a suitable reagent such as trimethylaluminium.
  • Compounds of formula (1) where R1 is COR5, wherein R5 is H, may be prepared from compounds of formula (1) where R1 is CO2R5 by standard methods such as reduction with an appropriate reducing agent such as DIBAL at low temperature. Compounds of formula (1) where R1 is COR5, wherein R5 is alkyl or aryl, may be prepared from compounds of formula (1) where R1 is COR5, wherein R5 is H, by standard methods such as initial treatment with an appropriate alkyl or arylithium or Grignard reagent, followed by oxidation.
  • Compounds of formula (1) where R1 is CO2R5 may be prepared according to Reaction Scheme 1 by the methods described above.
  • In a compound of formula (1) where R1 is alkyl or aryl or where the group R1 contains an alkyl or aryl substituent, the alkyl or aryl group may be substituted as defined above. Where the alkyl or aryl group is substituted by a reactive functional group it will be appreciated that derivatisation of the reactive functional group may lead to a wide variety of additional substituent groups. By way of example where the alkyl or aryl group is substituted by an amino group then the amino group may be derivatised to form a mono- or dialkylamine, urea, thiourea, amide, carbamate or sulphonamide by the use of standard reactions such as those described above. Where the alkyl or aryl group is substituted by an amino group it may be advantageous to protect the amino group during the synthesis by the use of a standard protecting group such as a BOC group. The protecting group may then be removed at the appropriate step in the synthesis, by standard methods such as treatment with TFA.
  • Compounds of formula (1) where R3 is halogen or NO2 may be prepared from compounds of formula (2) where R3 is halogen or NO2 as described above. Compounds of formula (2) where R3 is halogen or NO2 are either known in the literature or may be prepared from compounds of formula (2) where R3 is H by standard literature methods such as halogenation or nitration.
  • Compounds of formula (1) where R3 is hydroxy, alkoxy or cyano may be prepared from compounds of formula (2) where R3 is hydroxy, alkoxy or cyano as described above. Compounds of formula (2) where R3 is hydroxy, alkoxy or cyano may be prepared from compounds of formula (2) where R3 is halogen by standard literature methods such as nucleophilic displacement.
  • Compounds of formula (1) where R4 is aryl or heteroaryl may be prepared from compounds of formula (1) where R4 is halogen by standard methods such as palladium catalysed aryl coupling reactions as described above. Compounds of formula (1) where R4 is halogen are prepared from compounds of formula (2) where R4 is halogen as described above. Compounds of formula (2) where R4 is halogen are either known in the literature or prepared by methods analogous to those described in the literature.
  • Compounds of formula (1) where R4 is NH2 are prepared from compounds of formula (1) where R4 is NO2 by standard methods such as reduction. Compounds of formula (1) where R4 is NO2 are prepared from compounds of formula (2) where R4 is NO2 as described above. Compounds of formula (2) where R4 is NO2 are either known in the literature or prepared by methods analogous to those described in the literature.
  • Compounds of formula (1) where R4 is NR6R7, NR5CONR6R7, NR5COR6, NR5CO2R8 or NR5SO2R8 wherein R5 is H may be prepared from compounds of formula (1) where R4 is NH2 by standard methods for example by mono- or dialkylation, reductive alkylation or by treatment with an appropriate isocyanate (R6NCO or R7NCO), carbamoyl chloride (R6R7NCOCl), acid chloride (R6COCl), chloroformate (ClCO2R8) or sulphonyl chloride (ClSO2R8). Analogous compounds wherein R5 is alkyl may be prepared by initial alkylation or reductive alkylation followed by reaction with the appropriate reagent as described above.
  • Compounds of formula (1) where R4 is COR5 may be prepared from compounds of formula (2) where R4 is COR5 as described above. Compounds of formula (2) where R1 is COR5 may be prepared from compounds of formula (2) where R4 is H by standard methods such as Friedel-Crafts acylation.
  • Compounds of formula (1) where R4 is CO2R5, CONR6R7 or CONR5NR6R7 may be prepared from compounds of formula (2) where R4 is CO2R5, CONR6R7 or CONR5NR6R7 as described above. Compounds of formula (2) where R4 is CO2R5 or CONR6R7 may be prepared from compounds of formula (2) where R4 is halogen by standard methods such as palladium catalysed carbonylation reactions in the presence of an appropriate alcohol (R5OH) or amine (HNR6R7). Compounds of formula (2) where R4 is CONR6R7 or CONR5NR6R7 may be prepared from compounds of formula (2) where R4 is CO2R5 by standard methods such as reaction with a suitable amine (HNR6R7) or hydrazine (HNR5NR6R7) derivative.
  • Compounds of formula (1) where R4 is cyano may be prepared from compounds of formula (1) where R4 is CONR6R7, wherein R6 and R7 are both H, by standard literature methods such as dehydration.
  • Compounds of formula (1) where R4 is hydroxy, alkoxy, aryloxy, thioalkyl or thioaryl may be prepared by standard literature methods known to those skilled in the art. Such standard methods may include treatment of a compound of formula (1) where R4 is halogen with an appropriate nucleophile. Alternatively compounds of formula (1) where R4 is hydroxy or alkoxy may be prepare from a compound of formula (1) where R4 is COR5 by use of the Bayer Villiger reaction, followed by a hydrolysis step and followed, if desired, by an alkylation step.
  • According to a further aspect of the invention, there is provided a pharmaceutical composition comprising a compound of the present invention in combination with a pharmaceutically acceptable carrier or excipient and a method of making such a composition comprising combining a compound of the present invention with a pharmaceutically acceptable carrier or excipient.
  • The pharmaceutical compositions employed in the present invention comprise a compound of the present invention, or pharmaceutically acceptable salts or prodrugs thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients known to those skilled in the art. The term, “pharmaceutically acceptable salts”, refers to salts prepared from pharmaceutically acceptable non-toxic acids including inorganic acids and organic acids.
  • Where the compounds of the present invention are basic, salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, oxalic, p-toluenesulfonic and the like. Particularly preferred are hydrochloric, hydrobromic, phosphoric, and sulfuric acids, and most particularly preferred is the hydrochloride salt.
  • Any suitable route of administration may be employed for providing the patient with an effective dosage of a compound of the present invention. For example, oral, rectal, parenteral (intravenous, intramuscular), transdermal, subcutaneous, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches, and the like. The most suitable route in any given case will depend on the severity of the condition being treated. The most preferred route of administration of the present invention is the oral route. The compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.
  • In practical use, the compounds of the present invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g. oral or parenteral (e.g. intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed as carriers, such as, for example, water, glycols, oils, alcohols, flavouring agents, preservatives, colouring agents, and the like in the case of oral liquid preparations (such as suspensions, solutions and elixirs) or aerosols; or carriers such as starches, sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used in the case of oral solid preparations such as, for example, powders, capsules, and tablets, with the solid oral preparations being preferred over the liquid preparations. The most preferred solid oral preparation is tablets.
  • Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or non-aqueous techniques.
  • In addition to the common dosage forms set out above, the compounds of the present invention may also be administered by controlled release means and/or delivery devices such as those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 3,630,200; 4,008,719; 4,687,660; and 4,769,027, the disclosures of which are hereby incorporated by reference.
  • Pharmaceutical compositions employed in the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets, or tablets, or aerosol sprays each containing a predetermined amount of the active ingredient as a powder or granules, a solution or a suspension in an aqueous liquid, an oil-in-water emulsion, or a water-in-oil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy, but all methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
  • For example, a tablet may be prepared by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, a lubricant, an inert diluent, and/or a surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • The invention is further defined by reference to the following examples. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practised without departing from the purpose and interest of this invention.
    • EXAMPLES Synthetic Examples
  • The invention is illustrated with reference to the following Examples, as set out in Table 1. The syntheses of the Examples are performed using the general Synthetic Methods described hereinafter. The Method used for each Example is given in parentheses in column 1 of Table 1. Analytical data are given in Table 2.
  • TABLE 1
    Example Structure Compound Name
    1(A)
    Figure US20080153820A1-20080626-C00004
         		2-chloro-4-(2-thienyl)thieno[3,2-d]pyrimidine
    2(E)
    Figure US20080153820A1-20080626-C00005
         		N,N-dimethyl-4-(2-thienyl)thieno[3,2-d]pyrimidine-2-amine
    3(A)
    Figure US20080153820A1-20080626-C00006
         		2-chloro-4-(2-furyl)thieno[3,2-d]pyrimidine
    4(E)
    Figure US20080153820A1-20080626-C00007
         		(2R)-2-(2-hydroxymethylpyrrolidin-1-yl)-4-(2-thienyl)thieno[3,2-d]pyrimidine
    5(E)
    Figure US20080153820A1-20080626-C00008
         		N,N-dimethyl-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine
    6(E)
    Figure US20080153820A1-20080626-C00009
         		N-(3-(1H-imidazol-1-yl)propyl)-4-(2-thienyl)thieno[3,2-d]pyrimidine-2-amine
    7(E)
    Figure US20080153820A1-20080626-C00010
         		N-(2-hydroxyethyl)-4-(2-thienyl)thieno[3,2-d]pyrimidine-2-amine
    8(E)
    Figure US20080153820A1-20080626-C00011
         		2-methoxy-4-(2-thienyl)thieno[3,2-d]pyrimidine
    9(B)
    Figure US20080153820A1-20080626-C00012
         		2-ethyl-4-(2-thienyl)thieno[3,2-d]pyrimidine
    10(E)
    Figure US20080153820A1-20080626-C00013
         		N-(3-(1H-imidazol-1-yl)propyl)-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine
    11(A)
    Figure US20080153820A1-20080626-C00014
         		4-(2-furyl)-2-trifluoromethylthieno[3,2-d]pyrimidine
    12(A)
    Figure US20080153820A1-20080626-C00015
         		2-chloro-4-(2-furyl)-7-methylthieno[3,2-d]pyrimidine
    13(A)
    Figure US20080153820A1-20080626-C00016
         		7-bromo-2-chloro-4-(2-furyl)thieno[3,2-d]pyrimidine
    14(E)
    Figure US20080153820A1-20080626-C00017
         		4-(2-furyl)-N-(2-hydroxyethyl)thieno[3,2-d]pyrimidine-2-amine
    15(E)
    Figure US20080153820A1-20080626-C00018
         		7-bromo-4-(2-furyl)-N-(2-hydroxyethyl)thieno[3,2-d]pyrimidine-2-amine
    16(E)
    Figure US20080153820A1-20080626-C00019
         		4-(2-furyl)-N-(2-hydroxyethyl)-7-methylthieno[3,2-d]pyrimidine-2-amine
    17(A)
    Figure US20080153820A1-20080626-C00020
         		4-(2-benzothiophenyl)-2-chlorothieno[3,2-d]pyrimidine
    18(A)
    Figure US20080153820A1-20080626-C00021
         		2-ethyl-4-(2-furyl)thieno[3,2-d]pyrimidine
    19(E)
    Figure US20080153820A1-20080626-C00022
         		4-(2-benzothiophenyl)-N,N-dimethylthieno[3,2-d]pyrimidine-2-amine
    20(E)
    Figure US20080153820A1-20080626-C00023
         		4-(2-benzothiophenyl)-N-(2-hydroxyethyl)thieno[3,2-d]pyrimidine-2-amine
    21(E)
    Figure US20080153820A1-20080626-C00024
         		N-ethyl-4-(2-thienyl)thieno[3,2-d]pyrimidine-2-amine
    22(E)
    Figure US20080153820A1-20080626-C00025
         		7-bromo-N,N-dimethyl-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine
    23(E)
    Figure US20080153820A1-20080626-C00026
         		4-(2-furyl)-7,N,N-trimethylthieno[3,2-d]pyrimidine-2-amine
    24(A)
    Figure US20080153820A1-20080626-C00027
         		2-chloro-4-(2-pyridyl)thieno[3,2-d]pyrimidine
    25(E)
    Figure US20080153820A1-20080626-C00028
         		4-(2-furyl)-2-morpholinothieno[3,2-d]pyrimidine
    26(E)
    Figure US20080153820A1-20080626-C00029
         		N-benzyl-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine
    27(E)
    Figure US20080153820A1-20080626-C00030
         		N,N-dimethyl-4-(2-pyridyl)thieno[3,2-d]pyrimidine-2-amine
    28(B)
    Figure US20080153820A1-20080626-C00031
         		2-chloro-4-(1H-pyrrol-1-yl)thieno[3,2-d]pyrimidine
    29(A)
    Figure US20080153820A1-20080626-C00032
         		Ethyl 4-(2-furyl)thieno[3,2-d]pyrimidine-2-acetate
    30(A)
    Figure US20080153820A1-20080626-C00033
         		2-chloro-4-(2-pyrazinyl)thieno[3,2-d]pyrimidine
    31(P)
    Figure US20080153820A1-20080626-C00034
         		4,7-bis(2-furyl)-N,N-dimethylthieno[3,2-d]pyrimidine-2-amine
    32(E)
    Figure US20080153820A1-20080626-C00035
         		N,N-dimethyl-4-(1H-pyrrol-1-yl)thieno[3,2-d]pyrimidine-2-amine
    33(E)
    Figure US20080153820A1-20080626-C00036
         		N,N-dimethyl-4-(2-pyrazinyl)thieno[3,2-d]pyrimidine-2-amine
    34(E)
    Figure US20080153820A1-20080626-C00037
         		N-(2-hydroxyethyl)-4-(2-pyrazinyl)thieno[3,2-d]pyrimidine-2-amine
    35(E)
    Figure US20080153820A1-20080626-C00038
         		4-(2-furyl)-2-(4-methylpiperazinyl)thieno[3,2-d]pyrimidine
    36(E)
    Figure US20080153820A1-20080626-C00039
         		4-(2-furyl)-2-isopropylthiothieno[3,2-d]pyrimidine
    37(E)
    Figure US20080153820A1-20080626-C00040
         		2-ethylthio-4-(2-furyl)thieno[3,2-d]pyrimidine
    38(E)
    Figure US20080153820A1-20080626-C00041
         		(2R)-4-(2-furyl)-2-(2-hydroxymethylpyrrolidin-1-yl)thieno[3,2-d]pyrimidine
    39(E)
    Figure US20080153820A1-20080626-C00042
         		4-(2-furyl)-2-methylthiothieno[3,2-d]pyrimidine
    40(E)
    Figure US20080153820A1-20080626-C00043
         		N-allyl-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine
    41(A)
    Figure US20080153820A1-20080626-C00044
         		2-chloro-4-(2-furyl)-7-nitrothieno[3,2-d]pyrimidine
    42(E)
    Figure US20080153820A1-20080626-C00045
         		N-ethyl-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine
    43(E)
    Figure US20080153820A1-20080626-C00046
         		4-(2-furyl)-2-(pyrrolidin-1-yl)thieno[3,2-d]pyrimidine
    44(E)
    Figure US20080153820A1-20080626-C00047
         		N,N-dimethyl-4-(2-furyl)-7-nitrothieno[3,2-d]pyrimidine-2-amine
    45(E)
    Figure US20080153820A1-20080626-C00048
         		4-(2-furyl)-N-(2-pyridylmethyl)thieno[3,2-d]pyrimidine-2-amine
    46(A)
    Figure US20080153820A1-20080626-C00049
         		Ethyl 3-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-yl)propionate
    47(E)
    Figure US20080153820A1-20080626-C00050
         		N-(2-dimethylaminoethyl)-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine
    48(K)
    Figure US20080153820A1-20080626-C00051
         		3-(4-(2-furyl)thieno[3,2-d]pyrimidin-2-yl)propanol
    49(M)
    Figure US20080153820A1-20080626-C00052
         		3-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-yl)propionicacid
    50(N)
    Figure US20080153820A1-20080626-C00053
         		4-(2-furyl)-2-(3-oxo-3-(1-pyrrolidinyl)propyl)thieno[3,2-d]pyrimidine
    51(J)
    Figure US20080153820A1-20080626-C00054
         		7-amino-N,N-dimethyl-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine
    52(C)
    Figure US20080153820A1-20080626-C00055
         		2-ethyl-4-(2-pyridyl)thieno[3,2-d]pyrimidine
    53(E)
    Figure US20080153820A1-20080626-C00056
         		4-(5-chloro-2-thienyl)-N,N-dimethylthieno[3,2-d]pyrimidine-2-amine
    54(K)
    Figure US20080153820A1-20080626-C00057
         		2-(4-(2-furyl)thieno[3,2-d]pyrimidin-2-yl)ethanol
    55(I)
    Figure US20080153820A1-20080626-C00058
         		N-2-dimethylamino-4-(2-furyl)thieno[3,2-d]pyrimidine-7-yl)-N′-phenylurea
    56(G)
    Figure US20080153820A1-20080626-C00059
         		N-(2-dimethylamino-4-(2-furyl)thieno[3,2-d]pyrimidine-7-yl)acetamide
    57(G)
    Figure US20080153820A1-20080626-C00060
         		N-(2-dimethylamino-4-(2-furyl)thieno[3,2-d]pyrimidine-7-yl)benzamide
    58(E)
    Figure US20080153820A1-20080626-C00061
         		4-(2-furyl)-N-methylthieno[3,2-d]pyrimidine-2-amine
    59(G)
    Figure US20080153820A1-20080626-C00062
         		N-(2-chloro-4-(2-furyl)thieno[3,2-d]pyrimidine-7-yl)methanesulphonamide
    60(G)
    Figure US20080153820A1-20080626-C00063
         		N-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-yl)-N-methyl-3-oxobutanamide
    61(E)
    Figure US20080153820A1-20080626-C00064
         		4-(5-chloro-2-thienyl)-N-(2-hydroxyethyl)thieno[3,2-d]pyrimidine-2-amine
    62(C)
    Figure US20080153820A1-20080626-C00065
         		2-methyl-4-(2-pyridyl)thieno[3,2-d]pyrimidine
    63(C)
    Figure US20080153820A1-20080626-C00066
         		2-n-propyl-4-(2-pyridyl)thieno[3,2-d]pyrimidine
    64(C)
    Figure US20080153820A1-20080626-C00067
         		2-chloro-4-(2-thiazolyl)thieno[3,2-d]pyrimidine
    65(E)
    Figure US20080153820A1-20080626-C00068
         		N,N-dimethyl-4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine
    66(C)
    Figure US20080153820A1-20080626-C00069
         		4-(2-pyridyl)thieno[3,2-d]pyrimidine
    67(E)
    Figure US20080153820A1-20080626-C00070
         		N-(2-hydroxyethyl)-4-(2-pyridyl)thieno[3,2-d]pyrimidine-2-amine
    68(E)
    Figure US20080153820A1-20080626-C00071
         		N-(2-hydroxyethyl)-4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine
    69(L)
    Figure US20080153820A1-20080626-C00072
         		4-(2-furyl)-2-vinylthieno[3,2-d]pyrimidine
    70(C)
    Figure US20080153820A1-20080626-C00073
         		2-isopropyl-4-(2-pyridyl)thieno[3,2-d]pyrimidine
    71(E)
    Figure US20080153820A1-20080626-C00074
         		N-(2-methoxyethyl)-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine
    72(E)
    Figure US20080153820A1-20080626-C00075
         		(2R)-7-bromo-4-(2-furyl)-2-(2-hydroxymethylpyrrolidin-1-yl)thieno[3,2-d]pyrimidine
    73(A)
    Figure US20080153820A1-20080626-C00076
         		Ethyl 4-(2-furyl)thieno[3,2-d]pyrimidine-2-carboxylate
    74(E)
    Figure US20080153820A1-20080626-C00077
         		tert-butyl (2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)carbamate
    75(F)
    Figure US20080153820A1-20080626-C00078
         		N-(2-aminoethyl)-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine
    76(E)
    Figure US20080153820A1-20080626-C00079
         		N,N-dimethyl-4-(4-methyl-2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine
    77(H)
    Figure US20080153820A1-20080626-C00080
         		N-(2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)trifluoroacetamide
    78(E)
    Figure US20080153820A1-20080626-C00081
         		N-(3,4-dimethoxybenzyl)-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine
    79(F)
    Figure US20080153820A1-20080626-C00082
         		4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine
    80(C)
    Figure US20080153820A1-20080626-C00083
         		2-ethyl-4-(4-methyl-2-thiazolyl)thieno [3,2-d]pyrimidine
    81(K)
    Figure US20080153820A1-20080626-C00084
         		4-(2-furyl)thieno[3,2-d]pyrimidine-2-methanol
    82(C)
    Figure US20080153820A1-20080626-C00085
         		2-ethyl-4-(2-thiazolyl)thieno[3,2-d]pyrimidine
    83(H)
    Figure US20080153820A1-20080626-C00086
         		N-(2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)acetamide
    84(H)
    Figure US20080153820A1-20080626-C00087
         		N-(2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)-3-methylbutanamide
    85(H)
    Figure US20080153820A1-20080626-C00088
         		N-(2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)benzamide
    86(H)
    Figure US20080153820A1-20080626-C00089
         		N-(2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)thiophene-2-carboxamide
    87(H)
    Figure US20080153820A1-20080626-C00090
         		methyl (2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)carbamate
    88(H)
    Figure US20080153820A1-20080626-C00091
         		isobutyl (2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)carbamate
    89(H)
    Figure US20080153820A1-20080626-C00092
         		benzyl (2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)carbamate
    90(H)
    Figure US20080153820A1-20080626-C00093
         		9-fluorenylmethyl (2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)carbamate
    91(I)
    Figure US20080153820A1-20080626-C00094
         		N-allyl-N′-(2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)urea
    92(I)
    Figure US20080153820A1-20080626-C00095
         		N-benzyl-N′-(2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)urea
    93(I)
    Figure US20080153820A1-20080626-C00096
         		N-cyclohexyl-N′-(2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)urea
    94(I)
    Figure US20080153820A1-20080626-C00097
         		N-(2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)-N′-phenylurea
    95(I)
    Figure US20080153820A1-20080626-C00098
         		N-(4-chlorophenyl)-N′-(2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)urea
    96(I)
    Figure US20080153820A1-20080626-C00099
         		N-(2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)-N′-phenylthiourea
    97(I)
    Figure US20080153820A1-20080626-C00100
         		N-(4-chlorophenyl)-N′-(2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)thiourea
    98(H)
    Figure US20080153820A1-20080626-C00101
         		N-(2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)methanesulphonamide
    99(H)
    Figure US20080153820A1-20080626-C00102
         		N-(2-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)-4-tert-butylphenylsulphonamide
    100(A)
    Figure US20080153820A1-20080626-C00103
         		4-(2-furyl)-2-(2-pyridyl)thieno[3,2-d]pyrimidine
    101(G)
    Figure US20080153820A1-20080626-C00104
         		N-(4-(2-furyl)thieno[3,2-d]pyrimidin-2-yl)acetamide
    102(C)
    Figure US20080153820A1-20080626-C00105
         		2-chloro-4-(5-methyl-2-thiazolyl)thieno[3,2-d]pyrimidine
    103(C)
    Figure US20080153820A1-20080626-C00106
         		2-chloro-4-(4,5-dimethyl-2-thiazolyl)thieno[3,2-d]pyrimidine
    104(E)
    Figure US20080153820A1-20080626-C00107
         		N,N-dimethyl-4-(5-methyl-2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine
    105(E)
    Figure US20080153820A1-20080626-C00108
         		N,N-dimethyl-4-(4,5-dimethyl-2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine
    106(C)
    Figure US20080153820A1-20080626-C00109
         		2-ethyl-4-(5-phenyl-2-oxazolyl)thieno[3,2-d]pyrimidine
    107(D)
    Figure US20080153820A1-20080626-C00110
         		N,N-dimethyl-4-(1H-imidazol-2-yl)thieno[3,2-d]pyrimidine-2-amine
    108(E)
    Figure US20080153820A1-20080626-C00111
         		N-(3,4-dimethoxybenzyl)-4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine
    109(C)
    Figure US20080153820A1-20080626-C00112
         		2-chloro-4-(5-methyl-2-pyridyl)thieno[3,2-d]pyrimidine
    110(F)
    Figure US20080153820A1-20080626-C00113
         		4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine
    111(E)
    Figure US20080153820A1-20080626-C00114
         		(2R)-2-(2-hydroxymethylpyrrolidin-1-yl)-4-(2-thiazolyl)thieno[3,2-d]pyrimidine
    112(E)
    Figure US20080153820A1-20080626-C00115
         		N-allyl-4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine
    113(C)
    Figure US20080153820A1-20080626-C00116
         		2-isopropyl-4-(2-thiazolyl)thieno[3,2-d]pyrimidine
    114(C)
    Figure US20080153820A1-20080626-C00117
         		2-ethyl-4-(5-(4-methoxyphenyl)-2-oxazolyl)thieno[3,2-d]pyrimidine
    115(E)
    Figure US20080153820A1-20080626-C00118
         		N,N-dimethyl-4-(5-methyl-2-pyridyl)thieno[3,2-d]pyrimidine-2-amine
    116(G)
    Figure US20080153820A1-20080626-C00119
         		N-(4-(2-thiazolyl)thieno[3,2-d]pyrimidin-2-yl)acetamide
    117(A)
    Figure US20080153820A1-20080626-C00120
         		4-(2-furyl)-2-(2-thienylmethyl)thieno[3,2-d]pyrimidine
    118(A)
    Figure US20080153820A1-20080626-C00121
         		2-ethyl-4-(5-thiazolyl)thieno[3,2-d]pyrimidine
    119(A)
    Figure US20080153820A1-20080626-C00122
         		2-ethyl-4-(2-ethylthieno[3,2-d]pyrimidin-4-yl)thieno[3,2-d]pyrimidine
    120(D)
    Figure US20080153820A1-20080626-C00123
         		2-ethyl-4-(1H-triazol-3-yl)thieno[3,2-d]pyrimidine
    121(D)
    Figure US20080153820A1-20080626-C00124
         		2-ethyl-4-(1H-imidazol-2-yl)thieno[3,2-d]pyrimidine
    122(C)
    Figure US20080153820A1-20080626-C00125
         		4-(2-benzothiazolyl)-2-ethylthieno[3,2-d]pyrimidine
    123(E)
    Figure US20080153820A1-20080626-C00126
         		tert-butyl (2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)carbamate
    124(F)
    Figure US20080153820A1-20080626-C00127
         		N-(2-aminoethyl)-4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine
    125(H)
    Figure US20080153820A1-20080626-C00128
         		N-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)acetamide
    126(I)
    Figure US20080153820A1-20080626-C00129
         		N-ethyl-N′-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)urea
    127(I)
    Figure US20080153820A1-20080626-C00130
         		N-allyl-N′-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)urea
    128(I)
    Figure US20080153820A1-20080626-C00131
         		N-cyclohexyl-N′-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)urea
    129(H)
    Figure US20080153820A1-20080626-C00132
         		N-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)-3-methylbutanamide
    130(H)
    Figure US20080153820A1-20080626-C00133
         		methyl (2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)carbamate
    131(H)
    Figure US20080153820A1-20080626-C00134
         		isobutyl (2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)carbamate
    132(I)
    Figure US20080153820A1-20080626-C00135
         		N-tert-butyl-N′-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)urea
    133(I)
    Figure US20080153820A1-20080626-C00136
         		N-benzyl-N′-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)urea
    134(I)
    Figure US20080153820A1-20080626-C00137
         		N-phenyl-N′-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)urea
    135(I)
    Figure US20080153820A1-20080626-C00138
         		N-(4-chlorophenyl)-N′-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)urea
    136(I)
    Figure US20080153820A1-20080626-C00139
         		N-cyclohexyl-N′-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)thiourea
    137(I)
    Figure US20080153820A1-20080626-C00140
         		N-phenyl-N′-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)thiourea
    138(I)
    Figure US20080153820A1-20080626-C00141
         		N-(4-chlorophenyl)-N′-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)thiourea
    139(C)
    Figure US20080153820A1-20080626-C00142
         		2-tert-butyl-4-(2-thiazolyl)thieno[3,2-d]pyrimidine
    140(C)
    Figure US20080153820A1-20080626-C00143
         		2-cyclopropyl-4-(2-thiazolyl)thieno[3,2-d]pyrimidine
    141(C)
    Figure US20080153820A1-20080626-C00144
         		2-ethyl-4-(6-methyl-2-pyridyl)thieno[3,2-d]pyrimidine
    142(H)
    Figure US20080153820A1-20080626-C00145
         		N-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)cyclohexylcarboxamide
    143(H)
    Figure US20080153820A1-20080626-C00146
         		N-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)benzamide
    144(H)
    Figure US20080153820A1-20080626-C00147
         		4-chloro-N-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)benzamide
    145(H)
    Figure US20080153820A1-20080626-C00148
         		N-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)thiophene-2-carboxamide
    146(H)
    Figure US20080153820A1-20080626-C00149
         		phenyl (2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)carbamate
    147(H)
    Figure US20080153820A1-20080626-C00150
         		benzyl (2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)carbamate
    148(H)
    Figure US20080153820A1-20080626-C00151
         		N-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)methanesulphonamide
    149(H)
    Figure US20080153820A1-20080626-C00152
         		N-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)butanesulphonamide
    150(E)
    Figure US20080153820A1-20080626-C00153
         		(1RS)-N-(2-hydroxy-1-methylethyl)-4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine
    151(E)
    Figure US20080153820A1-20080626-C00154
         		N-(3-(1H-imidazol-1-yl)propyl)-4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-amine
    152(E)
    Figure US20080153820A1-20080626-C00155
         		(2S)-2-(2-hydroxymethylpyrrolidin-1-yl)-4-(2-thiazolyl)thieno[3,2-d]pyrimidine
    153(C)
    Figure US20080153820A1-20080626-C00156
         		4-(2-thiazolyl)-2-(2-thienyl)thieno[3,2-d]pyrimidine
    154(C)
    Figure US20080153820A1-20080626-C00157
         		2-(2-chloroethyl)-4-(2-thiazolyl)thieno[3,2-d]pyrimidine
    155(O)
    Figure US20080153820A1-20080626-C00158
         		4-(2-furyl)thieno[3,2-d]pyrimidine-2-carboxamide
    156(B)
    Figure US20080153820A1-20080626-C00159
         		2-chloro-4-(3-thienyl)thieno[3,2-d]pyrimidine
    157(E)
    Figure US20080153820A1-20080626-C00160
         		N,N-dimethyl-4-(3-thienyl)thieno[3,2]pyrimidine-2-amine
    158(B)
    Figure US20080153820A1-20080626-C00161
         		2-chloro-4-phenylthieno[3,2-d]pyrimidine
    159(E)
    Figure US20080153820A1-20080626-C00162
         		N,N-dimethyl-4-phenylthieno[3,2-d]pyrimidine-2-amine
    160(B)
    Figure US20080153820A1-20080626-C00163
         		2-chloro-4-(3-furyl)thieno[3,2-d]pyrimidine
    161(E)
    Figure US20080153820A1-20080626-C00164
         		N,N-dimethyl-4-(3-furyl)thieno[3,2-d]pyrimidine-2-amine
    162(A)
    Figure US20080153820A1-20080626-C00165
         		2-chloro-4-(2-furyl)-6-nitrothieno[3,2-d]pyrimidine
    163(A)
    Figure US20080153820A1-20080626-C00166
         		2-ethyl-4-(3-furyl)thieno[3,2-d]pyrimidine
    164(B)
    Figure US20080153820A1-20080626-C00167
         		4-(3,5-dimethyl-4-isoxazolyl)-2-ethylthieno[3,2-d]pyrimidine
    165(B)
    Figure US20080153820A1-20080626-C00168
         		2-chloro-4-(3-pyridyl)thieno[3,2-d]pyrimidine
    166(E)
    Figure US20080153820A1-20080626-C00169
         		N,N-dimethyl-4-(3-pyridyl)thieno[3,2-d]pyrimidine-2-amine
    167(C)
    Figure US20080153820A1-20080626-C00170
         		2-chloro-4-(1-methyl-1H-imidazol-2-yl)thieno[3,2-d]pyrimidine
    168(E)
    Figure US20080153820A1-20080626-C00171
         		N,N-dimethyl-4-(1-methyl-1H-imidazol-2-yl)thieno[3,2-d]pyrimidine-2-amine
    169(E)
    Figure US20080153820A1-20080626-C00172
         		N,N-dimethyl-4-(3-hydroxymethyl-2-furyl)thieno[3,2-d]pyrimidine-2-amine
    170(E)
    Figure US20080153820A1-20080626-C00173
         		N-(2-hydroxyethyl)-4-(1-methyl-1H-imidazol-2-yl)thieno[3,2-d]pyrimidine-2-amine
    171(E)
    Figure US20080153820A1-20080626-C00174
         		N-2-hydroxyethyl)-4-(3-hydroxymethyl-2-furyl)thieno[3,2-d]pyrimidine-2-amine
    172(C)
    Figure US20080153820A1-20080626-C00175
         		2-chloro-4-(1-ethyl-1H-imidazol-2-yl)thieno[3,2-d]pyrimidine
    173(E)
    Figure US20080153820A1-20080626-C00176
         		N,N-dimethyl-4-(1-ethyl-1H-imidazol-2-yl)thieno[3,2-d]pyrimidine-2-amine
    174(E)
    Figure US20080153820A1-20080626-C00177
         		4-(1-ethyl-1H-imidazol-2-yl)-N-(2-hydroxyethyl)thieno[3,2-d]pyrimidine-2-amine
    175(C)
    Figure US20080153820A1-20080626-C00178
         		2-chloro-4-(1-(2-trimethylsilylethoxymethyl)-1H-imidazol-2-yl)thieno[3,2-d]pyrimidine
    176(E)
    Figure US20080153820A1-20080626-C00179
         		N,N-dimethyl-4-(1-(2-trimethylsilylethoxymethyl)-1H-imidazol-2-yl)thieno[3,2-d]pyrimidine-2-amine
    177(C)
    Figure US20080153820A1-20080626-C00180
         		N,N-dimethyl-4-((1-ethoxycarbonylmethyl)-1H-imidazol-2-yl)thieno[3,2-d]pyrimidine-2-amine
    178(K)
    Figure US20080153820A1-20080626-C00181
         		N,N-dimethyl-4-(1-(2-hydroxyethyl)-1H-imidazol-2-yl)thieno[3,2-d]pyrimidine-2-amine
    179(C)
    Figure US20080153820A1-20080626-C00182
         		2-ethyl-4-(1-methoxymethyl-1H-imidazol-2-yl)thieno[3,2-d]pyrimidine
    180(C)
    Figure US20080153820A1-20080626-C00183
         		2-ethyl-4-(4-(2-trimethylsilylethoxymethyl)-4H-1,2,4-triazol-3-yl)thieno[3,2-d]pyrimidine
    181(C)
    Figure US20080153820A1-20080626-C00184
         		2-chloro-4-(1-(2-trimethylsilylethoxymethyl)-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidine
    182(C)
    Figure US20080153820A1-20080626-C00185
         		2-chloro-4-(1-methyl-1H-pyrazol-5-yl)thieno[3,2-d]pyrimidine
    183(E)
    Figure US20080153820A1-20080626-C00186
         		N,N-dimethyl-4-(1-(2-trimethylsilylethoxymethyl)-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidine-2-amine
    184(E)
    Figure US20080153820A1-20080626-C00187
         		N,N-dimethyl-4-(1-methyl-1H-pyrazol-5-yl)thieno[3,2-d]pyrimidine-2-amine
    185(D)
    Figure US20080153820A1-20080626-C00188
         		N,N-dimethyl-4-(1H-pyrazol-4-yl)thieno[3,2-d]pyrimidine-2-amine
    186(C)
    Figure US20080153820A1-20080626-C00189
         		N,N-dimethyl-4-(1-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidine-2-amine
    187(C)
    Figure US20080153820A1-20080626-C00190
         		2-ethyl-4-(4-methyl-4H-1,2,4-triazol-3-yl)thieno[3,2-d]pyrimidine
    188(A)
    Figure US20080153820A1-20080626-C00191
         		2-ethyl-4-(2-furyl)-6-methylthieno[3,2-d]pyrimidine
  • The general synthetic methods used for the preparation of these examples are set out below as Methods A to T.
    • Method A 2-Chloro-4-(2-furyl)thieno[3,2-d]pyrimidine (Example 3)
  • A solution of 2,4-dichlorothieno[3,2-d]pyrimidine (205 mg, 1 mmol) in DMF (4 mL) was treated with PdCl2(PPh3)2 (35 mg, 0.05 mmol) and 2-(tributylstannyl)-furan (315 μL, 1 mmol), stirred at room temperature for 16 h, the reaction mixture purified directly by chromatography (SiO2: EtOAc:Heptane, 1:9) and the resulting cream solid recrystallised (EtOAc/Heptane) to give the title compound (122 mg, 52%) as a cream solid.
    • Method B 2-Chloro-4-(5-chloro-2-thienyl)thieno[3,2-d]pyrimidine
  • A solution of Pd(OAc)2 (12 mg, 5 mmol %) and PPh3 (52 mg, 20 mol %) in THF (2 mL) was stirred for 5 min, treated dropwise with a solution of 2,4-dichlorothieno[3,2-d]pyrimidine (205 mg, 1 mmol) in THF (1 mL), stirred for 5 min, treated with 5-chlorothiophene-2-boronic acid (244 mg, 1.5 mmol) then saturated aqueous NaHCO3 (1 mL) refluxed for 4 h, cooled, diluted with H2O and filtered to give the title compound (268 mg, 94%) as a grey solid; NMR δH (400 MHz, CDCl3) 7.10 (1H, d, J 4.0 Hz), 7.55 (1H, d, J 5.5 Hz), 7.85 (1H, d, J 4.5 Hz) and 8.08 (1H, d, J 5.5 Hz)
    • Method C 2-Chloro-4-(2-thiazolyl)thieno[3,2-d]pyrimidine (Example 64)
  • A stirred solution of thiazole (0.14 mL, 2 mmol) in dry THF (10 mL) at −78° C., under argon was treated with n-BuLi (1.6-M in hexanes, 1.3 mL, 2 mmol), stirred for 30 min, treated with a solution of ZnCl2 (1.0-M in Et2O, 2.0 mL, 2 mmol) and allowed to warm gradually to room temperature. The mixture was treated with a solution of 2,4-dichlorothieno[3,2-d]pyrimidine (205 mg, 1 mmol) in THF (5 mL) then Pd(PPh3)4 (100 mg, 10 mol %) refluxed for 17 h, cooled, diluted with saturated NH4Cl solution and extracted with EtOAc. The organic extracts were dried (MgSO4), concentrated in vacuo and purified by chromatography [SiO2; isohexane:CH2Cl2 (2:1)] to give the title compound (75 mg, 26%) as a white solid.
    • Method D 2-Ethyl-4-(1H-imidazol-2-yl)thieno[3,2-d]pyrimidine (Example 121)
  • A stirred solution of 1-(2-trimethylsilyl)ethoxymethyl-1H-imidazole (295 mg, 1.5 mmol) in dry THF (10 mL) at −78° C., under argon was treated with n-BuLi (1.6-M in hexanes, 0.93 mL, 1.5 mmol), stirred for 30 min, treated with a solution of ZnCl2 (1.0-M in Et20, 1.5. mL, 1.5 mmol) and the mixture allowed to warm gradually to room temperature. The mixture was treated with 4-chloro-2-ethylthieno[3,2-d]pyrimidine (148 mg, 0.75 mmol) and Pd(PPh3)4 (100 mg), refluxed for 3 h, cooled, diluted with saturated NH4Cl solution, extracted with EtOAc, dried (MgSO4), concentrated in vacuo and purified by chromatography [SiO2; heptane:EtOAc (7:1) then (4:1)] to give the intermediate coupled product as a viscous oil (140 mg). A portion of this material (130 mg, 0.36 mmol) was dissolved in THF (5 mL), treated with a solution of tetra-n-butylammonium fluoride (1-M in THF, 0.72 mL, 0.72 mmol), refluxed for 4 hr, cooled, extracted with EtOAc, dried (MgSO4) concentrated in vacuo and purified by chromatography [SiO2; heptane:EtOAc (4:1) then (2:1)] to give the title compound (62 mg, 39%) as a white solid.
    • Method E 7-Bromo-4-(2-furyl)-N-(2-hydroxyethyl)thieno[3,2-d]pyrimidine-2-amine (Example 15
  • A solution of 7-bromo-2-chloro-4-(2-furyl)thieno[3,2-d]pyrimidine (110 mg, 0.35 mmol) in 1-methyl-2-pyrrolidinone (1 mL) was treated with ethanolamine (32 μL, 0.52 mmol), heated at 90° C. for 16 h, cooled, poured into water, extracted with EtOAc, dried (MgSO4), concentrated in vacuo and purified by chromatography (SiO2: EtOAc: Heptane, 1:1) to give the title compound (45 mg, 38%) as a yellow solid.
    • Method F 4-(2-Furyl)thieno[3,2-d]pyrimidine-2-amine (Example 79)
  • A solution of N-(3,4-dimethoxybenzyl)-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine (199 mg, 0.54 mmol) in TFA (1 mL) was heated at 60° C. for 1 h, cooled, poured into sat. NaHCO3, extracted with EtOAc, dried (MgSO4), concentrated in vacuo and purified by chromatography (SiO2:EtOAc:Heptane, 1:1 and MeOH:DCM, 1:19) to give the title compound (108 mg, 92%) as a cream solid.
    • Method G N-(4-(2-Furyl)thieno[3,2-d]pyrimidin-2-yl)acetamide (Example 101)
  • An ice-cold solution of 4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine (130 mg, 0.6 mmol) in pyridine (1 mL) was treated with acetyl chloride (47 μL, 0.66 mmol), stirred at room temperature for 16 h, poured into water, extracted with EtOAc, dried (MgSO4) and concentrated in vacuo and purified by chromatography (SiO2:EtOAc:Heptane, 1:1) to give the title compound (125 mg, 80%) as a cream solid.
    • Method H N-(2-(4-(2-Thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)acetamide (Example 125)
  • A solution of N-(2-aminoethyl)-4-(2-thiazolyl))thieno[3,2-d]pyrimidine-2-amine (0.040 g, 0.14 mmol) in DMF (2 mL) was treated with triethylammonium methylpolystyrene carbonate (0.066 g, 0.22 mmol) followed by acetyl chloride (0.023 g, 0.29 mmol), shaken at room temperature for 7 h, treated with tris-(2-aminoethyl)amine polystyrene (0.19 g, 0.87 mmol), shaken at room temperature for 16 h, treated with polystyrene 4-benzyloxybenzaldehyde (0.19 g, 0.28 mmol), shaken for a further 3 h, filtered and concentrated in vacuo to give the title compound as a yellow solid.
    • Method I N-Ethyl-N′-(2-(4-(2-thiazolyl)thieno[3,2-d]pyrimidine-2-ylamino)ethyl)urea (Example 126)
  • A solution of N-(2-aminoethyl)-4-(2-thiazolyl))thieno[3,2-d]pyrimidine-2-amine (0.040 g, 0.14 mmol) in anhydrous DMF (2 mL) was treated with ethyl isocyanate (0.015 g, 0.22 mmol), shaken at 35° C. for 1 h, treated with tris-(2-aminoethyl)amine polystyrene (0.19 g, 0.88 mmol), shaken at 35° C. for 4 h, filtered and concentrated in vacuo to give the title compound as a yellow solid.
    • Method J 7-Amino-N,N-dimethyl-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine (Example 51)
  • A solution of N,N-dimethyl-4-(2-furyl)-7-nitrothieno[3,2-d]pyrimidine (85 mg, 0.29 mmol) in MeOH (4 mL), under argon, was treated with a catalytic amount of Pd on carbon (10%), hydrogenated at room temperature for 1 h, filtered through celite, concentrated in vacuo and purified by chromatography (SiO2:EtOAc:Heptane, 1:4) to give the title compound (62 mg, 82%) as a brown solid.
    • Method K 2-(4-(2-Furyl)thieno[3,2-d]pyrimidin-2-yl)ethanol (Example 54)
  • A solution of ethyl 4-(2-furyl)thieno[3,2-d]pyrimidine-2-acetate (0.10 g, 0.35 mmol) in dichloromethane (13 mL) at −75° C. was treated dropwise with di-iso-butylaluminium hydride (0.87 mL, 1.0-M), stirred for 17 h, warmed to ambient temperature and partitioned between Rochelle's salt and dichloromethane. The combined organic phase was dried (MgSO4), concentrated in vacuo and purified by chromatography (SiO2:EtOAc) to give the title compound (21 mg, 25%) as a white solid.
    • Method L 4-(2-Furyl)-2-vinylthieno[3,2-d]pyrimidine (Example 69)
  • A solution of 2-(4-(2-furyl)thieno[3,2-d]pyrimidin-2-yl)ethanol (0.15 g, 0.61 mmol) in THF (5 mL) at 0° C. was treated with diisopropylethylamine (0.095 g, 0.73 mmol) then methanesulfonyl chloride (0.72 g, 0.67 mmol), warmed to room temperature over 16 h, partitioned between ethyl acetate and water, the organic phase dried (MgSO4) and concentrated in vacuo to give the intermediate mesylate (0.10 g, 50%) as a white solid. A sample of this compound (59 mg, 0.18 mmol) was dissolved in CH2Cl2, treated with DBU (0.042 g, 0.27 mmol), stirred at room temperature for 18 h, partitioned between ethyl acetate and water and the organic phase was dried (MgSO4) and concentrated in vacuo to give the title compound (22 mg, 50%) as a white solid.
    • Method M 3-(4-(2-Furyl)thieno[3,2-d]pyrimidine-2-yl)propionic acid (Example 49)
  • A solution of ethyl 3-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-yl)propionate (0.07 g, 0.23 mmol) in THF (1.0 mL) and water (1.0 mL) was treated with lithium hydroxide (0.10 g, 2.32 mmol), stirred at room temperature for 16 h, concentrated in vacuo, dissolved in water, acidified to pH 2 by the addition of HCl (0.1 mL, 6.0-M), cooled in ice and filtered to give the title compound (0.052 g, 81%) as a white solid.
    • Method N 4-(2-Furyl)-2-(3-oxo-3-(1-pyrrolidinyl)propyl)thieno[3,2-d]pyrimidine (Example 50)
  • A mixture of trimethylaluminium in toluene (1.3 mL, 2.0-M) and pyrrolidine (0.22 mL, 2.65 mmol) in toluene was heated at 80° C. for 0.5 h, treated with a solution of ethyl 3-(4-(2-furyl)thieno[3,2-d]pyrimidine-2-yl)propionate (0.1 g, 0.33 mmol) in toluene (2.0 mL), stirred at 80° C. for 17 h, cooled to room temperature and partitioned between sat. aq. NH4Cl and ethyl acetate. The combined organic phase was dried MgSO4), concentrated in vacuo and purified by chromatography (SiO2:EtOAc-methanol, 9:1) to give the title compound (27 mg, 25%).
    • Method O 4-(2-Furyl)thieno[3,2-d]pyrimidine-2-carboxamide (Example 155)
  • Ammonia gas was bubbled through a hot solution of ethyl 4-(2-furyl)thieno[3,2-d]pyrimidine-2-carboxylate (0.156 g, 0.57 mmol) in ethanol (20 mL) for 3 h then the mixture cooled and the resulting white solid filtered to give the title compound (94 mg, 67%) as a white solid.
    • Method P 4,7-Bis(2-furyl)-N,N-dimethylthieno[3,2-d]pyrimidine-2-amine (Example 31)
  • A mixture of AsPh3 (73 mg, 0.24 mmol) in DMF (2 mL) was treated with Pd(OAc)4 (13 mg, 0.06 mmol), stirred at room temperature for 10 min, treated with 7-bromo-N,N-dimethyl-4-(2-furyl)thieno[3,2-d]pyrimidine-2-amine (194 mg, 0.6 mmol) and 2-(tributylstannyl)-furan (340 μL, 1.1 mmol), heated to 100° C. for 16 h, cooled, poured into water, extracted with EtOAc, dried (MgSO4), concentrated in vacuo and purified by chromatography (SiO2:EtOAc:Heptane, 1:9) to give the title compound (27 mg, 15%) as a orange solid.
    • Method Q 2-Isopropylthieno[3,2-d]pyrimidine-4-ol
  • A mixture of 3-aminothiophene-2-carboxamide (2.0 g, 14.1 mmol) and triethylamine (1.71 g, 16.9 mmol) in toluene (20 mL) at room temperature was treated with 2-methylpropionic anhydride (2.45 g, 15.5 mmol), refluxed for 4 h, cooled, poured into saturated NaHCO3 (100 mL) and extracted with ethyl acetate (4×50 mL). The combined organic phase was washed with brine(2×50 mL), dried (Na2SO4) and concentrated in vacuo to the intermediate N-acylated compound (2.90 g, 99%) as a pale yellow solid. A sample of this compound (2.85 g, 13.44 mmol) was dissolved in NaOH (34 mL, 1.0-M), refluxed for 1 h, cooled, acidified to pH 2 by addition of HCl (7.0 mL, 6.0-M), filtered and dried to give the title compound (2.30 g, 88%) as a white solid: IR νmax (Nujol)/cm−1 2956, 2925, 1676, 1599, 1464, 780; NMR δH (400 MHz, DMSO) 1.20 (6H, d J 6.5 Hz), 2.90 (1H, heptet, J 6.5 Hz), 7.40 (1H, d J 5.0 Hz), 8.15 (1H, d, J 5.0 Hz) and 12.30 (1H, br).
    • Method R 2-Cyclopropylthieno[3,2-d]pyrimidine-4-ol
  • Dry HCl gas was bubbled through a solution of methyl 3-aminothiophene-2-carboxylate (1.64 g, 10.4 mmol) and cyclopropanecarbonitrile (27 mL) in dioxane (40 mL) for 1 h then the reaction mixture was diluted with cold water (2 volumes), basified with NH4OH (50 mL) and the resulting solid filtered and air dried to give the title compound (1.44 g, 72%) as a white solid: IR νmax (Nujol)/cm−1 2925, 1664, 1597, 788; NMR δH (400 MHz, DMSO) 1.04 (4H, m), 2.00 (1H, m), 7.20 (1H, d J 5.0 Hz), 8.10 (1H, d, J 5.0 Hz) and 12.60 (1H, br).
    • Method S 4-Chloro-2-isopropylthieno[3,2-d]pyrimidine
  • A suspension of 2-isopropylthieno[3,2-d]pyrimidine-4-ol (1.66 g, 8.56 mmol) in POCl3 (30 mL) was refluxed for 1 h, cooled, diluted with chloroform (100 mL) and poured into a mixture of ice and NH4OH (150 mL). The organic phase was separated, washed with saturated NaHCO3 (20 mL), water and brine, dried (MgSO4) and concentrated in vacuo to give the title compound (2.01 g, 99%) as a pale yellow solid: IR νmax (Nujol)/cm−1 3065, 2960, 2926, 2855, 1561, 1513, 1457, 803; NMR δH (400 MHz, CDCl3) 1.40 (6H, d J 6.5 Hz), 3.38 (1H, heptet, J 6.5 Hz), 7.60 (1H, d J 5.0 Hz), 8.05 (1H, d, J 5.0 Hz).
    • Method T Ethyl 4-hydroxythieno[3,2-d]pyrimidine-2-carboxylate
  • A mixture of 3-aminothiophene-2-carboxamide (1.23 g, 8.65 mmol) and EtOH (25 mL) was treated with NaOEt (1.2 g, 17.3 mmol) and diethyloxalate (2.3 mL, 17.3 mmol), refluxed for 18 h, cooled, concentrated in vacuo, treated with water, acidified with HOAc and filtered to give the title compound (1.43 g, 74%) as a cream solid: IR vmax Nujol)/cm−1 3180, 3119, 3078, 3006, 2955, 2924, 2854, 1737, 1667, 1651, 1300 and 1176; NMR δH (400 MHz, DMSO) 1.37 (3H, t, J 7.0 Hz), 4.40 (2H, q, J 7.0 Hz), 7.58 (1H, d, J 5.0 Hz), 8.30 (1H, d, J 5.1 Hz), and 12.92 (1H, s).
  • TABLE 2
    Analytical data
    HPLC is carried out using the following conditions: Column. Supelcosil ABZ+ (170 × 4.6 mm),
    particle size 5 μM, mobile phase MeOH: 10 mM aq NH4OAc (80:20), (70:30) or
    (60:40) (specified in Table 2), flow rate 1.0 mL/min., detection wavelength λ = 230 nM
    (unless otherwise stated), retention times are provided in Table 2.
    Example Yield(%) Physical Data
    1 61 Mp 135.6-135.8° C.; IR νmax (Nujol)/cm−1 3111, 3082, 3072, 1529,
    1467, 1425, 1254, 1238 and 1205; NMR δH (400 MHz, CDCl3) 7.28 (1H,
    dd, J 5.0, 4.0 Hz), 7.54 (1H, d, J 5.5 Hz), 7.69 (1H, dd, J 5.0, 1.0 Hz),
    8.07 (1H, d, J 5.5 Hz), 8.08 (1H, dd, J 4.0, 1.0 Hz); Anal. Calcd for
    C10H5ClN2S2: C, 47.52; H, 1.99, N, 11.08. Found: C, 47.54; H, 2.00; N,
    10.93; M/Z 253 (M + H)+.
    2 98 mp 139.2-140.0° C.; IR νmax (Nujol)/cm−1 1551, 1517, 1466, 1393,
    1361, 793 and 707; NMR δH (400 MHz, CDCl3) 3.30 (6H, s), 7.22 (1H,
    dd, J 5.0, 4.0 Hz), 7.27 (1H, d, J 5.5 Hz), 7.54 (1H, dd, J 5.5, 1.0 Hz),
    7.79 (1H, d, J 5.5 Hz), 7.95 (1H, dd, J 3.5, 1.0 Hz); Anal. Calcd for
    C12H11N3S2: C, 55.15; H, 4.24, N, 16.07. Found: C, 55.05; H, 4.12; N,
    15.88.
    3 52 mp 146.9-147.6° C.; IR νmax (Nujol)/cm−1 3132, 3105, 3064, 1594,
    1522, 1463 and 1264; NMR δH (400 MHz, CDCl3) 6.69-6.72 (1H, m),
    5.50 (1H, d, J 5.5 Hz), 7.60 (1H, dd, J 3.5, 1.0 Hz), 7.80 (1H, d, J 1.0 Hz),
    8.10 (1H, d, J 5.5 Hz); Anal. Calcd for C10H5ClN2OS + 0.4 H2O: C,
    49.25; H, 2.40, N, 11.49. Found: C, 48.87; H, 2.04; N, 11.65.
    4 78 mp 128.5-128.9° C.; IR νmax (Nujol)/cm−1 3314, 3065, 1542, 1498, 1466
    and 1363; NMR δH (400 MHz, CDCl3) 1.71-1.81 (1H, m),
    1.88-2.08 (2H, m), 2.13-2.23 (1H, m), 3.68-3.79 (3H, m), 3.82-3.98 (2H, m),
    4.40 (1H, s), 7.21-7.27 (2H, m), 7.56 (1H, dd, J 5.0, 1.0 Hz), 7.83 (1H,
    d, J 5.5 Hz), 7.98 (1H, dd, J 4.0, 1.0 Hz); Anal. Calcd for C15H15N3OS2:
    C, 56.76; H, 4.76, N, 13.23. Found: C, 56.72; H, 4.80; N, 13.14.
    5 77 mp 129.3-130.4° C.; IR νmax (Nujol)/cm−1 3125, 3095, 3066, 1601,
    1554, 1462, 1403 and 792; NMR δH (400 MHz, CDCl3) 3.29 (6H, s),
    6.60-6.64 (1H, m), 7.23 (1H, d, J 5.5 Hz), 7.38 (1H, d, J 3.5 Hz),
    7.70-7.72 (1H, m), 7.80-7.84 (1H, d, J 5.5 Hz); Anal. Calcd for C12H11N3OS:
    C, 58.76; H, 4.52, N, 17.12. Found: C, 58.89; H, 4.52; N, 16.89.
    6 75 mp dec. >230° C.; IR νmax (Nujol)/cm−1 3426, 3160, 3075, 1616, 1573,
    1523 and 1447; NMR δH (400 MHz, DMSO) 2.13-2.22 (2H, m),
    3.45 (2H, t, J 6.5 Hz), 4.33 (2H, t, J 7.0 Hz), 4.49-4.87 (1H, s),
    7.36-7.39 (1H, m), 7.43-7.46 (1H, m), 7.69-7.72 (1H, m), 7.84-7.87 (1H, m),
    8.00 (1H, d, J 4.5 Hz), 8.04 (1H, d, J 4.0 Hz), 8.42 (1H, d, J 5.5 Hz),
    9.23 (1H, s); Anal. Calcd for C16H15N5S2 + 2HCl + 0.25 H2O: C, 44.44, H,
    4.43, N, 16.20. Found: C, 44.09; H, 4.34; N, 16.14.
    7 61 mp 110.6-111.8° C.; IR νmax (Nujol)/cm−1 3266, 1590, 1553, 1516, 1461
    and 791; NMR δH (400 MHz, CDCl3) 3.67-3.73 (2H, m),
    3.89-3.93 (2H, m), 3.93-4.08 (1H, s), 5.56 (1H, t, J 5.0 Hz), 7.21-7.25 (2H, m),
    7.56 (1H, dd, J 5.0, 1.0 Hz), 7.83 (1H, d, J 5.5 Hz), 7.97 (1H, dd, J 3.5,
    1.0 Hz); Anal. Calcd for C12H11N3OS2: C, 51.97, H, 4.00, N, 15.14.
    Found: C, 51.75; H, 3.96; N, 15.11.
    8 95 mp 114.6-115.1° C.; IR νmax (Nujol)/cm−1 3412, 3059, 1549, 1481,
    1464, 1341, 1327 and 725; NMR δH (400 MHz, CDCl3) 4.13 (3H, s),
    7.24-7.27 (1H, m), 7.42 (1H, d, J 5.5 Hz), 7.62 (1H, dd, J 5.0, 1.0 Hz),
    7.96 (1H, d, J 5.5 Hz), 8.04 (1H, dd, J 3.5, 1.0 Hz); Anal. Calcd for
    C11H8N2OS2: C, 53.21, H, 3.25, N, 11.28. Found: C, 53.21; H, 3.27; N,
    11.24.
    9 36 IR νmax (Nujol)/cm−1 3065, 2925, 2855, 1539, 1464, 1352, 716; NMR
    δH (400 MHz, CDCl3) 1.50 (3H, t J 7.5 Hz), 3.10 (2H, q, J 7.5 Hz),
    7.26 (1H, m), 7.54 (1H, d, J 5.5 Hz), 7.61 (1H, dd, J 1.0, 5.0 Hz), 7.96 (1H, d,
    J 5.5 Hz), 8.04 (1H, dd, J 1.0, 3.8 Hz).
    10 57 mp dec. >235° C.; IR νmax (Nujol)/cm−1 3417, 3105, 2623, 1654, 1633,
    1508 and 1466; NMR δH (400 MHz, DMSO) 2.13-2.22 (2H, m),
    3.49 (2H, t, J 6.5 Hz), 4.33 (2H, t, J 7.0 Hz), 4.02-4.66 (2H, s),
    6.88-6.90 (1H, m), 7.45 (1H, s), 7.51 (1H, s), 7.70 (1H, t, J 1.7 Hz), 7.85 (1H, t, J
    1.7 Hz), 8.23 (1H, s), 8.45 (1H, d, J 5.0 Hz), 9.22 (1H, s),
    14.59-14.87 (1H, s); Anal. Calcd for C16H15N5OS + 2HCl + 1.5 H2O: C, 45.18, H,
    4.74, N, 16.47, Cl, 16.67. Found: C, 45.40; H, 4.39; N, 16.59, Cl, 16.42.
    11 82 mp 147.6-148.8° C.;; IR νmax (Nujol)/cm−1 3141, 3112, 3074, 1594,
    1536, 1524, 1487, 1471, 1239, 1192, 1167, 1131 and 810; NMR δH (400 MHz,
    CDCl3) 6.71-6.73 (1H, m), 7.66 (1H, dd, J 3.5, 1.0 Hz), 7.69 (1H,
    d, J 5.5 Hz), 7.81-7.83 (1H, m), 8.19 (1H, d, J 5.5 Hz); Anal. Calcd for
    C11H5F3N2OS: C, 48.89, H, 1.86, N, 10.36. Found: C, 48.67; H, 1.92; N,
    10.25.
    12 78 mp 164.4-164.9° C.; IR νmax (Nujol)/cm−1 3153, 3121, 1596, 1498,
    1466, 1272 and 804; NMR δH (400 MHz, CDCl3) 2.51 (3H, s),
    6.68-6.70 (1H, m), 7.57 (1H, dd, J 3.5, 1.0 Hz), 7.72 (1H, dd, J 2.5, 1.0 Hz),
    7.78-7.79 (1H, m); Anal. Calcd for C11H7ClN2OS: C, 52.70, H, 2.82, N,
    11.17. Found: C, 52.91; H, 2.82; N, 11.05.
    13 34 mp dec. 213.9° C.; IR νmax (Nujol)/cm−1 3142, 3113, 3898, 3070, 1594,
    1515, 1460, 1271 and 765; NMR δH (400 MHz, DMSO) 6.90-6.93 (1H,
    m), 7.68 (1H, d, J 3.5 Hz), 8.27 (1H, s), 8.83 (1H, s); Anal. Calcd for
    C10H4BrClN2OS: C, 38.06, H, 1.28, N, 8.87. Found: C, 38.22; H, 1.38;
    N, 8.74.
    14 75 mp 107.9-108.9° C.; IR νmax (Nujol)/cm−1 3279, 1607, 1572, 1460,
    1377, 1067 and 791; NMR δH (400 MHz, CDCl3) 3.66-3.72 (2H, m),
    3.88-3.93 (2H, m), 4.33-4.60 (1H, s), 5.56 (1H, t, J 5.0 Hz),
    6.62-6.65 (1H, m), 7.21 (1H, d, J 5.5 Hz), 7.38 (1H, d, J 3.5 Hz), 7.73 (1H, s),
    7.88 (1H, d, J 5.5 Hz); Anal. Calcd for C12H11N3O2S: C, 55.16, H, 4.24,
    N, 16.07. Found: C, 55.16; H, 4.23; N, 15.97.
    15 38 mp 173.4-174.4° C.; IR νmax (Nujol)/cm−1 3394, 3260, 3110, 3083,
    1600, 1555, 1463 and 1439; NMR δH (400 MHz, CDCl3)
    3.70-3.72 (2H, m), 3.89-3.95 (2H, m), 4.47-4.67 (1H, s), 5.67-5.74 (1H, m),
    6.64-6.67 (1H, m), 7.40 (1H, d, J 3.5 Hz), 7.74 (1H, s), 7.87 (1H, s);
    Anal. Calcd for C12H10BrN3O2S + 0.25 H2O: C, 41.27; H, 3.18, N, 12.03.
    Found: C, 41.28; H, 3.04; N, 12.04.
    16 75 mp 149.9-150.6° C.; IR νmax (Nujol)/cm−1 3404, 3219, 1602, 1550,
    1507, 1464 and 1440; NMR δH (400 MHz, CDCl3) 2.38 (3H, s),
    3.67-3.73 (2H, m), 3.88-3.94 (2H, m), 5.13 (1H, s), 5.57 (1H, t, J 5.0 Hz),
    6.62-6.64 (1H, m), 7.37 (1H, dd, J 3.5, 1.0 Hz), 7.51 (1H, d, J 1.0 Hz),
    7.72-7.73 (1H, m); Anal. Calcd for C13H13N3O2S: C, 56.71; H, 4.76, N,
    15.25. Found: C, 56.67; H, 4.79; N, 15.19.
    17 64 mp 231.0-231.6° C.; IR νmax (Nujol)/cm−1 3109, 3094, 1531, 1469, 1232
    and 790; NMR δH (400 MHz, DMSO) 7.48-7.58 (2H, m), 7.72 (1H, d, J
    5.5 Hz), 8.10-8.17 (2H, m), 8.52 (1H, s), 8.75 (1H, d, J 5.5 Hz); Anal.
    Calcd for C14H7ClN2S2: C, 55.33; H, 2.33, N, 9.25. Found: C, 55.22; H,
    2.32; N, 9.41.
    18 56 IR νmax (Nujol)/cm−1 3096, 2924, 1595, 1528, 1488, 1463, 1303, 1016,
    808 and 768; NMR δH (400 MHz, DMSO) 1.36 (3H, t, J 7.7 Hz),
    3.00 (2H, q, J 7.7 Hz), 6.85 (1H, dd, J 1.8, 3.5 Hz), 7.54 (1H, dd, J 0.8, 3.5 Hz),
    7.58 (1H, d, J 5.5 Hz), 8.17 (1H, dd, J 0.8, 1.8 Hz), 8.49 (1H, d, J
    5.5 Hz).
    19 89 mp 166.5-167.3° C.; IR νmax (Nujol)/cm−1 3094, 3053, 1556, 1463,
    1407, 1354 and 793; NMR δH (400 MHz, CDCl3) 3.33 (6H, s), 7.29 (1H,
    d, J 5.5 Hz), 7.37-7.43 (2H, m), 7.82 (1H, d, J 5.5 Hz), 7.87-7.92 (2H,
    m), 8.16 (1H, s); Anal. Calcd for C16H13N3S2: C, 61.71; H, 4.21, N,
    13.49. Found: C, 61.82; H, 4.26; N, 13.52.
    20 64 mp 173.4-174.4° C.; IR νmax (Nujol)/cm−1 3409, 3260, 3126, 3094,
    1587, 1545 and 1339; NMR δH (400 MHz, CDCl3) 3.70-3.77 (2H, m),
    3.90-3.97 (2H, m), 5.60 (1H, t, J 5.0 Hz), 7.27 (1H, d, J 5.5 Hz),
    7.39-7.46 (2H, m), 7.86-7.93 (3H, m), 8.19 (1H, s); Anal. Calcd for
    C16H13N3OS2 + 0.25 H2O: C, 57.93; H, 4.10, N, 12.66. Found: C, 57.78;
    H, 3.96; N, 12.76.
    21 42 mp 112.3-122.7° C.; NMR δH (400 MHz, CDCl3) 1.30 (3H, t, J 7.3 Hz),
    3.54-3.62 (2H, m), 5.06 (1H, s), 7.26 (1H, d, J 5.5 Hz), 7.45-7.48 (1H,
    m), 7.81 (1H, d, J 5.5 Hz), 7.90 (1H, dd, J 5.0 Hz), 8.20-8.23 (1H, m);
    Anal. Calcd for C12H11N3S2: C, 55.15; H, 4.24, N, 16.07. Found: C,
    55.13; H, 4.29; N, 15.90.
    22 63 mp 118.7-119.5° C.; IR νmax (Nujol)/cm−1 3094, 1602, 1552, 1464 and
    1377; NMR δH (400 MHz, CDCl3) 3.33 (6H, s), 6.61-6.64 (1H, m),
    7.40 (1H, d, J 3.5 Hz), 7.71-7.72 (1H, m), 7.81 (1H, s); Anal. Calcd for
    C12H10BrN3OS: C, 44.46; H, 3.11, N, 12.96. Found: C, 44.24; H, 3.06; N,
    13.01.
    23 90 mp 113.1-113.7° C.; IR νmax (Nujol)/cm−1 3115, 1602, 1560, 1548,
    1508, 1466 and 1409; NMR δH (400 MHz, CDCl3) 2.38 (3H, s),
    3.31 (6H, s), 6.58-6.62 (1H, m), 7.36 (1H, d, J 3.5 Hz), 7.44-7.45 (1H, m),
    7.69-7.70 (1H, m); Anal. Calcd for C16H13N3OS + 0.15 H2O: C, 59.59;
    H, 5.12, N, 16.04. Found: C, 59.83; H, 2.89; N, 15.70.
    24 31 mp 209.2-209.5° C.; IR νmax (Nujol)/cm−1 1531, 1523, 1463, 1377, 1247
    and 781; NMR δH (400 MHz, CDCl3) 7.47 (1H, m), 7.54 (1H, d, J 6.0 Hz),
    7.95 (1H, dt, J 8.0, 2.0 Hz), 8.19 (1H, d, J 5.5 Hz), 8.73-8.77 (1H,
    m), 8.84-8.87 (1H, m); Anal. Calcd for C11H6ClN3S + 0.1 H2O: C,
    52.56; H, 2.45, N, 16.72. Found: C, 52.69; H, 2.41; N, 16.64.
    25 IR νmax (Nujol)/cm−1 2955, 2924, 2854, 1600, 1555, 1526, 1490, 1456,
    1378 and 1270; NMR δH (400 MHz, DMSO) 8.18 (1H, m) 7.97 (1H, s),
    7.35 (1H, m), 7.14 (1H, m), 6.67 (1H, m), 3.68-3.58 (4H, m),
    3.58-3.48 (4H, m).
    26 IR νmax (Nujol)/cm−1 3261, 2924, 2854, 1604, 1573, 1547, 1513, 1455,
    1443 and 1330; NMR δH (400 MHz, CDCl3) 7.86 (1H, d, J 5.5 Hz),
    7.72 (1H, s), 7.48-7.23 (7H, m), 6.62 (1H, dd, J 4.0, 1.5 Hz), 5.53 (1H, br s),
    4.76 (2H, d, J 5.9 Hz).
    27 13 mp 186.6-188.0° C.; IR νmax (Nujol)/cm−1 3053, 1556, 1466, 1359 and
    786; NMR δH (400 MHz, CDCl3) 3.37 (6H, s), 7.27-7.33 (1H, m),
    7.39-7.45 (1H, m), 7.86-7.95 (2H, m), 8.66 (1H, d, J 8.0 Hz),
    8.81-8.84 (1H, m).
    28 40 mp 197.1-197.7° C.; IR νmax (Nujol)/cm−1 3406, 3103, 3084, 1569, 1520
    and 1464; NMR δH (400 MHz, CDCl3) 6.49-6.50 (1H, m), 7.14 (1H, dt,
    J 3.0, 1.0 Hz), 7.20-7.23 (1H, m), 7.48 (1H, d, J 5.5 Hz), 8.01 (1H, d, J
    5.5 Hz), 9.88-10.01 (1H, s); Anal. Calcd for C10H6ClN3S: C, 50.96; H,
    2.57, N, 17.82. Found: C, 50.87; H, 2.54; N, 17.64.
    29 31 IR νmax (Nujol)/cm−1 2924, 2854, 1739, 1727, 1598, 1532, 1467, 1369,
    1348 and 1191; NMR δH (400 MHz, CDCl3) 8.05 (1H, m), 7.78 (1H, m),
    7.60 (1H, m), 7.49 (1H, m), 6.42 (1H, m), 4.20 (2H, q, J 7.0 Hz),
    4.18 (2H, s) and 1.22 (3H, t, J 7.0 Hz); M/Z 289 (M + H)+.
    30 67 mp 183.2-183.8° C.; IR νmax (Nujol)/cm−1 3071, 1536, 1522, 1465 and
    1252; NMR δH (400 MHz, CDCl3) 7.58 (1H, d, J 5.5 Hz), 8.23 (1H, d, J
    5.5 Hz), 8.79-8.83 (2H, m), 9.95 (1H, d, J 1.5 Hz); Anal. Calcd for
    C10H5ClN4S: C, 48.30; H, 2.03, N, 22.52. Found: C, 48.28; H, 2.10; N,
    22.40.
    31 15 IR νmax (Nujol)/cm−1 2726, 1561, 1509, 1461 and 1377; NMR δH (400 MHz,
    CDCl3) 3.35 (6H, s), 6.54-6.55 (1H, m), 6.62-6.64 (1H, m),
    7.41 (1H, dd, J 3.5, 1.0 Hz), 7.45 (1H, d, J 3.5 Hz), 7.48-7.49 (1H, m),
    7.72-7.73 (1H, m), 8.05 (1H, s); Anal. Calcd for C16H13N3O2S + 0.3
    H2O: C, 60.67; H, 4.33, N, 13.27. Found: C, 60.49; H, 4.09; N, 13.33.
    32 94 mp 247.4-248.6° C.; IR νmax (Nujol)/cm−1 3080, 3072, 1568, 1544, 1462
    and 1402; NMR δH (400 MHz, CDCl3) 3.29 (6H, s), 6.41-6.44 (1H, m),
    7.04-7.06 (1H, m), 7.09-7.12 (1H, m), 7.23 (1H, d, J 5.5 Hz),
    7.76 (1H, d, J 5.0 Hz), 9.74-9.83 (1H, s); Anal. Calcd for C12H12N4S + 0.2
    H2O: C, 58.14; H, 5.04, N, 22.60. Found: C, 58.16; H, 4.84; N, 22.64.
    33 100 mp 173.9-174.3° C.; IR νmax (Nujol)/cm−1 1586, 1558, 1531, 1462, 1352
    and 793; NMR δH (400 MHz, CDCl3) 3.36 (6H, s), 7.29 (1H, d, J 5.5 Hz),
    7.92 (1H, d, J 5.5 Hz), 8.70 (1H, d, J 2.5 Hz), 8.76-8.78 (1H, m),
    8.76-8.78 (1H, m), 9.87 (1H, d, J 1.5 Hz); Anal. Calcd for C12H11N5S + 0.1
    H2O: C, 55.62; H, 4.36, N, 27.03. Found: C, 55.46; H, 4.25; N, 26.83.
    34 55 mp 191.5-192.4° C.; IR νmax (Nujol)/cm−1 3298, 3082, 3060, 1589,
    1567, 1533, 1465, 1344, 1062 and 797; NMR δH (400 MHz, DMSO)
    3.47-3.56 (2H, m), 3.57-3.65 (2H, m), 4.73 (1H, s), 7.19 (1H, s),
    7.28 (1H, d, J 5.0 Hz), 8.31 (1H, d, J 5.5 Hz), 8.86 (1H, d, J 2.5 Hz),
    8.91 (1H, dd, J 2.5, 1.5 Hz), 9.72 (1H, s).
    35 IR νmax (Nujol)/cm−1 3140, 3089, 2925, 2854, 1601, 1552, 1527, 1519,
    1493, 1455 and 1265; NMR δH (400 MHz, CDCl3) 7.85 (1H, d, J 5.5 Hz),
    7.72 (1H, s), 7.38 (1H, m), 7.22 (1H, d, J 5.5 Hz), 6.65 (1H, m),
    4.05-3.91 (4H, m), 2.68-2.53 (4H, m), 2.41 (3H, s).
    36 IR νmax (Nujol)/cm−1 3107, 3080, 2963, 2927, 2865, 1596, 1525, 1484,
    1463, 1272 and 1236; NMR δH (400 MHz, CDCl3) 7.97 (1H, d, J 5.5 Hz),
    7.77 (1H, s), 7.48 (1H, m), 7.39 (1H, d, J 5.5 Hz), 6.67 (1H, m),
    4.13 (1H, sept, J 7.0 Hz), 1.52 (3H, J 7.0 Hz).
    37 95 mp 207-208° C.; IR νmax (Nujol)/cm−1 3073, 2956, 1592, 1513, 1462
    1263, 1012, 794 and 768; NMR δH (400 MHz, CDCl3) 1.47 (3H, t, J 7.5 Hz),
    3.28 (2H, q, J 7.5 Hz), 6.66 (1H, dd, J 3.5, 1.5 Hz), 7.49 (1H, d, J
    5.5 Hz), 7.74-7.79 (1H, m) and 7.97 (1H, d, J 5.5 Hz)
    38 75 mp 109-110° C.; IR νmax (Nujol)/cm−1 3314, 2927, 1598, 1551, 1379,
    1346, 1078, 795 and 744; NMR δH (400 MHz, CDCl3) 1.60-1.80 (2H,
    m), 1.86-2.07 (2H, m), 2.14-2.26 (1H, m), 3.64-3.99 (4H, m),
    4.38 (1H, m), 6.61-6.66 (2H, m), 7.22-7.28 (1H, m), 7.41 (1H, d, J 3.5 Hz),
    7.74 (1H, d, J 2.5 Hz) and 7.88 (1H, d, J 5.5 Hz)
    39 66 IR νmax (Nujol)/cm−1 3058, 22925, 1595, 1524, 1462, 1268 and 794;
    NMR δH (400 MHz, CDCl3) 2.69 (3H, s), 6.66 (1H, dd, J 4.0, 2.0 Hz),
    7.42 (1H, d, J 5.5 Hz), 7.51 (1H, d, J 3.5 Hz), 7.76 (1H, d, J 2.5 Hz) and
    7.98 (1H, d, J 5.5 Hz)
    40 73 mp 101-102° C.; IR νmax (Nujol)/cm−1 3255, 2925, 1610, 1550, 1515,
    1446, 1331, 907 and 793; NMR δH (400 MHz, CDCl3) 4.16-4.23 (2H,
    m), 5.16 (1H, dq, J 10.0, 1.5 Hz), 5.21-5.29 (1H, m); 5.32 (1H, dq, J
    17.0, 1.5 Hz), 5.97-6.09 (1H, m), 6.63 (1H, dd, J 3.5, 2.0 Hz), 7.25 (1H,
    d, J 5.5 Hz), 7.39 (1H, d, J 3.5 Hz), 7.73 (1H, dd, J 2.5, 1.0 Hz) and
    7.86 (1H, d, J 5.5 Hz)
    41 56 mp 220.5-221.0° C.; IR νmax (Nujol)/cm−1 3135, 3082, 3080, 1594,
    1544, 1519, 1505, 1463, 1341, 1265, 867, 782 and 750; NMR δH (400 MHz,
    DMSO) 6.94-6.96 (1H, m), 7.75 (1H, dd, J 3.5, 1.0 Hz),
    8.33 (1H, d, J 1.0 Hz), 9.79 (1H, s); Anal. Calcd for C10H4ClN5O3S2O: C,
    42.64; H, 1.43, N, 14.91. Found: C, 42.94; H, 1.81; N, 15.05.
    42 IR νmax (Nujol)/cm−1 3261, 2925, 2854, 1608, 1599, 1549, 1516, 1458,
    1377 and 1329. NMR δH (400 MHz, CDCl3) 7.86 (1H, d, J 5.5 Hz),
    7.72 (1H, s), 7.38 (1H, m), 7.25 (1H, d, J 5.5 Hz), 7.65 (1H, m), 5.16 (1H, br
    s), 5.59 (2H, q, J 8.5 Hz), 1.32 (3H, t, J 8.5 Hz).
    43 IR νmax (Nujol)/cm−1 2956, 2925, 2855, 1598, 1547, 1521, 1508, 1478,
    1458 and 1349; NMR δH (400 MHz, CDCl3) 7.80 (1H, m), 7.72 (1H, m),
    7.39 (1H, m), 7.22 (1H, m), 6.62 (1H, m), 3.68 (4H, m) and 2.02 (4H, m).
    44 21 mp 182.8-183.8° C.; IR νmax (Nujol)/cm−1 3152, 3128, 3107, 1601,
    1558, 1543, 1498, 1477, 1406, 1321, 765 and 756; NMR δH (400 MHz,
    CDCl3) 3.35 (6H, s), 6.65-6.67 (1H, m), 7.45 (1H, d, J 3.5 Hz),
    7.74-7.75 (1H, m), 8.88 (1H, s); Anal. Calcd for C12H10N4O3S: C, 49.65; H,
    3.47, N, 19.29. Found: C, 49.27; H, 3.49; N, 19.04.
    45 IR νmax (Nujol)/cm−1 3250, 3084, 2924, 2854, 1608, 1580, 1548, 1515,
    1485, 1443 and 1330; NMR δH (400 MHz, CDCl3) 8.59 (1H, m),
    7.88 (1H, m), 7.72 (1H, m), 7.66 (1H, m), 7.41-7.38 (1H, m), 7.25 (1H, m),
    7.18 (1H, m), 6.63 (1H, m), 6.21 (1H, br s) and 4.89 (2H, d, J 5.6 Hz).
    46 44 IR νmax (Nujol)/cm−1 3094, 2926, 2855, 1716, 1593, 1523, 1489, 1468,
    1421, 1332 and 1190; NMR δH (400 MHz, CDCl3) 8.00 (1H, m),
    7.78 (1H, m), 7.50 (2H, m), 6.62 (1H, m), 4.15 (2H, m), 3.40 (2H, m),
    2.95 (2H, m) and 1.20 (3H, t, J 7.0 Hz); M/Z 303 (M + H)+.
    47 IR νmax (Nujol)/cm−1 3417, 3103, 2974, 2944, 2859, 2820, 2776, 1599,
    1556, 1538, 1488, 1462, 1337 and 1256. NMR δH (400 MHz, CDCl3)
    7.84 (1H, d, J 5.5 Hz), 7.73 (1H, s), 7.38 (1H, m), 7.22 (1H, d, J 5.5 Hz),
    6.63 (1H, m), 5.64 (1H, br s), 3.60 (2H, q, J 6.0 Hz), 2.59 (2H, t, J 6.0 Hz),
    2.28 (6H, s).
    48 44 NMR δH (400 MHz, CDCl3) 8.01 (1H, m), 7.79 (1H, m), 7.50 (2H, m),
    6.80 (1H, m), 4.10 (1H, br m), 3.80 (2H, m), 3.30 (2H, m) and 2.18 (2H,
    m); Retention time 2.42 (80:20).
    49 81 IR νmax (Nujol)/cm−1 3079, 2923, 1745, 1729, 1698, 1594, 1531, 1466,
    1336, 809; NMR δH (400 MHz, DMSO) 2.84 (2H, t, J 7.0 Hz), 3.24 (2H,
    t, J 7.0 Hz), 6.86 (1H, dd, J 1.8, 3.5 Hz), 7.54 (1H, dd, J 0.8, 3.5 Hz),
    7.58 (1H, d, J 5.5 Hz), 8.17 (1H, dd, J 0.8, 1.8 Hz), 8.51 (1H, d, J 5.5 Hz),
    12.05 (1H, br).
    50 25 NMR δH (400 MHz, CDCl3) 1.85 (2H, m), 1.95 (2H, m), 2.95 (2H, t, J
    7.8 Hz), 3.50 (6H, m), 6.65 (1H, dd, J 1.7, 3.5 Hz), 7.48 (2H, m),
    7.76 (1H, m), 7.99 (1H, d, J 5.5 Hz).
    51 82 mp 145.8-146.5° C.; IR νmax (Nujol)/cm−1 3403, 3310, 3135, 1600,
    1551, 1517, 1463 and 750; NMR δH (400 MHz, CDCl3) 3.30 (6H, s),
    4.13 (2H, s), 6.59-6.61 (2H, m), 7.35 (1H, dd, J 3.5, 1.0 Hz),
    7.68-7.71 (1H, m); Anal. Calcd for C12H12N4OS + 0.3 H2O: C, 54.24; H, 4.78,
    N, 21.08. Found: C, 54.37; H, 4.51; N, 20.93.
    52 52 IR νmax (Nujol)/cm−1 3070, 2924, 2854, 1541, 1464, 1352, 779, 650;
    NMR δH (400 MHz, CDCl3) 1.50 (3H, t, J 7.50 Hz), 3.20 (2H, q, J 7.50 Hz),
    7.45 (1H, m), 7.53 (1H, d, J 5.6 Hz), 7.92 (1H, m), 8.07 (1H, d, J
    5.6 Hz), 8.79 (1H, m), 8.85 (1H, m).
    53 IR νmax (Nujol)/cm−1 2924, 2854, 1567, 1548, 1522, 1461, 1440, 1377
    and 1353; NMR δH (400 MHz, CDCl3) 7.80 (1H, d, J 5.5 Hz), 7.67 (1H,
    d, J 4.0 Hz), 7.26 (1H, d, J 5.5 Hz), 7.02 (1H, d, J 4.0 Hz), 3.28 (6H, s).
    54 25 NMR δH (400 MHz, CDCl3) 3.35 (2H, m), 4.12 (2H, m), 4.41 (1H, m),
    6.65 (1H, d, J 1.8, 3.5 Hz), 7.46 (2H, m), 7.78 (1H, d, J 0.8, 1.8 Hz),
    8.05 (1H, d, J 5.5 Hz).
    55 52 mp 244.4-244.9° C.; IR νmax (Nujol)/cm−1 3309, 3139, 1663, 1652,
    1602, 1557, 1510, 1490, 1470, 1465, 1446, 1377 and 743; NMR δH (400 MHz,
    CDCl3) 3.23 (6H, s), 6.61-6.63 (1H, m), 6.75 (1H, s),
    7.17-7.22 (1H, m), 7.34-7.46 (5H, m), 7.72 (1H, s), 7.93 (1H, s), 8.04 (1H, s).
    56 51 mp 210.9-211.3° C.; IR νmax (Nujol)/cm−1 3346, 3140, 1666, 1558,
    1541, 1462 and 1377; NMR δH (400 MHz, CDCl3) 2.29 (3H, s),
    3.31 (6H, s), 6.61-6.64 (1H, m), 7.39 (1H, d, J 3.5 Hz), 7.73 (1H, d, J 1.0 Hz),
    8.25 (1H, s), 8.30 (1H, s); Anal. Calcd for C14H14N4O2S: C, 55.62;
    H, 4.67, N, 18.52. Found: C, 55.46; H, 4.57; N, 18.27.
    57 47 mp 192.2-192.8° C.; IR νmax (Nujol)/cm−1 3409, 3133, 3110, 1665, 1603,
    1550, 1526, 1463, 1376 and 1261; NMR δH (400 MHz, CDCl3) 3.33 (6H,
    s), 6.62-6.64 (1H, m), 7.40 (1H, dd, J 3.5, 1.0 Hz), 7.51-7.62 (3H, m),
    7.73-7.74 (1H, m), 7.96-8.01 (2H, m), 8.45 (1H, s), 9.10 (1H, s);
    Anal. Calcd for C19H16N4O2S + 0.75 H2O: C, 60.38; H, 4.67, N, 14.82.
    Found: C, 60.47; H, 4.63; N, 14.72.
    58 65 mp 183.8-184.3° C.; IR νmax (Nujol)/cm−1 3269, 3134, 3069, 1613, 1583,
    1551, 1520, 1449 and 794; NMR δH (400 MHz, CDCl3) 3.10 (3H, d, J
    5.0 Hz), 5.09-5.10 (1H, s), 6.62-6.64 (1H, m), 7.26 (1H, d, J 4.5 Hz),
    7.38 (1H, dd, J 3.5, 1.0 Hz), 7.71-7.73 (1H, m), 7.85 (1H, d, J 5.5 Hz);
    Anal. Calcd for C11H9N3OS + 0.3 H2O: C, 55.82; H, 4.09, N, 17.75.
    Found: C, 55.85; H, 3.94; N, 17.68.
    59 6 mp 211.9° C.; NMR δH (400 MHz, CDCl3) 3.09 (3H, s), 6.72-6.74 (1H,
    m), 7.40 (1H, s), 7.63 (1H, d, J 3.5 Hz), 7.83 (1H, d, J 1.0 Hz), 7.90 (1H,
    s); M/Z 330 (M + H)+.
    60 32 mp 108.3-108.6° C.; IR νmax (Nujol)/cm−1 3104, 3073, 1702, 1667,
    1598, 1545, 1467, 1373, 804 and 744; NMR δH (400 MHz, CDCl3)
    2.31 (3H, s), 3.66 (3H, s), 3.96 (2H, s), 6.68-6.70 (1H, m), 7.42 (1H, d, J 5.5 Hz),
    7.47 (1H, d, J 3.5 Hz), 7.87 (1H, d, J 1.0 Hz), 8.07 (1H, d, J 5.5 Hz);
    Anal. Calcd for C15H13N3O3S + 0.2 H2O: C, 56.49; H, 4.23, N, 13.17.
    Found: C, 56.63; H, 4.14; N, 13.09; M/Z 316 (M + H)+.
    61 23 NMR δH (400 MHz, CDCl3) 3.69 (2H, q, J 5.5 Hz), 3.90 (2H, t, J 4.5 Hz),
    5.47-5.58 (1H, m), 7.03 (1H, d, J 4.0 Hz), 7.24 (1H, d, J 5.5 Hz),
    7.71 (1H, d, J 4.0 Hz) and 7.84 (1H, d, J 5.5 Hz); Retention time (80/20):
    5.12min
    62 82 IR νmax (Nujol)/cm−1 2925, 2855, 1541, 1406, 1362, 783; NMR δH (400 MHz,
    CDCl3) 2.93 (3H, s), 7.45 (1H, m), 7.51 (1H, d, J 5.6 Hz),
    7.92 (1H, m), 8.07 (1H, d, J 5.6 Hz), 8.76 (1H, m), 8.85 (1H, m).
    63 83 IR νmax (Nujol)/cm−1 3048, 2926, 2855, 1541, 1468, 1335, 790; NMR
    δH (400 MHz, CDCl3) 1.05 (3H, t, J 7.5 Hz), 2.00 (2H, sextet, J 7.5 Hz),
    3.10 (2H, m), 7.45 (1H, m), 7.51 (1H, d, J 5.6 Hz), 7.92 (1H, m),
    8.07 (1H, d, J 5.6 Hz), 8.76 (1H, m), 8.85 (1H, m).
    64 26 IR νmax (Nujol)/cm−1 3418, 3096, 2924, 1516, 1460, 1377, 1228, 827 and
    795; NMR δH (400 MHz, CDCl3) 7.55 (1H, d, J 6.0 Hz), 7.69 (1H, d, J
    3.0 Hz), 8.18 (1H, d, J 3.0 Hz) and 8.20 (1H, d, J 5.5 Hz)
    65 62 mp 152-153° C.; IR νmax (Nujol)/cm−1 3056, 2925, 1566, 1532, 1464,
    1354, 1132 and 792; NMR δH (400 MHz, CDCl3) 3.32 (6H, s), 7.26 (1H,
    d, J 5.5 Hz), 7.54 (1H, d, J, 3.0 Hz), 7.91 (1H, d, J 5.5 Hz) and 8.10 (1H,
    d, J 3.0 Hz)
    66 10 IR νmax (Nujol)/cm−1 3057, 2956, 2855, 1530, 1467, 1450; NMR δH (400 MHz,
    CDCl3) 7.45 (1H, m), 7.51 (1H, d, J 5.6 Hz), 7.92 (1H, m),
    8.07 (1H, d, J 5.6 Hz), 8.76 (1H, m), 8.85 (1H, m), 9.28 (1H, s).
    67 IR νmax (Nujol)/cm−1 3288, 2956, 2925, 2554, 1597, 1584, 1557, 1523,
    1459, 1427 and 1333. NMR δH (400 MHz, CDCl3) 8.82 (1H, d, J 5.0 Hz),
    8.57 (1H, d, J 8.0 Hz), 7.95 (1H, d, J 5.0 Hz), 7.92-7.82 (1H, m),
    7.44 (7.40 (1H, m), 7.29-7.22 (1H, m), 5.60 (1H, br s), 4.10 (1H, br s),
    3.95-3.92 (2H, m), 3.77-3.75 (2H, m).
    68 87 mp 140-142° C.; IR νmax (Nujol)/cm−1 3435, 2924, 1572, 1528, 1462,
    1320, 1086, 793, 702 and 600; NMR δH (400 MHz, CDCl3) 3.73 (2H, m),
    3.93 (2H, t, J 5.0 Hz), 5.53-5.66 (1H, m), 7.24 (1H, d, J 5.5 Hz),
    7.96 (1H, d, J 5.5 Hz) and 8.12 (1H, d, 3.0 Hz)
    69 50 NMR δH (400 MHz, CDCl3) 5.78 (1H, dd, J 1.8, 10.5 Hz), 6.68 (1H, dd,
    J 1.7, 3.5 Hz), 6.75 (1H, dd, J 1.8, 17.3 Hz), 7.05 (1H, dd, J 10.5, 17.3 Hz),
    7.53 (1H, d, J 5.5 Hz), 7.55 (1H, dd, J 3.5, 5.5 Hz), 7.78 (1H, dd, J
    0.8, 1.7 Hz), 8.01 (1H, d, J 5.5 Hz).
    70 16 IR νmax (Nujol)/cm−1 3072, 2923, 1696, 1540, 1464, 788; NMR δH (400 MHz,
    CDCl3) 1.50 (6H, d, J 6.9 Hz), 3.44 (1H, heptet, J 6.9 Hz),
    7.44 (1H, ddd, J 1.3, 4.9, 7.5 Hz), 7.54 (1H, d, J 5.5 Hz), 7.93 (1H, dt, J 1.3,
    7.5 Hz), 8.06 (1H, d, J 5.5 Hz), 8.81 (1H, m), 8.85 (1H, m).
    71 13 mp 65.0-65.4° C.; IR νmax (Nujol)/cm−1 3326, 3090, 1598, 1558, 1488,
    1466, 1330 and 1088; NMR δH (400 MHz, CDCl3) 3.41 (3H, s),
    3.63 (2H, t, J 5.5 Hz), 3.79 (2H, q, J 5.5 Hz), 5.61 (1H, t, J 5.0 Hz),
    6.63-6.65 (1H, m), 7.38 (1H, d, J 3.0 Hz), 7.72-7.73 (1H, m), 7.84 (1H, s);
    Anal. Calcd for C13H12N3BrO2S: C, 44.08; H, 3.41, N, 11.86. Found: C,
    43.89; H, 3.48; N, 11.77.
    72 42 mp 75.4-76.3° C.; IR νmax (Nujol)/cm−1 3288, 3098, 1597, 1548, 1516,
    1462, 1376, 1341 and 767; NMR δH (400 MHz, CDCl3) 1.68-1.80 (1H,
    m), 1.83-2.08 (2H, m), 2.17-2.28 (1H, m), 3.65-3.81 (2H, m),
    3.82-3.90 (1H, m), 3.97-4.07 (1H, m), 4.34-4.43 (1H, m), 6.63-6.65 (1H,
    m), 7.42 (1H, d, J 1.0 Hz), 7.73-7.74 (1H, m), 7.85 (1H, s).
    73 68 IR νmax (Nujol)/cm−1 3061, 2925, 2854, 1727, 1595, 1523, 1484, 1467,
    1377 and 1230; NMR δH (400 MHz, CDCl3) 8.15 (1H, m), 7.82 (1H, m),
    7.74 (1H, m), 7.70 (1H, m), 6.70 (1H, m), 4.60 (2H, q, J 7.0 Hz), and
    1.50 (3H, t, J 7.0 Hz).
    74 47 NMR δH (400 MHz, CDCl3) 1.43 (9H, s), 3.42 (2H, q, J 5.5 Hz),
    3.65 (2H, q, J 5.5 Hz), 5.34 (1H, t, J 5.5 Hz), 6.63 (1H, dd, J 2.0, 3.5 Hz),
    7.20 (1H, d, J 5.5 Hz), 7.39 (1H, d, J 3.5 Hz), 7.72 (1H, dd, J 1.0, 1.5 Hz) and
    7.85 (1H, d, J 5.5 Hz); Retention time 3.26min (8:2)
    75 67 NMR δH (400 MHz, CDCl3) 1.40 (2H, br s), 2.99 (2H, t, J 6.0 Hz),
    3.60 (2H, q, J 6.0 Hz), 5.40 (1H, t, J 5.5 Hz), 6.63 (1H, dd, J 2.0, 3.5 Hz),
    7.22 (1H, d, J 5.5 Hz), 7.37 (1H, d, J 3.5 Hz), 7.72 (1H, dd, J 1.0, 2.0 Hz) and
    7.84 (1H, d, J 5.5 Hz); Retention time 2.65min (7:3)
    76 49 mp 112-113° C.; IR νmax (Nujol)/cm−1 3089, 2925, 1561, 1352, 1136 and
    794; NMR δH (400 MHz, CDCl3) 2.60 (3H, s), 3.31 (6H, s), 7.09 (1H, s),
    7.24 (1H, d, J 5.5 Hz) and 7.90 (1H, d, J 5.5 Hz)
    77 5 NMR δH (400 MHz, CDCl3) 3.61 (2H, q, J 6.0 Hz), 3.75 (2H, q, J 6.0 Hz),
    5.56 (1H, t, J 6.0 Hz), 6.65 (1H, dd, J 1.5, 3.5 Hz), 7.21 (1H, d, J 5.5 Hz),
    7.39 (1H, d, J 3.5 Hz) 7.75 (1H, dd, J 1.0, 2.0 Hz), 7.92 (1H, d, J 5.5 Hz)
    and 9.31 (1H, br s); Retention time 2.89min (80:20)
    78 51 mp 155-156° C.; NMR δH (400 MHz, CDCl3) 3.86 (3H, s), 3.87 (3H, s),
    4.68 (2H, d, J 5.5 Hz), 5.40 (1H, t, J 5.5 Hz), 6.62-6.64 (1H, m),
    6.82 (1H, d, J 8.0 Hz), 6.94-6.99 (2H, m), 7.24 (1H, d, J 5.5 Hz), 7.37 (1H,
    dd, J 3.5, 1.0 Hz), 7.72-7.73 (1H, m), 7.86 (1H, d, J 5.5 Hz); Anal.
    Calcd for C19H17N3O3S: C, 62.11; H, 4.66, N, 11.43. Found: C, 62.19; H,
    4.67; N, 11.44.
    79 92 mp 169.6-169.9° C.; NMR δH (400 MHz, CDCl3) 5.02 (2H, s),
    6.63-6.66 (1H, m), 7.22 (1H, d, J 5.5 Hz), 7.39 (1H, dd, J 3.5, 1.0 Hz),
    7.22-7.74 (1H, m), 7.89 (1H, d, J 5.5 Hz); Anal. Calcd for C10H7N3OS + 0.2
    H2O: C, 54.38; H, 3.38, N, 19.03. Found: C, 54.69; H, 3.35; N, 18.74.
    80 45 IR νmax (Nujol)/cm−1 2925, 2855, 1545, 1464, 1356; NMR δH (400 MHz,
    CDCl3) 1.45 (3H, t, J 7.5 Hz), 2.61 (3H, s), 3.15 (2H, q, J 7.5 Hz),
    7.15 (1H, s), 7.50 (1H, d, J 5.5 Hz), 8.02 (1H, d, J 5.5 Hz).
    81 20 NMR δH (400 MHz, CDCl3) 8.08 (1H, m), 7.80 (1H, m), 7.55 (2H, m),
    6.70 (1H, m), 4.90 (2H, s) and 3.80 (1H, br m); Retention time
    3.06 (80:20).
    82 37 IR νmax (Nujol)/cm−1 3050, 2925, 2855, 1543, 1526, 1460, 1356; NMR
    δH (400 MHz, CDCl3) 1.45 (3H, t, J 7.5 Hz), 3.18 (2H, q, J 7.5 Hz),
    7.54 (1H, d, J 7.5 Hz), 7.61 (1H, d, J 3.1 Hz), 8.09 (1H, d, J 7.5 Hz),
    8.15 (1H, d, J 3.1 Hz).
    83 IR νmax (Nujol)/cm−1 3287, 3089, 2924, 2854, 1633, 1603, 1548, 1516,
    1486, 1462, 1377 and 1331; NMR δH (400 MHz, CDCl3) 1.93 (3H, s),
    3.54 (2H, q, J 5.5 Hz), 3.69 (2H, q, J 5.5 Hz), 5.43 (1H, t, J 6.0 Hz),
    6.65 (1H, dd, J 1.5, 3.5 Hz), 6.76 (1H, br s), 7.22 (1H, d, J 5.5 Hz), 7.39 (1H,
    dd, J 1.0, 3.5 Hz), 7.73 (1H, dd, J 1.0, 1.5 Hz) and 7.89 (1H, d, J 5.5 Hz);
    Retention time 3.08min (70:30).
    84 IR νmax (Nujol)/cm−1 3317, 3265, 2924, 2854, 1635, 1613, 1580, 1558,
    1514, 1463, 1377 and 1335; NMR δH (400 MHz, CDCl3), 0.90 (6H, d, J
    5.5 Hz), 2.01 (2H, m), 2.07 (1H, m), 3.56 (2H, q, J 5.5 Hz), 3.68 (2H, q,
    J 5.5 Hz), 5.49 (1H, t, J 6.0 Hz), 6.65 (1H, dd, J 1.5, 3.5 Hz), 7.21 (1H, d,
    J 5.5 Hz), 7.39 (1H, dd, J 1.0, 3.5 Hz), 7.73 (1H, dd, J 1.0, 1.5 Hz) and
    7.89 (1H, d, J 5.5 Hz); Retention time 4.43min (70:30).
    85 IR νmax (Nujol)/cm−1 3318, 3083, 2974, 2871, 1644, 1600 1549, 1488,
    1461 and 1337; NMR δH (400 MHz, CDCl3) 3.75 (2H, q, J 5.5 Hz),
    3.83 (2H, q, J 5.5 Hz), 5.68 (1H, t, J 5.0 Hz), 6.62 (1H, dd, J 1.5, 3.5 Hz),
    7.21 (1H, d, J 5.5 Hz), 7.29 (2H, m), 7.38 (2H, m), 7.71 (3H, m), 7.87 (1H, m)
    and 7.90 (1H, d, J 5.5 Hz); Retention time 5.05min (70:30).
    86 IR νmax (Nujol)/cm−1 3267, 3108, 2925, 2854, 1641, 1611, 1548, 1517,
    1485, 1464, 1422 and 1334; NMR δH (400 MHz, CDCl3) 3.71 (2H, q, J
    5.5 Hz), 3.81 (2H, q, J 5.5 Hz), 5.65 (1H, t, J 6.0 Hz), 6.63 (1H, dd, J 1.5,
    3.5 Hz), 6.92 (1H, m), 7.24 (1H, d, J 5.5 Hz), 7.37 (3H, m), 7.56 (1H, br
    s), 7.72 (1H, dd, J 1.0, 1.5 Hz) and 7.89 (1H, d, J 5.5 Hz); Retention time
    4.79min. (70:30).
    87 NMR δH (400 MHz, CDCl3) 3.52 (2H, m), 3.64 (3H, s), 3.79 (2H, m),
    5.53 (1H, br s), 6.73 (1H, dd, J 1.5, 3.5 Hz), 7.34 (1H, d, J 5.5 Hz),
    7.65 (1H, m), 7.83 (1H, m) and 8.02 (1H, d, J 5.5 Hz); Retention time
    3.46min. (70:30).
    88 NMR δH (400 MHz, CDCl3) 0.87 (6H, d, J 6.4 Hz), 1.83 (2H, m),
    3.52 (2M, q, J 5.5 Hz), 3.73 (2H, m), 3.85 (2H, m), 5.50 (1H, br s) 6.71 (1H,
    dd, J 1.5, 3.5 Hz), 7.32 (1H, d, J 5.5 Hz), 7.61 (1H, m), 7.81 (1H, m) and
    7.96 (1H, d, J 5.5 Hz); Retention time 5.69min. (70:30).
    89 99 NMR δH (400 MHz, CDCl3) 3.55 (2H, q, J 5.8 Hz), 3.78 (2H, q, J 5.8 Hz),
    5.07 (2H, s), 5.55 (1H, m), 6.73 (1H, dd, J 1.5, 3.5 Hz), 7.29 (5H,
    m), 7.40 (1H, d, J 5.5 Hz), 7.76 (1H, m), 7.85 (1H, m), 8.11 (1H, d, J 5.5 Hz)
    and 10.05 (1H, br s); Retention time 6.16min (70:30)
    90 NMR δH (400 MHz, CDCl3) 3.01 (1H, t, J 5.8 Hz), 3.60 (2H, q, J 5.5 Hz),
    4.04 (2H, d, J 5.8 Hz), 4.11 (2H, q, J 5.5 Hz), 5.46 (1H, m),
    6.61 (1H, dd, J 1.5, 3.5 Hz), 7.31 (1H, d, J 5.5 Hz), 7.33-7.45 (4H, m),
    7.71-7.79 (4H, m) and 7.82 (1H, d, J 5.5 Hz); Retention time
    17.2min (70:30).
    91 NMR δH (400 MHz, DMSO) 3.27 (2H, m), 3.42 (2H, m), 3.63 (2H, m),
    5.01 (1H, m), 5.08 (1H, m), 5.77 (1H, m), 6.10 (1H, br s), 6.85 (1H, dd, J
    1.5, 3.5 Hz), 7.29 (1H, d, J 5.5 Hz), 7.48 (2H, m), 8.17 (1H, m) and
    8.35 (1H, d, J 5.5 Hz); Retention time 3.39min. (70:30).
    92 99 NMR δH (400 MHz, DMSO) 3.30 (2H, t, J 6.0 Hz), 3.45 (2H, t, J 6.0 Hz),
    4.23 (2H, s), 6.46 (1H, br s), 6.85 (1H, dd, J 2.0, 3.5 Hz),
    7.18-7.33 (7H, m), 7.49 (2H, m), 8.17 (1H, m) and 8.36 (1H, d, J 5.5 Hz);
    Retention time 4.61min (7:3)
    93 NMR δH (400 MHz, DMSO) 1.02-1.25 (5H, m), 1.51-1.78 (5H, m),
    3.26 (2H, m), 3.34 (1H, m), 3.43 (2H, m), 5.75 (1H, br s), 6.78 (1H, br s),
    6.87 (1H, dd, J 1.5, 3.5 Hz), 7.34 (1H, d, J 5.5 Hz), 7.49 (1H, m),
    7.96 (1H, br s), 8.15 (1H, m) and 8.36 (1H, d, J 5.5 Hz); Retention time
    5.30min, (70:30).
    94 NMR δH (400 MHz, DMSO) 3.35 (2H, m), 3.44 (2H, m), 6.30 (1H, t, J
    6.0 Hz), 6.79 (1H, dd, J 1.5, 3.5 Hz), 7.17-7.31 (5H, m),
    7.36-7.47 (3H, m), 8.10 (1H, m), 5.27 (1H, d, J 5.5 Hz) and 8.52 (1H, m);
    Retention time 5.46min, (70:30).
    95 NMR δH (400 MHz, DMSO) 3.35 (2H, q, J 5.8 Hz), 3.46 (2H, q, J 5.8 Hz),
    6.35 (1H, t, J 6.0 Hz), 6.80 (1H, dd, J 1.5, 3.5 Hz), 7.19 (1H, m),
    7.25 (3H, m), 7.41 (3H, m), 8.10 (1H, dd, J 1.0, 1.5 Hz), 8.28 (1H, d, J
    5.5 Hz) and 8.70 (1H, m); Retention time 9.61min. (70:30).
    96 NMR δH (400 MHz, CDCl3) 3.56 (2H, q, J 5.8 Hz), 3.78 (2H, m),
    5.07 (2H, s), 5.55 (1H, br s), 6.73 (1H, dd, J 1.5, 3.5 Hz), 7.29-7.36 (5H, m),
    7.39 (1H, d, J 5.5 Hz), 7.76 (1H, m), 7.85 (1H, m) 8.11 (1H, d, J 5.5 Hz)
    and 10.07 (1H, br s); Retention time 6.16min (70:30).
    97 NMR δH (400 MHz, DMSO) 3.58 (2H, m), 3.76 (2H, m), 6.80 (1H, dd, J
    1.5, 3.5 Hz), 7.22 (1H, d, J 5.5 Hz), 7.35 (4H, m), 7.42 (3H, m),
    7.96 (1H, m) 8.11 (1H, m), 8.27 (1H, d, J 5.5 Hz) and 9.68 (1H, br s);
    Retention time 8.41min, (70:30).
    98 NMR δH (400 MHz, DMSO) 2.93 (3H, s), 3.21 (2H, m), 3.64 (2H, m),
    6.86 (1H, dd, J 1.5, 3.5 Hz), 7.18 (1H, m), 7.32 (1H, m), 7.52 (1H, m),
    7.86 (1H, m), 8.17 (1H, m) and 8.37 (1H, m); Retention time
    2.93min (70:30).
    99 NMR δH (400 MHz, CDCl3) 1.21 (9H, s), 3.28 (2H, q, J 5.8 Hz),
    3.61 (2H, q, J 5.9 Hz), 5.41 (1H, t, J 6.0 Hz), 6.58 (1H, t, J 6.0 Hz) 6.65 (1H,
    dd, J 1.5, 3.5 Hz), 7.23 (1H, d, J 5.5 Hz), 7.40 (3H, m), 7.69 (2H, d, J 6.4 Hz),
    7.74 (1H, m) and 7.87 (1H, d, J 5.5 Hz); Retention time 10.30min
    100 35 NMR δH (400 MHz, CDCl3) 8.88 (1H, m), 8.70 (1H, m), 8.08 (1H, m),
    7.88 (1H, m), 7.82 (1H, m), 7.78 (1H, m), 7.64 (2H, m) and 6.30 (1H,
    m); Retention time 3.52 (80:20).
    101 80 mp 193.9-195.0° C.; IR νmax (Nujol)/cm−1 3246, 3149, 3080, 3064,
    1683, 1664, 1599, 1547, 1497, 1315 and 1298; NMR δH (400 MHz,
    DMSO) 2.26 (3H, s), 6.86-6.88 (1H, m), 7.51 (1H, d, J 3.0 Hz),
    7.48 (1H, d, J 5.5 Hz), 8.20 (1H, s), 8.51 (1H, d, J 5.5 Hz), 10.58 (1H, s);
    Anal. Calcd for C12H9N3O2S + 0.5 H2O: C, 53.72; H, 3.76, N, 15.66.
    Found: C, 53.81; H, 3.44; N, 15.41.
    102 Mp 243-244° C., IR νmax (Nujol)/cm−1 2955, 2924, 2854, 1543, 1526,
    1574, 1468, 1435, 1358 and 1236. NMR δH (400 MHz, CDCl3) 8.18 (1H,
    d, J 5.5 Hz), 7.82 (1H, s), 7.53 (1H, d, J 5.5 Hz), 2.63 (3H, s).
    103 Mp 240-241° C., IR νmax (Nujol)/cm−1 2955, 2925, 2854, 1537, 1516,
    1481, 1460, 1359 and 1230. NMR δH (400 MHz, CDCl3) 8.15 (1H, d, J
    5.5 Hz), 7.51 (1H, d, J 5.5 Hz), 2.50 (6H, s).
    104 71 mp 208-211° C.; IR νmax (Nujol)/cm−1 2855, 1567, 1520, 1358, 1101, 817
    and 794; NMR δH (400 MHz, CDCl3) 2.57 (3H, d, J 1.0 Hz), 3.30 (6H,
    s), 7.24 (1H, d, J 5.5 Hz), 7.74 (1H, d, J 1.5 Hz) and 7.89 (1H, d, J 5.5 Hz)
    105 99 Mp 148-149° C.; IR νmax (Nujol)/cm−1 2854, 1564, 1356, 1236 and 7932;
    NMR δH (400 MHz, CDCl3) 2.45 (3H, s), 2.47 (3H, s), 3.30 (6H, s),
    7.23 (1H, d, J 5.5 Hz) and 7.87 (1H, d, J 5.5 Hz)
    106 Mp 170-170.5° C.; IR νmax (Nujol)/cm−1 3061, 2955, 2925, 2854, 1545,
    1519, 1480, 1465, and 1377. NMR δH (400 MHz, CDCl3) 8.09 (1H, d, J
    5.5 Hz), 7.88 (2H, d, J 7.0 Hz), 7.71 (1H, s), 7.57 (1H, d, J 5.5 Hz),
    7.50 (2H, t, J 7.5 Hz), 7.42 (1H, t, J 7.5 Hz), 3.25 (2H, q, J 7.5 Hz), 1.53 (3H,
    t, J 7.5 Hz).
    107 Mp 258-258.5° C.; IR νmax (Nujol)/cm−1 3136, 3073, 2955, 2924, 2854,
    1573, 1559, 1514, 1475, 1408, 1335 and 1251. NMR δH (400 MHz,
    CDCl3) 10.43 (1H, br s), 7.91 (1H, d, J 5.5 Hz), 7.43 (1H, s),
    7.25-7.21 (2H, m), 3.30 (6H, s)
    108 80 Mp 178.7-179.5° C.; IR νmax (Nujol)/cm−1 3245, 2924, 2845, 1600,
    1554, 1530, 1515, 1467, 1344, 1321, 1251 and 1232, NMR δH (400 MHz,
    CDCl3) 8.11 (1H, d, J 3.2 Hz), 7.97 (1H, m), 7.55 (1H, d, J 3.2 Hz),
    7.25 (1H, s), 7.00 (1H, s), 6.98 (1H, m), 6.84 (1H, m), 5.46 (1H, t, J
    5.6 Hz), 4.70 (2H, d, J 6.0 Hz), 3.87 (3H, s) and 3.87 (3H, s); Anal
    Calcd. for C18H16N4O2S2: C, 56.23; H, 4.19; N, 14.57. Found: C, 56.23;
    H, 4.11; N 14.41.
    109 Mp 221-222° C.; IR νmax (Nujol)/cm−1 3083, 2925, 2854, 1528, 1519,
    1461, 1377, 1303, 1241 and 1161. NMR δH (400 MHz, CDCl3)
    8.68 (1H, s), 8.63 (1H, d, J 8.0 Hz), 8.17 (1H, d, J 5.5 Hz), 7.74 (1H, d, J 8.0 Hz),
    7.52 (1H, d, J 5.5 Hz), 2.48 (3H, s).
    110 63 mp 190.1-190.7° C.; IR νmax (Nujol)/cm−1 3464, 3296, 3165, 3122,
    3038, 1635, 1555, 1541, 1481 and 1360; NMR δH (400 MHz, CDCl3)
    5.10 (2H, s), 7.24 (1H, d, J 5.5 Hz), 7.58 (1H, d, J 3.0 Hz), 7.98 (1H, d, J
    5.5 Hz), 8.12 (1H, d, J 3.0 Hz); Anal. Calcd for C9H6N4S2: C, 46.14; H,
    2.58, N, 23.90. Found: C, 46.14; H, 2.67; N, 23.02.
    111 85 mp 139.3-139.7° C.; IR νmax (Nujol)/cm−1 3326, 3118, 3078, 3062,
    1557, 1537, 1506, 1356 and 795; NMR δH (400 MHz, CDCl3)
    1.75-7.84 (1H, m), 1.91-2.10 (2H, m), 2.15-2.26 (1H, m), 3.70-3.82 (2H,
    m), 3.84-3.98 (2H, m), 4.38-4.56 (1H, s), 7.24 (1H, d, J 5.5 Hz),
    7.56 (1H, d, J 3.5 Hz), 7.95 (1H, d, J 5.5 Hz), 8.12 (1H, d, J 3.5 Hz); Anal.
    Calcd for C14H14N4OS2: C, 52.81; H, 4.43, N, 17.59. Found: C, 53.08; H,
    4.53; N, 17.22.
    112 62 mp 128-129° C.; IR νmax (Nujol)/cm−1 3251, 3102, 3076, 3019, 1596,
    1552, 1528, 1448, 1336 and 794; NMR δH (400 MHz, CDCl3)
    4.19-4.24 (2H, m), 5.14-5.37 (3H, m), 5.99-6.10 (1H, m), 7.24 (1H, d, J 5.5 Hz),
    7.56 (1H, d, J 3.0 Hz), 7.95 (1H, d, J 5.5 Hz), 8.11 (1H, d, J 3.0 Hz).
    113 84 mp 90.6-90.7° C.; IR νmax (Nujol)/cm−1 3056, 2961, 2855, 1546, 1529,
    1480, 806; NMR δH (400 MHz, CDCl3) 1.48 (6H, d, J 6.9 Hz), 3.40 (1H,
    heptet, J 6.9 Hz), 7.55 (1H, d, J 5.5 Hz), 7.59 (1H, d, J 3.1 Hz), 8.08 (1H,
    d, J 5.5 Hz), 8.14 (1H, d, J 3.1 Hz).
    114 7 IR νmax (Nujol)/cm−1 2925, 2854, 1615, 1545, 1498, 1459, 1377, 1265
    and 1174; NMR δH (400 MHz, CDCl3) 8.05 (1H, m), 7.80 (1H, m),
    7.60 (2H, m), 7.00 (1H, m), 3.83 (3H, s), 3.25 (2H, q, J 7.0 Hz) and 1.50 (3H,
    t, J 7.0 Hz).
    115 93 mp 133-133.5° C.; IR νmax (Nujol)/cm−1 2925, 1553, 1467, 1404, 1356,
    1241 and 796; NMR δH (400 MHz, CDCl3) 2.44 (3H, s), 3.35 (6H, s),
    7.25 (1H, d, J 5.5 Hz), 7.67 (1H, dd, J 7.5, 2.5 Hz), 7.89 (1H, d, J 5.5 Hz),
    8.54 (1H, d, J 8.5 Hz) and 8.64 (1H, d, J 2.0 Hz)
    116 37 mp 242.6-243.9° C.; IR νmax (Nujol)/cm−1 3251, 3079, 3060, 1687,
    1672, 1560, 1496 and 1320; NMR δH (400 MHz, DMSO) 2.29 (3H, s),
    7.54 (1H, d, J 5.5 Hz), 8.15 (1H, d, J 3.5 Hz), 8.27 (1H, d, J 3.0 Hz),
    8.56 (1H, d, J 5.5 Hz), 10.68 (1H, s).
    117 67 Mp 149° C.; IR νmax (Nujol)/cm−1 2955, 2925, 2854, 1595, 1523, 1485,
    1468 and 1333; NMR δH (400 MHz, CDCl3) 8.00 (1H, m), 7.76 (1H, m),
    7.60 (1H, m), 7.56 (1H, m), 7.36 (1H, m), 7.05 (1H, m), 6.92 (1H, m),
    6.63 (1H, m) and 4.59 (2H, s).
    118 IR νmax (Nujol)/cm−1 3036, 2925, 2854, 1535, 1481, 1468, 1351, 1129 and
    1098; NMR δH (400 MHz, CDCl3) 9.01 (1H, m), 8.78 (1H, s), 8.01 (1H,
    d, J 5.6 Hz), 7.57 (1H, d, J 5.2 Hz), 3.13 (2H, q, J 7.6 Hz) and 1.47 (3H,
    t, J 7.6 Hz).
    119 3 Mp 179° C.; IR νmax (Nujol)/cm−1 3057, 2924, 2854, 1525, 1465, 1438,
    1378 and 1296; NMR δH (400 MHz, CDCl3) 8.12 (2H, m), 7.58 (2H, m),
    3.30 (4H, q, J 7.0 Hz) and 1.60 (6H, t, J 7.0 Hz); M/Z 327 (M + H)+.
    120 IR νmax (Nujol)/cm−1 3388, 3060, 2924, 2855, 1662, 1561, 1541, 1461,
    1376, 1356, 1309, 1266 and 1096. NMR δH (400 MHz, CDCl3) 8.32 (1H,
    br s), 8.13 (1H, d, J 5.5 Hz), 7.58 (1H, J 5.5 Hz), 7.26 (1H, s), 3.19 (2H,
    q, J 7.5 Hz), 1.48 (3H, t, J 7.5 Hz).
    121 39 mp 178.6-179.6° C.; IR νmax (Nujol)/cm−1 3080, 2925, 1569, 1525, 1468,
    1092, 854, 815 and 750; NMR δH (400 MHz, CDCl3) 1.47 (3H, t, J 7.5 Hz),
    3.11 (2H, q, J 7.5 Hz), 7.29 (1H, s), 7.47 (1H, s), 7.51 (1H, d, J, 5.5 Hz),
    8.07 (1H, d, J 5.5 Hz) and 10.65 (1H, br s)
    122 13 Mp 131° C.; IR νmax (Nujol)/cm−1 2960, 1547, 1529, 1377, 1314, 1301
    and 1096; NMR δH (400 MHz, CDCl3) 8.24 (1H, m), 8.12 (1H, m),
    8.02 (1H, m), 7.48-7.60 (3H, m), 3.20 (2H, q, J 7.0 Hz) and 1.50 (3H, t, J 7.0 Hz).
    123 73 IR νmax (Nujol)/cm−1 3392, 3254, 1681, 1586, 1552, 1515, 1342, 1318,
    1274, 1252, 1165 and 1150; NMR δH (400 MHz, CDCl3) 1.43 (9H, s),
    3.46 (2H, q, J 5.5 Hz), 3.70 (2H, q, J 5.5 Hz), 5.12 (1H, br s), 5.42 (1H, t,
    J 5.5 Hz), 7.23 (1H, d, J 5.5 Hz), 7.55 (1H, d, J 3.5 Hz), 7.95 (1H, d, J
    5.5 Hz) and 8.11 (1H, d, J 3.0 Hz); Retention time 5.17min (70:30)
    124 60 IR νmax (Nujol)/cm−1 3352, 3241, 3045, 1558, 1349, 1315, 1280 and
    1116; NMR δH (400 MHz, CDCl3) 1.27 (2H, br s), 3.02 (2H, t, J 6.0 Hz),
    3.63 (2H, q, J 6.0 Hz), 5.46 (1H, m), 7.23 (1H, d, J 5.5 Hz), 7.55 (1H, d,
    J 3.5 Hz), 7.94 (1H, d, J 5.5 Hz) and 8.11 (1H, d, J 3.5 Hz); Retention
    time 2.35min (60:40)
    125 61 NMR δH (400 MHz, DMSO) 1.81 (3H, s), 3.30 (2H, q, J 6.0 Hz),
    3.44 (2H, q, J 6.0 Hz), 7.28 (2H, m), 7.97 (1H, m), 8.07 (1H, d, J 3.0 Hz),
    8.21 (1H, d, J 3.0 Hz) and 8.32 (1H, d, J 5.5 Hz); Retention time
    2.83min (70:30)
    126 NMR δH (400 MHz, DMSO) 0.97 (3H, t, J 7.2 Hz), 3.00 (2H, m),
    3.26 (2H, q, J 6.0 Hz), 3.40 (2H, q, J 6.0 Hz), 5.86 (1H, t, J 5.5 Hz), 5.96 (1H,
    t, J 5.5 Hz), 7.29 (2H, m), 8.08 (1H, d, J 3.2 Hz), 8.22 (1H, d, J 3.3 Hz)
    and 8.32 (1H, d, J 5.5 Hz); Retention time 2.42 (80:20).
    127 NMR δH (400 MHz, DMSO) 3.30 (2H, q, J 5.8 Hz), 3.42 (2H, q, J 5.8 Hz),
    3.63 (2H, m), 5.00 (1H, dd, J 1.6, 10.2 Hz), 5.09 (1H, dd, J 1.8, 17.2 Hz),
    5.79 (1H, m), 6.05 (2H, m), 7.29 (2H, m) 8.08 (1H, d, J 3.1 Hz),
    8.22 (1H, d, J 3.1 Hz) and 8.32 (1H, d, J 5.5 Hz); Retention time
    2.50min (80:20).
    128 81 NMR δH (400 MHz, DMSO) 0.99-1.28 (5H, m), 1.48-1.74 (5H, m),
    3.25 (2H, q, J 6.0 Hz), 3.33 (1H, m), 3.39 (2H, q, J 6.0 Hz), 5.77 (1H, d,
    J 8.0 Hz), 5.86 (1H, t, J 5.5 Hz), 7.28 (1H, m), 8.07 (1H, d, J 3.0 Hz),
    8.21 (1H, d, J 3.0 Hz) and 8.31 (1H, d, J 5.5 Hz); Retention time
    3.11min (80:20)
    129 42 NMR δH (400 MHz, DMSO) 0.84 (6H, d, J 6.5 Hz), 1.95 (3H, m),
    3.37 (2H, m), 3.43 (2H, q, J 6.0 Hz), 7.26 (2H, m), 7.89 (1H, m), 8.08 (1H, d,
    J 3.0 Hz), 8.21 (1H, d, J 3.0 Hz) and 8.32 (1H, d, J 5.5 Hz); Retention
    time 2.77min (80:20)
    130 58 NMR δH (400 MHz, DMSO) 3.25 (2H, q, J 6.0 Hz), 3.44 (2H, q, J 6.0 Hz),
    3.52 (3H, s), 7.21 (1H, t, J 5.5 Hz), 7.26 (1H, d, J 5.5 Hz), 7.30 (1H,
    m), 8.07 (1H, d, J 3.0 Hz), 8.21 (1H, d, J 3.0 Hz) and 8.32 (1H, d, J 5.5 Hz);
    Retention time 2.53min (80:20)
    131 62 NMR δH (400 MHz, DMSO) 0.84 (6H, d, J 6.5 Hz), 1.79 (1H, m),
    3.25 (2H, q, J 6.0 Hz), 3.45 (2H, q, J 6.0 Hz), 3.71 (2H, d, J 6.5 Hz),
    7.16 (1H, t, J 5.5 Hz), 7.26 (1H, d, J 5.5 Hz), 7.30 (1H, m), 8.07 (1H, d, J 3.0 Hz),
    8.21 (1H, d, J 3.0 Hz) and 8.32 (1H, d, J 5.5 Hz); Retention time
    3.23min (80:20)
    132 NMR δH (400 MHz, DMSO) 1.21 (9H, s), 3.24 (2H, q, J 5.8 Hz),
    3.39 (2H, q, J 5.8 Hz), 5.68 (1H, s), 5.80 (1H, t, J 6.0 Hz), 7.28 (2H, m),
    8.07 (1H, d, J 3.1 Hz), 8.22 (1H, d, J 3.1 Hz), and 8.32 (1H, d, J 5.5 Hz);
    Retention time 2.83min, (80:20).
    133 95 NMR δH (400 MHz, DMSO) 3.30 (2H, q, J 6.0 Hz), 3.42 (2H, q, J 6.0 Hz),
    4.20 (2H, d, J 5.6 Hz), 6.10 (1H, t, J 5.9 Hz), 6.41 (1H, t, J 6.0 Hz),
    7.16-7.33 (7H, m), 8.07 (1H, d, J 3.5 Hz), 8.21 (1H, d, J 3.0 Hz) and
    8.31 (1H, d, J 5.5 Hz); Retention time 2.87min (80:20)
    134 NMR δH (400 MHz, DMSO) 3.38 (2H, q, J 5.8 Hz), 3.47 (2H, q, J 5.8 Hz),
    6.29 (1H, t, J 6.0 Hz), 6.88 (1H, t, J 6.0 Hz), 7.21 (1H, t, J 6.0 Hz),
    7.27 (3H, m), 7.37 (3H, m), 8.07 (1H, d, J 3.1 Hz), 8.22 (1H, d, J 3.2 Hz)
    and 8.32 (1H, d, J 5.5 Hz); Retention time 3.22min (80:20).
    135 NMR δH (400 MHz, DMSO) 3.38 (2H, q, J 5.8 Hz), 3.48 (2H, q, J 5.8 Hz),
    6.33 (1H, t, J 6.0 Hz), 7.27 (3H, m), 7.40 (3H, m), 8.06 (1H, d, J
    3.1 Hz), 8.21 (1H, d, J 3.1 Hz), 8.32 (1H, d, J 5.5 Hz) and 8.67 (1H, s);
    Retention time 4.32min (80:20).
    136 NMR δH (400 MHz, DMSO) 1.08-1.32 (6H, m), 1.51-1.85 (4H, m),
    3.53 (2H, m), 3.62 (3H, m), 7.29 (2H, m), 7.36 (1H, m), 8.08 (1H, d, J
    3.1 Hz), 8.22 (1H, d, J 3.1 Hz) and 8.31 (1H, d, J 5.5 Hz); Retention time
    3.58min. (80:20).
    137 NMR δH (400 MHz, DMSO) 3.60 (2H, m), 3.79 (2H, m), 7.07 (1H, t, J
    6.0 Hz), 7.26 (3H, m), 7.36 (2H, m), 7.42 (1H, m), 7.83 (1H, br s),
    8.07 (1H, d, J 3.2 Hz), 8.22 (1H, d, J 3.2 Hz), 8.32 (1H, d, J 5.5 Hz) and
    9.58 (1H, br s); Retention time 2.98min (80:20).
    138 99 NMR δH (400 MHz, DMSO) 3.59 (2H, q, J 6.0 Hz), 3.78 (2H, m),
    7.25 (1H, d, J 5.5 Hz), 7.29 (2H, d, J 9.1 Hz), 7.41 (1H, m), 7.42 (2H, d, J 9.0 Hz),
    7.95 (1H, m), 8.07 (1H, d, J 3.5 Hz), 8.21 (1H, d, J 3.0 Hz),
    8.32 (1H, d, J 5.5 Hz) and 9.63 (1H, br s); Retention time 3.98min (80:20)
    139 93 IR νmax (Nujol)/cm−1 3063, 2926, 2855, 1547, 1530, 1466; NMR δH (400 MHz,
    CDCl3) 1.55 (9H, s), 7.56 (1H, d, J 7.5 Hz), 7.58 (1H, d, J 3.1 Hz),
    8.60 (1H, d, J 7.5 Hz), 8.18 (1H, d, J 3.1 Hz).
    140 13 IR νmax (Nujol)/cm−1 3061, 2924, 1550, 1531, 1480; NMR δH (400 MHz,
    CDCl3) 1.10 (2H, m), 1.24 (2H, m), 2.39 (1H, m), 7.42 (1H, d, J 7.5 Hz),
    7.58 (1H, d, J 3.1 Hz), 8.00 (1H, d, J 7.5 Hz), 8.10 (1H, d, J 3.1 Hz).
    141 65 mp 74.7-74.9° C.; IR νmax (Nujol)/cm−1 2925, 1531, 1455, 1350, 1078,
    and 799; NMR δH (400 MHz, CDCl3) 1.52 (3H, t, J 7.5 Hz), 2.74 (3H, s),
    3.19 (2H, q, J 7.5 Hz), 7.29 (1H, d, J 7.5 Hz), 7.52 (1H, d, J 6.0 Hz),
    7.80 (1H, t, J 8.0 Hz), 8.06 (1H, d, J 5.5 Hz) and 8.58 (1H, d, J 8.0 Hz)
    142 NMR δH (400 MHz, DMSO) 8.32 (1H, m), 8.22 (1H, m), 8.08 (1H, m),
    7.79 (1H, m), 7.34-7.26 (2H, m), 3.45-3.29 (4H, m), 2.19 (1H, m) and
    1.81-1.15 (10H, m); Retention time 3.26min, (80:20).
    143 NMR δH (400 MHz, DMSO) 8.59 (1H, br s), 8.33 (1H, m), 8.22 (1H, m),
    8.08 (1H, m), 7.94 (1H, m), 7.85 (2H, m), 7.63 (1H, m), 7.52-7.43 (1H,
    m), 7.28 (1H, m) and 3.60-3.37 (4H, br m); Retention time 3.03min,
    (80:20).
    144 NMR δH (400 MHz, DMSO) 8.66 (1H, br s), 8.33 (1H, m), 8.22 (1H, m),
    8.08 (1H, m), 7.88 (2H, m), 7.52 (2H, m), 7.45 (1H, br s), 7.27 (1H, m),
    3.59-3.54 (2H, br m) and 3.30-3.20 (2H, m); Retention time 3.95min,
    (80:20).
    145 70 NMR δH (400 MHz, DMSO) 3.36 (2H, q, J 6.0 Hz), 3.46 (2H, q, J 6.0 Hz),
    7.12 (1H, dd, J 4.0, 5.0 Hz), 7.26 (1H, d, J 5.5 Hz), 7.72 (1H, m),
    7.88 (1H, d, J 5.0 Hz), 8.07 (1H, d, J 3.0 Hz), 8.21 (1H, d, J 3.5 Hz),
    8.32 (1H, d, J 5.5 Hz) and 8.60 (1H, m); Retention time 2.98min (80:20)
    146 45 NMR δH (400 MHz, DMSO) 3.34 (2H, q, J 6.0 Hz), 3.53 (2H, q, J 6.0 Hz),
    7.22-7.40 (8H, m), 8.08 (1H, d, J 3.0 Hz), 8.22 (1H, d, J 3.0 Hz)
    and 8.33 (1H, d, J 5.5 Hz); Retention time 3.08min (80:20)
    147 62 NMR δH (400 MHz, DMSO) 3.28 (2H, q, J 6.0 Hz), 3.46 (2H, q, J 6.0 Hz),
    5.01 (2H, s), 7.22-7.38 (8H, m), 8.07 (1H, d, J 3.0 Hz), 8.21 (1H,
    d, J 3.5 Hz) and 8.32 (1H, d, J 5.5 Hz); Retention time 3.39min (80:20)
    148 29 NMR δH (400 MHz, DMSO) 2.92 (3H, s), 3.22 (2H, q, J 6.0 Hz),
    3.51 (2H, q, J 6.0 Hz), 7.14 (1H, t, J 5.9 Hz), 7.31 (1H, d, J 5.5 Hz), 7.35 (1H,
    m), 8.08 (1H, d, J 3.5 Hz), 8.22 (1H, d, J 3.5 Hz) and 8.34 (1H, d, J 5.5 Hz);
    Retention time 2.36min (80:20)
    149 70 NMR δH (400 MHz, DMSO) 0.83 (3H, t, J 7.5 Hz), 1.32 (2H, m),
    1.60 (2H, m), 2.99 (2H, m), 3.20 (2H, q, J 6.0 Hz), 3.49 (2H, q, J 6.0 Hz),
    7.15 (1H, t, J 5.9 Hz), 7.26 (1H, d, J 5.6 Hz), 7.32 (1H, m), 8.08 (1H, d, J
    3.0 Hz), 8.22 (1H, d, J 3.0 Hz) and 8.33 (1H, d, J 5.5 Hz); Retention time
    2.82min (80:20)
    150 22 NMR δH (400 MHz, CDCl3) 1.34 (3H, d, J 6.5 Hz), 3.71 (1H, dd, J 6.7,
    10.7 Hz), 3.85 (1H, dd, J 3.0, 11.0 Hz), 4.29 (1H, m), 5.20 (1H, d, J 6.5 Hz),
    7.22 (1H, d, J 5.5 Hz), 7.56 (1H, d, J 3.5 Hz), 7.95 (1H, d, J 5.5 Hz)
    and 8.11 (1H, d, J 3.0 Hz); Retention time 2.67min (80:20)
    151 33 NMR δH (400 MHz, CDCl3) 2.21 (2H, quintet, J 6.7 Hz), 3.59 (2H, q, J
    6.5 Hz), 4.12 (2H, t, J 7.0 Hz), 5.20 (1H, t, J 6.0 Hz), 6.98 (1H, m),
    7.09 (1H, m), 7.24 (1H, d, J 5.5 Hz), 7.55 (1H, m), 7.56 (1H, d, J 3.0 Hz),
    7.97 (1H, d, J 5.5 Hz) and 8.12 (1H, d, J 3.0 Hz); Retention time 2.65min
    (80:20)
    152 64 NMR δH (400 MHz, CDCl3) 1.80 (1H, m), 1.97 (1H, m), 2.03 (1H, m),
    2.20 (1H, m), 3.71-3.80 (2H, m), 3.85-3.97 (2H, m), 4.41 (1H, m),
    7.23 (1H, d, J 5.5 Hz), 7.57 (1H, d, J 3.0 Hz), 7.94 (1H, d, J 5.5 Hz) and
    8.12 (1H, d, J 3.0 Hz); Retention time 3.63min (80:20)
    153 23 Mp 221.9° C.; IR νmax (Nujol)/cm−1 3069, 2923, 2854, 1539, 1523, 1465,
    1377, 1366 and 1319; NMR δH (400 MHz, CDCl3) 8.16 (2H, m),
    8.10 (1H, m), 7.64 (1H, m), 7.58 (1H, m), 7.50 (1H, m) and 7.20 (1H, m).
    154 50 IR νmax (Nujol)/cm−1 3074, 2924, 1546, 1529, 1473 and 1350; NMR
    δH (400 MHz, CDCl3) 3.60 (2H, m), 4.15 (2H, m), 7.42 (1H, d, J 7.5 Hz),
    7.58 (1H, d, J 3.1 Hz), 8.1 (1H, d, J 7.5 Hz), 8.15 (1H, d, J 3.1 Hz).
    155 67 mp 300° C. dec; IR νmax (Nujol)/cm−1 3472, 3051, 2925, 2853, 1707,
    1598, 1525, 1466, 791, 742, 506; NMR δH (400 MHz, DMSO) 6.91 (1H,
    dd J 1.7, 3.6 Hz), 7.75 (1H, d, J 5.5 Hz), 7.82 (1H, br), 7.89 (1H, dd, J
    0.8, 3.6 Hz), 8.23 (1H, dd, J 0.8, 1.7 Hz), 8.40 (1H, br), 8.64 (1H, d, J 5.5 Hz).
    156 Mp 117.7-118.2° C.; IR νmax (Nujol)/cm−1 3062, 2924, 2854, 1545, 1528,
    1517, 1465, 1378, 1239 and 1134; NMR δH (400 MHz, CDCl3) 8.39 (1H,
    m), 8.08 (1H, d, J 5.5 Hz), 7.98 (1H, dd, J 5.1, 1.1 Hz), 7.55 (1H, d, J 5.5 Hz)
    and 7.52 (1H, dd, J 5.1, 2.8 Hz); Anal Calcd for C10H5ClN2S2 0.5
    H2O: C45.89; H, 2.31; N, 10.70. Found C, 45.48; H, 2.18; N, 10.53.
    157 84 Mp 119.0-119.4° C.; IR νmax (Nujol)/cm−1 2924, 2854, 1557, 1524,
    1468, 1388, 1334, 1279, 1234 and 1092; NMR δH (400 MHz, CDCl3)
    8.23 (1H, dd, J 2.9, 1.3 Hz), 7.95 (1H, dd, J 5.0, 1.0 Hz), 7.45 (1H, dd, J
    5.1, 3.0 Hz), 7.27 (1H, m) and 3.31 (6H, s). Anal Calcd for C12H11N3S2: C,
    55.15; H, 4.24; N, 16.07. Found: C55.36; H, 4.22; N, 16.05
    158 28 Mp 146.5-147.2° C.; IR νmax (Nujol)/cm−1 3054, 2925, 2854, 1537,
    1516, 1495, 1467, 1365, 1244 and 1138; NMR δH (400 MHz, CDCl3)
    8.20 (2H, m), 8.11 (1H, d, J 5.6 Hz), and 7.62-7.57 (4H, m); Anal
    Calcd for C12H7ClN2S 0.25 H2O; C, 57.37; H, 3.01; N, 11.15. Found: C,
    57.25; H, 2.84; N, 11.40.
    159 97 Mp 112.9-114.1° C.; IR νmax (Nujol)/cm−1 2924, 2854, 1585, 1556,
    1523, 1468, 1409, 1355 and 1241, NMR δH (400 MHz, CDCl3) 8.18 (2H,
    m), 7.80 (1H, d, J 5.5 Hz), 7.56-7.51 (3H, m), 7.29 (1H, d, J 5.5 Hz) and
    3.33 (6H, s). Anal. Calcd for C14H13N3S 0.1 H2O: C, 65.39; H, 5.13; N,
    16.45; Found: C, 65.18; H, 5.14; N, 16.16.
    160 33 Mp 129.3-129.9° C.; IR νmax (Nujol)/cm−1 3117, 2955, 2924, 2854,
    1576, 1542, 1527, 1512, 1472, 1382, 1264, 1243, 1226, 1184 and 1155,
    NMR δH (400 MHz, CDCl3) 8.40 (1H, s), 8.05 (1H, d, J 5.5 Hz),
    7.62 (1H, m), 7.54 (1H, d, J 5.5 Hz), and 7.22 (1H, m); Anal. Calcd for
    C10H5ClN2OS: C, 50.75; H, 2.13; N, 11.83. Found: C, 50.71; H, 2.13; N,
    11.72.
    161 50 Mp 98.4-99.0° C.; IR νmax (Nujol)/cm−1 2924, 2854, 1562, 1540, 1527,
    1463, 1404, 1381, 1348 and 1229, NMR δH (400 MHz, CDCl3) 8.27 (1H,
    d, J 1.2 Hz), 7.76 (1H, d, J 5.4 Hz), 7.55 (1H, m), 7.26 (1H, m),
    7.17 (1H, d, J 1.2 Hz), and 3.28 (6H, s); Anal Calcd. for C12H11N3OS 0.1 H2O:
    C, 58.33; H, 4.57; N, 17.01. Found: C, 58.59; H, 4.56; N, 16.69.
    162 31 Mp 204.0-204.9° C.; IR νmax (Nujol)/cm−1 2926, 2854, 1590, 1526,
    1494, 1465, 1377, 1335 and 1268, NMR δH (400 MHz, DMSO)
    8.71 (1H, s), 8.33 (1H, d, J 1.2 Hz), 7.76 (1H, d, J 4.1 Hz), and 6.95 (1H, dd, J
    3.8, 1.8 Hz): Anal Calcd for C10H4ClN3O3S 0.1 H2O: C, 42.37; H, 1.49; N,
    14.82. Found: C, 42.01; H, 1.42; N, 14.75.
    163 69 IR νmax (Nujol)/cm−1 2924, 2854, 1585, 1547, 1529, 1463, 1377 and
    1154; NMR δH (400 MHz, CDCl3) 8.39 (1H, m), 7.95 (1H, m), 7.62 (1H,
    m), 7.53 (1H, m), 7.24 (1H, m), 3.10 (2H, d, J 7.0 Hz) and 1.42 (3H, t, J
    7.0 Hz); M/Z 231 (M + H)+.
    164 41 IR νmax (Nujol)/cm−1 2925, 2854, 1615, 1546, 1526, 1482, 1463, 1420
    and 1376; NMR δH (400 MHz, CDCl3) 8.00 (1H, m), 7.58 (1H, m),
    3.18 (2H, m), 2.50 (3H, s), 2.39 (3H, s) and 1.43 (3H, m); M/Z 260 (M + H)+.
    165 IR νmax (Nujol)/cm−1 3093, 2955, 2924, 2854, 1589, 1572, 1538, 1522,
    1467 and 1253. NMR δH (400 MHz, CDCl3) 9.45 (1H, d, J 2.0 Hz),
    8.85 (1H, m), 8.54-8.51 (1H, m), 8.18 (1H, d, J 5.5 Hz), 7.62 (1H, d, J 5.5 Hz),
    7.56-7.53 (1H, m).
    166 IR νmax (Nujol)/cm−1 3056, 2925, 2854, 1580, 1557, 1524, 1467, 1361
    and 1249. NMR δH (400 MHz, CDCl3) 9.43 (1H, d, J 1.8 Hz), 8.76 (1H,
    dd, J 4.7, 1.5 Hz), 8.48-8.45 (1H, m), 7.83 (1H, d, J 5.5 Hz),
    7.53-7.46 (1H, m), 7.32 (1H, d, J 5.5 Hz), 3.32 (6H, s).
    167 NMR δH (400 MHz, CDCl3) 8.12 (1H, d, J 5.5 Hz), 7.49 (1H, d, J 5.5 Hz),
    7.38 (1H, s), 7.16 (1H, s), 7.30 (3H, s).
    168 NMR δH (400 MHz, CDCl3) 7.86 (1H, d, J 5.5 Hz), 7.31 (1H, s),
    7.24 (1H, d, J 5.5 Hz), 7.06 (1H, s), 4.28 (3H, s), 3.29 (6H, s).
    169 IR νmax (Nujol)/cm−1 3332, 3072, 2924, 2854, 1606, 1547, 1516, 1489,
    1464, 1409, 1387 and 1261; NMR δH (400 MHz, CDCl3) 7.87 1H, d, J
    5.5 Hz), 7.64 (1H, d, J 1.5 Hz), 7.23 (1H, d, J 5.5 Hz), 6.57 (1H, d, J 1.5 Hz),
    5.79 (1H, t, J 7.0 Hz), 4.83 (2H, d, J 7.0 Hz), 3.28 (6H, s).
    170 IR νmax (Nujol)/cm−1 3443, 3218, 3122, 2954, 2925, 2854, 1560, 1532,
    1513, 1484, 1457, 1389 and 1318; NMR δH (400 MHz, CDCl3) 7.90 (1H,
    dd, J 5.5, 1.8 Hz), 7.30 (1H, s), 7.20 (1H, dd, J 5.5, 1.8 Hz), 7.06 (1H, s),
    5.46 (1H, br s), 4.22 (3H, s), 3.91-3.90 (2H, m), 3.72-3.68 (3H, m).
    171 IR νmax (Nujol)/cm−1 3267, 3124, 2924, 2854, 1609, 1547, 1514, 1487,
    1459, 1378; NMR δH (400 MHz, CDCl3) 7.91 (1H, d, J 5.5 Hz),
    7.65 (1H, s), 7.21 (1H, d, J 5.5 Hz), 6.56 (1H, s), 6.20 (1H, br s), 5.50 (1H, br
    s), 4.79 (2H, s), 3.90-3.88 (2H, m), 3.70-3.66 (2H, m), 1.61 (1H, br s).
    172 IR νmax (Nujol)/cm−1 2925, 2854, 1546, 1528, 1517, 1465, 1377 and
    1222; NMR δH (400 MHz, CDCl3) 8.12 (1H, d, J 5.5 Hz), 7.50 (1H, d, J
    5.5 Hz), 7.38 (1H, s), 7.20 (1H, s), 4.80 (2H, q, J 7.0 Hz), 1.55 (3H, t, J
    7.0 Hz).
    173 IR νmax (Nujol)/cm−1 3041, 2926, 2855, 1563, 1528, 1511, 1478, 1460,
    1392 and 1377; NMR δH (400 MHz, CDCl3) 7.86 (1H, d, J 5.5 Hz),
    7.32 (1H, s), 7.23 (1H, d, J 5.5 Hz), 7.11 (1H, s), 4.83 (1H, q, J 7.0 Hz),
    3.28 (6H, s), 1.52 (3H, t, J 7.0 Hz),
    174 IR νmax (Nujol)/cm−1 3458, 3334, 2925, 2855, 1560, 1516, 1480, 1466,
    1427 and 1334; NMR δH (400 MHz, CDCl3) 7.90 (1H, d, J 5.5 Hz),
    7.32 (1H, s), 7.19 (1H, d, J 5.5 Hz), 7.11 (1H, s), 5.45 (1H, br t, J 5.5 Hz),
    4.74 (2H, q, J 7.0 Hz), 3.91-3.89 (2H, m), 3.71-3.67 (2H, m),
    1.52 (3H, t, J 7.0 Hz).
    175 IR νmax (Nujol)/cm−1 3069, 2954, 2925, 2854, 1548, 1531, 1517, 1467,
    1408, 1249 and 1225; NMR δH (400 MHz, CDCl3) 8.19 (1H, d, J 5.5 Hz),
    7.54 (1H, d, J 5.5 Hz), 7.47-7.41 (2H, m), 6.22 (2H, s), 3.76 (2H, t,
    J 8.5 Hz), 1.02 (2H, t, J 8.5 Hz).
    176 Mp 131-132° C.; IR νmax (Nujol)/cm−1 2924, 2854, 1560, 1533, 1512,
    1480, 1465, 1419, 1389, 1250 and 1089; NMR δH (400 MHz, CDCl3)
    7.95 (1H, d, J 5.5 Hz), 7.43 (1H, d, J 1.5 Hz), 7.38 (1H, d, J 1.5 Hz),
    7.30 (1H, d, J 5.5 Hz), 6.28 (2H, s), 3.66 (2H, t, 8.0 Hz), 3.36 (6H, s),
    0.97 (3H, t, J 8.0 Hz).
    177 Mp 209-210° C.; IR νmax (Nujol)/cm−1 2925, 2854, 1749, 1559, 1530,
    1508, 1476, 1388, 1376, 1241 and 1214; NMR δH (400 MHz, CDCl3)
    7.88 (1H, d, J 5.5 Hz), 7.37 (1H, d, J 1.0 Hz), 7.21 (1H, d, J 5.5 Hz),
    7.08 (1H, d, J 1.5 Hz), 5.61 (2H, s), 4.18 (2H, q, J 7.5 Hz), 3.24 (6H, s),
    1.18 (3H, t, J 7.0 Hz).
    178 Mp 162.2-164.9° C.; IR νmax (Nujol)/cm−1 3365, 2924, 2854, 1559,
    1528, 1512, 1465, 1389, 1378, 1336, and 1236; NMR δH (400 MHz,
    CDCl3) 7.89 (1H, d, J 5.5 Hz), 7.34 (1H, d, J 1.0 Hz), 7.22 (1H, d, J 5.5 Hz),
    7.19 (1H, d, J 1.0 Hz), 4.94 (2H, t, J 5.0 Hz), 4.09 (2H, br q, J 5.0 Hz),
    3.26 (6H, s), 2.50 (1H, br t, J 5.0 Hz).
    179 Mp 69-70° C.; IR νmax (Nujol)/cm−1 3090, 2925, 2854, 1542, 1514, 1477,
    1376, 1336, 1221 and 1109; NMR δH (400 MHz, CDCl3) 8.04 (1H, d, J
    5.5 Hz), 7.50 (1H, d, J 5.5 Hz), 7.40 (1H, d, J 1.0 Hz), 7.34 (1H, d, J 1.0 Hz),
    6.29 (2H, s), 3.40 (3H, s), 3.15 (2H, q, 7.5 Hz), 1.49 (3H, t, 7.5 Hz).
    180 Mp <100° C.; IR νmax (Nujol)/cm−1 2953, 2925, 2854, 1547, 1514, 1495,
    1458, 1378, 1316, 1248 and 1095; NMR δH (400 MHz, CDCl3) 8.17 (1H,
    s), 8.10 (1H, d, J 5.5 Hz), 7.56 (1H, d, J 5.5 Hz), 6.41 (2H, s), 3.73 (2H,
    t, J 8.0 Hz), 3.20 (2H, q, J 7.5 Hz), 1.50 (3H, t, J 8.0 Hz), 0.90 (2H, t, J
    8.0 Hz), 0.09 (9H, s).
    181 Mp 108-109° C.; IR νmax (Nujol)/cm−1 3076, 2954, 2923, 2854, 1571,
    1537, 1519, 1443, 1400, 1249, 1129 and 1116; NMR δH (400 MHz,
    CDCl3) 8.49 (1H, s), 8.38 (1H, s), 8.05 (1H, d, J 5.5 Hz), 7.54 (1H, d, J
    5.5 Hz), 5.55 (2H, s), 3.66 (2H, t, J 8.0 Hz), 0.96 (2H, t, J 8.5 Hz),
    0.00 (9H, s).
    182 Mp 141-142° C.; IR νmax (Nujol)/cm−1 2925, 2854, 1545, 1522, 1462,
    1378 and 1225; NMR δH (400 MHz, CDCl3) 8.10 (1H, d, J 5.5 Hz),
    7.65 (1H, d, J 2.0 Hz) 7.57 (1H, d, J 5.5 Hz), 7.11 (1H, d, J 2.0 Hz), 4.37 (3H,
    s).
    183 Mp 60-61° C.; IR νmax (Nujol)/cm−1 2924, 2854, 1579, 1556, 1458, 1404,
    1377, 1278, 1247 and 1100; NMR δH (400 MHz, CDCl3) 8.36 (1H, s),
    8.32 (1H, s), 7.77 (1H, d, J 5.5 Hz), 7.27 (1H, d, J 5.5 Hz), 5.53 (2H, s),
    3.66 2H, t, J 8.5 Hz) 3.30 (6H, s), 0.96 (3H, t, J 8.0 Hz), 0.00 (9H, s).
    184 Mp 126.5-127° C.; IR νmax (Nujol)/cm−1 3052, 2954, 2924, 2854, 1553,
    1515, 1465, 1412, 1386, 1353 and 1232; NMR δH (400 MHz, CDCl3)
    7.80 (1H, d, J 5.5 Hz), 7.60 (1H, d, J 2.0 Hz), 7.27 (1H, d, J 5.5 Hz),
    7.01 (1H, d, J 2.0 Hz), 4.34 (3H, s), 3.29 (6H, s).
    185 Mp 210-211° C.; IR νmax (Nujol)/cm−1 3146, 3090, 3058, 2924, 2854,
    1582, 1556, 1465, 1404, 1377, 1277 and 1236; NMR δH (400 MHz,
    CDCl3) 10.47 (1H, br s), 8.39 (2H, s), 7.77 (1H, d, J 5.5 Hz),
    7.33-7.23 (1H, d, J 5.5 Hz), 3.30 (6H, s).
    186 Mp 175.4-175.9° C.; IR νmax (Nujol)/cm−1 2925, 2854, 1548, 1458,
    1407, 1383, 1279 and 1228; NMR δH (400 MHz, CDCl3) 8.25 (1H, s),
    8.15 (1H, s), 7.75 (1H, d, J 5.5 Hz), 7.25 (1H, d, J 5.5 Hz), 4.02 (3H, s),
    3.29 (6H, s),
    187 Mp 110.2-111.4° C.; NMR δH (400 MHz, CDCl3) 8.10 (1H, d, J 5.5 Hz),
    7.56 (1H, d, J 5.5 Hz), 7.26 (1H, s), 4.58 (3H, s), 3.20 (2H, q, J 7.5 Hz),
    1.50 (3H, t, J 7.5 Hz).
    188 Mp 104.7-104.8° C.; IR νmax (Nujol)/cm−1 3095, 2926, 2854, 1595,
    1552, 1532, 1505, 1483, 1458, 1434, 1377, 1349 and 1302; p NMR
    δH (400 MHz, CDCl3) 7.45 (1H, d, J 3.5 Hz), 7.26 (1H, s), 7.15 (1H, d, J 1.5 Hz),
    6.64 (1H, dd, J 3.5 Hz, 2.0 Hz), 3.08 (2H, q, J 7.5 Hz), 2.69 (3H, s),
    1.45 (3H, t, J 7.5 Hz).
    • Adenosine Receptor Binding
  • Binding Affinities at hA2A Receptors
  • The compounds were examined in an assay measuring in vitro binding to human adenosine A2A receptors by determining the displacement of the adenosine A2A receptor selective radioligand [3 H]-CGS 21680 using standard techniques. The results are summarised in Table 3.
  • TABLE 3
    Example Ki (nM)
    Example 15 11
    Example 40 19
    Example 65 2
    Example 70 4
    Example 71 8
    Example 76 1
    Example 79 14
    Example 80 1
    Example 82 2
    Example 89 20
    Example 104 5
    Example 105 6
    Example 110 35
    Example 111 2
    Example 113 1
    Example 139 3
    Example 140 2
    Example 141 9
    Example 152 3
    Example 154 6
    • Evaluation of Potential Anti-Parkinsonian Activity In Vivo Haloperidol-Induced Hypolocomotion Model
  • It has previously been demonstrated that adenosine antagonists, such as theophylline, can reverse the behavioural depressant effects of dopamine antagonists, such as haloperidol, in rodents (Mandhane S. N. et al., Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats. Eur. J. Pharmacol. 1997, 328, 135-141). This approach is also considered a valid method for screening drugs with potential antiparkinsonian effects. Thus, the ability of novel adenosine antagonists to block haloperidol-induced deficits in locomotor activity in mice can be used to assess both in vivo and potential antiparkinsonian efficacy.
    • Method
  • Female TO mice (25-30 g) obtained from TUCK, UK, are used for all experiments. Animals are housed in groups of 8 [cage size—40 (width)×40 (length)×20 (height)cm] under 12 hr light/dark cycle (lights on 08:00 hr), in a temperature (20±2° C.) and humidity (55±15%) controlled environment. Animals have free access to food and water, and are allowed at least 7 days to acclimatize after delivery before experimental use.
    • Drugs
  • Liquid injectable haloperidol (1 ml Serenance ampoules from Baker Norton, Harlow, Essex, each containing haloperidol BP 5 mg, batch #P424) are diluted to a final concentration of 0.02 mg/ml using saline. Test compounds are typically prepared as aqueous suspensions in 8% Tween. All compounds are administered intraperitoneally in a volume of 10 ml/kg.
    • Procedure
  • 1.5 hours before testing, mice are administered 0.2 mg/kg haloperidol, a dose that reduces baseline locomotor activity by at least 50%. Test substances are typically administered 5-60 minutes prior to testing. The animals are then placed individually into clean, clear polycarbonate cages [20 (width)×40 (length)×20 (height) cm, with a flat perforated, Perspex lid]. Horizontal locomotor activity is determined by placing the cages within a frame containing a 3×6 array of photocells linked to a computer, which tabulates beam breaks. Mice are left undisturbed to explore for 1 hour, and the number of beams breaks made during this period serves as a record of locomotor activity which is compared with data for control animals for statistically significant differences.
    • 6-OHDA Model
  • Parkinson's disease is a progressive neurodegenerative disorder characterised by symptoms of muscle rigidity, tremor, paucity of movement (hypokinesia), and postural instability. It has been established for some time that the primary deficit in PD is a loss of dopaminergic neurones in the substantia nigra which project to the striatum, and indeed a substantial proportion of striatal dopamine is lost (ca 80-85%) before symptoms are observed. The loss of striatal dopamine results in abnormal activity of the basal ganglia, a series of nuclei which regulate smooth and well co-ordinated movement (Blandini F. et al., Glutamate and Parkinson's Disease. Mol. Neurobiol. 1996, 12, 73-94). The neurochemical deficits seen in Parkinson's disease can be reproduced by local injection of the dopaminergic neurotoxin 6-hydroxydopamine into brain regions containing either the cell bodies or axonal fibres of the nigrostriatal neurones.
  • By unilaterally lesioning the nigrostriatal pathway on only one-side of the brain, a behavioural asymmetry in movement inhibition is observed. Although unilaterally-lesioned animals are still mobile and capable of self maintenance, the remaining dopamine-sensitive neurones on the lesioned side become supersensitive to stimulation. This is demonstrated by the observation that following systemic administration of dopamine agonists, such as apomorphine, animals show a pronounced rotation in a direction contralateral to the side of lesioning. The ability of compounds to induce contralateral rotations in 6-OHDA lesioned rats has proven to be a sensitive model to predict drug efficacy in the treatment of Parkinson's Disease.
    • Animals
  • Male Sprague-Dawley rats, obtained from Charles River, are used for all experiments. Animals are housed in groups of 5 under 12 hr light/dark cycle (lights on 08:00 hr), in a temperature (20±2° C.) and humidity (55±15%) controlled environment. Animals have free access to food and water, and are allowed at least 7 days to acclimatize after delivery before experimental use.
    • Drugs
  • Ascorbic acid, desipramine, 6-OHDA and apomorphine (Sigma-Aldrich, Poole, UK). 6-OHDA is freshly prepared as a solution in 0.2% ascorbate at a concentration of 4 mg/mL prior to surgery. Desipramine is dissolved in warm saline, and administered in a volume of 1 ml/kg. Apomorphine is dissolved in 0.02% ascorbate and administered in a volume of 2 mL/kg. Test compounds are suspended in 8% Tween and injected in a volume of 2 mL/kg.
    • Surgery
  • 15 minutes prior to surgery, animals are given an intraperitoneal injection of the noradrenergic uptake inhibitor desipramine (25 mg/kg) to prevent damage to non-dopamine neurones. Animals are then placed in an anaesthetic chamber and anaesthetised using a mixture of oxygen and isoflurane. Once unconscious, the animals are transferred to a stereotaxic frame, where anaesthesia is maintained through a mask. The top of the animal's head is shaved and sterilised using an iodine solution. Once dry, a 2 cm long incision is made along the midline of the scalp and the skin retracted and clipped back to expose the skull. A small hole is then drilled through the skill above the injection site. In order to lesion the nigrostriatal pathway, the injection cannula is slowly lowered to position above the right medial forebrain bundle at −3.2 mm anterior posterior, −1.5 mm medial lateral from bregma, and to a depth of 7.2 mm below the duramater. 2 minutes after lowing the cannula, 2 μL of 6-OHDA is infused at a rate of 0.5 μL/min over 4 minutes, yielding a final dose of 8 μg. The cannula is then left in place for a further 5 minutes to facilitate diffusion before being slowly withdrawn. The skin is then sutured shut using Ethicon W501 Mersilk, and the animal removed from the stereotaxic frame and returned to its homecage. The rats are allowed 2 weeks to recover from surgery before behavioural testing.
    • Apparatus
  • Rotational behaviour is measured using an eight station rotameter system provided by Med Associates, San Diego, USA. Each station is comprised of a stainless steel bowl (45 cm diameter×15 cm high) enclosed in a transparent Plexiglas cover running around the edge of the bowl, and extending to a height of 29 cm. To assess rotation, rats are placed in cloth jacket attached to a spring tether connected to optical rotameter positioned above the bowl, which assesses movement to the left or right either as partial (45°) or full (360°) rotations. All eight stations are interfaced to a computer that tabulated data.
    • Procedure
  • To reduce stress during drug testing, rats are initially habituated to the apparatus for 15 minutes on four consecutive days. On the test day, rats are given an intraperitoneal injection of test compound 30 minutes prior to testing. Immediately prior to testing, animals are given a subcutaneous injection of a subthreshold dose of apomorphine, then placed in the harness and the number of rotations recorded for one hour. The total number of full contralateral rotations during the hour test period serves as an index of antiparkinsonian drug efficacy.

Claims (13)

1.-49. (canceled)
50. A method for blocking a purine receptor in a subject, comprising administering to said subject an effective dose of a compound of formula (I):
Figure US20080153820A1-20080626-C00192
wherein:
X is S or O;
R1 is selected from the group consisting of H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, COR5, CO2R5, CONR6R7, CONR5NR6R7, NR6R7, NR5CONR6R7, NR5COR6, NR5CO2R8, and NR5SO2R8;
R2 is selected from aryl attached via an unsaturated carbon atom;
R3 is selected from the group consisting of H, alkyl, hydroxy, alkoxy, halogen, CN and NO2;
R4 is selected from the group consisting of H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, NO2, COR5, CO2R5, CONR6R7, CONR5NR6R7, NR6R7, NR5CONR6R7, NR5COR6, NR5CO2R8 and NR5SO2R8;
R5, R6 and R7 are independently selected from the group consisting of H, alkyl and aryl, or where R6 and R7 are in an (NR6R7) group, R6 and R7 may be linked to form a heterocyclic group, or where R5, R6 and R7 are in a (CONR5NR6R7) group, R5 and R6 may be linked to form a heterocyclic group; and
R8 is selected from alkyl and aryl,
or a pharmaceutically acceptable salt thereof.
51. The method according to claim 50, wherein the purine receptor is an adenosine receptor.
52. The method according to claim 51, wherein the adenosine receptor is an A2A receptor.
53. The method according to claim 50, wherein the subject is human.
54. A method for treating a subject suffering from or at risk of a condition selected from the group consisting of:
(i) a movement disorder;
(ii) an affective disorder;
(iii) a central or peripheral nervous system degenerative disorder;
(iv) schizophrenia or a related psychosis;
(v) a cognitive disorder;
(vi) an attention disorder;
(vii) a central nervous system injury;
(viii) cerebral ischaemia;
(ix) myocardial ischaemis;
(x) muscle ischaemia;
(xi) a sleep disorder;
(xii) an eye disorder selected from the group consisting of retinal ischaemia-reperfusion injury and diabetic neuropathy;
(xiii) a cardiovascular disorder;
(xiv) memory impairment;
(xv) ADHD;
(xvi) narcolepsy; and
(xvii) diabetes and its complications,
the method comprising administering to said subject an effective dose of a compound of formula (I):
Figure US20080153820A1-20080626-C00193
wherein:
X is S or O;
R1 is selected from the group consisting of _H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, COR5, CO2R5, CONR6R7, CONR5NR6R7, NR6R7, NR5CONR6R7, NR5COR6, NR5CO2R8, and NR5SO2R8;
R2 is selected from aryl attached via an unsaturated carbon atom;
R3 is selected from the group consisting of H, alkyl, hydroxy, alkoxy, halogen, CN and NO2;
R4 is selected from the group consisting of H, alkyl, aryl, hydroxy, alkoxy, aryloxy, thioalkyl, thioaryl, halogen, CN, NO2, COR5, CO2R5, CONR6R7, CONR5NR6R7, NR6R7, NR5CONR6R7, NR5COR6, NR5CO2R8 and NR5SO2R8;
R5, R6 and R7 are independently selected from the group consisting of H, alkyl and aryl, or where R6 and R7 are in an (NR6R7) group, R6 and R7 may be linked to form a heterocyclic group, or where R5, R6 and R7 are in a (CONR5NR6R7) group, R5 and R6 may be linked to form a heterocyclic group; and
R8 is selected from alkyl and aryl,
or a pharmaceutically acceptable salt thereof.
55. The method according to claim 54, wherein the movement disorder is Parkinson's disease.
56. The method according to claim 55, wherein the Parkinson's disease is selected from the group consisting of drug-induced Parkinsonism, post-encephalitic Parkinsonism, Parkinsonism induced by poisoning and post-traumatic Parkinson's disease.
57. The method according to claim 54, wherein the movement disorder is selected from the group consisting of progressive supernuclear palsy, Huntingtons disease, multiple system atrophy, corticobasal degeneration, Wilsons disease, Hallerrorden-Spatz disease, progressive pallidal atrophy, Dopa-responsive dystonia-Parkinsonism, spasticity, and other disorders of the basal ganglia which result in dyskinesias.
58. The method according to claim 54, wherein the compound of formula (I) is administered in combination with one or more additional drugs useful in the treatment of movement disorders, and wherein the compound of formula (I) and the one or more additional drugs are in the same formulation or in separate formulations for simultaneous or sequential administration.
59. The method according to claim 58, wherein the one or more additional drugs are effective in treating Parkinson's disease.
60. The method according to claim 58, wherein the one or more additional drugs are selected from the group consisting of L-DOPA and a dopamine agonist.
61. The method according to claim 54, wherein the subject is human.
US12/071,577 2001-01-10 2008-02-22 Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists Abandoned US20080153820A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/071,577 US20080153820A1 (en) 2001-01-10 2008-02-22 Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0100620.4A GB0100620D0 (en) 2001-01-10 2001-01-10 Chemical cokpounds V
GB0100620.4 2001-01-10
US10/250,938 US7384949B2 (en) 2001-01-10 2002-01-10 Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists
PCT/GB2002/000084 WO2002055524A1 (en) 2001-01-10 2002-01-10 THIENO(3,2-d)PYRIMIDINES AND FURANO(3,2-d)PYRIMIDINES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS
US12/071,577 US20080153820A1 (en) 2001-01-10 2008-02-22 Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/250,938 Division US7384949B2 (en) 2001-01-10 2002-01-10 Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists
PCT/GB2002/000084 Division WO2002055524A1 (en) 2001-01-10 2002-01-10 THIENO(3,2-d)PYRIMIDINES AND FURANO(3,2-d)PYRIMIDINES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
US20080153820A1 true US20080153820A1 (en) 2008-06-26

Family

ID=9906567

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/250,938 Expired - Fee Related US7384949B2 (en) 2001-01-10 2002-01-10 Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists
US12/071,577 Abandoned US20080153820A1 (en) 2001-01-10 2008-02-22 Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/250,938 Expired - Fee Related US7384949B2 (en) 2001-01-10 2002-01-10 Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists

Country Status (8)

Country Link
US (2) US7384949B2 (en)
EP (1) EP1349861B1 (en)
JP (1) JP4390454B2 (en)
AT (1) ATE407935T1 (en)
CA (1) CA2434005A1 (en)
DE (1) DE60228817D1 (en)
GB (1) GB0100620D0 (en)
WO (1) WO2002055524A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105465A1 (en) * 2008-05-29 2011-05-05 Kyowa Hakko Kirin Co., Ltd. Inhibitor of analgesic tolerance

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2942082B1 (en) * 2002-01-28 2019-03-06 Kyowa Hakko Kogyo Co., Ltd A2a receptor antogonists for use in the treatment of movement disorders
AU2003216322A1 (en) 2002-02-15 2003-09-09 Rigel Pharmaceuticals, Inc. Inhibitors of tubulin polymerization
JP2004137270A (en) * 2002-09-26 2004-05-13 Nippon Nohyaku Co Ltd New herbicide, method for using the same, new substituted thienopyrimidine derivative, intermediate for the same and method for producing the same
JP5089395B2 (en) 2004-10-29 2012-12-05 バイオクライスト ファーマシューティカルズ， インコーポレイテッド Therapeutic furopyrimidine and thienopyrimidine
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
WO2006137350A1 (en) * 2005-06-22 2006-12-28 Kissei Pharmaceutical Co., Ltd. Novel furopyridine derivative, pharmaceutical composition comprising the derivative, and use of the derivative or composition
ES2273599B1 (en) * 2005-10-14 2008-06-01 Universidad De Barcelona COMPOUNDS FOR THE TREATMENT OF HEADPHONE FIBRILATION.
WO2007103776A2 (en) * 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
CN102105168A (en) * 2008-07-23 2011-06-22 协和发酵麒麟株式会社 Therapeutic agent for migraine
US20100093702A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent METHYLENE AMINES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US20100093763A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent PHENYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
CN103442568A (en) 2010-10-08 2013-12-11 Abbvie公司 Furo[3,2-d]pyrimidine compounds
US10227357B2 (en) 2012-09-06 2019-03-12 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP2947084B8 (en) * 2013-01-18 2021-03-10 Guangzhou Maxinovel Pharmaceuticals Co. Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof
JP7114076B2 (en) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー Compounds for the treatment of cancer and inflammatory diseases
MX2019014875A (en) 2017-06-21 2021-01-29 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease.
EP3675856A4 (en) 2017-08-31 2021-04-14 Corvus Pharmaceuticals, Inc. Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor
EP4263539A1 (en) * 2020-12-18 2023-10-25 Institut National De La Sante Et De La Recherche Medicale - Inserm 6-6 or 5-6 fused bicyclic compounds comprising a pyri(mi)dine ring useful in the treatment of infectious diseases
KR20230158542A (en) * 2021-03-29 2023-11-20 길리애드 사이언시즈, 인코포레이티드 KHK inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197788B1 (en) * 1997-11-26 2001-03-06 Vernalis Research Limited (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
US6583156B1 (en) * 1998-09-04 2003-06-24 Vernalis Research Limited 4-Quinolinemethanol derivatives as purine receptor antagonists (1)
US6608085B1 (en) * 1998-09-04 2003-08-19 Vernalis Research Limited 4-quinolinemethanol derivatives as purine receptor antagonists (II)
US6787541B1 (en) * 1999-07-01 2004-09-07 Vernalis Research Limited Thieno-and furopyrimidine derivatives as A2A-receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0436284A (en) 1990-05-29 1992-02-06 Sumitomo Chem Co Ltd Diphenylfuropyrimidine derivative, its production and herbicide containing the same derivative as active ingredient
US5939432A (en) 1997-10-29 1999-08-17 Medco Research, Inc. Thiophenes useful for modulating the adenosine receptor
DE69815554T2 (en) 1998-01-05 2004-05-06 Eisai Co., Ltd. PURINE DERIVATIVES AND ANTAGONISTS OF THE ADENOSINE A2 RECEPTOR, WHICH SERVE TO PREVENT OR CURE DIABETES
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
DK1221444T3 (en) 1999-07-02 2005-11-14 Eisai Co Ltd Condensed imidazole compounds and anti-diabetes mellitus drugs
HUP0300029A2 (en) * 2000-02-25 2003-05-28 Hoffmann La Roche Adenosine receptor modulators, pharmaceutical compositions containing them and their use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197788B1 (en) * 1997-11-26 2001-03-06 Vernalis Research Limited (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders
US6583156B1 (en) * 1998-09-04 2003-06-24 Vernalis Research Limited 4-Quinolinemethanol derivatives as purine receptor antagonists (1)
US6608085B1 (en) * 1998-09-04 2003-08-19 Vernalis Research Limited 4-quinolinemethanol derivatives as purine receptor antagonists (II)
US6787541B1 (en) * 1999-07-01 2004-09-07 Vernalis Research Limited Thieno-and furopyrimidine derivatives as A2A-receptor antagonists

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105465A1 (en) * 2008-05-29 2011-05-05 Kyowa Hakko Kirin Co., Ltd. Inhibitor of analgesic tolerance
US8865731B2 (en) 2008-05-29 2014-10-21 Kyowa Hakko Kirin Co., Ltd. Inhibitor of analgesic tolerance

Also Published As

Publication number Publication date
US20040097524A1 (en) 2004-05-20
EP1349861A1 (en) 2003-10-08
ATE407935T1 (en) 2008-09-15
GB0100620D0 (en) 2001-02-21
EP1349861B1 (en) 2008-09-10
US7384949B2 (en) 2008-06-10
JP4390454B2 (en) 2009-12-24
DE60228817D1 (en) 2008-10-23
JP2004524293A (en) 2004-08-12
WO2002055524A1 (en) 2002-07-18
CA2434005A1 (en) 2002-07-18

Similar Documents

Publication Publication Date Title
US20080153820A1 (en) Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists
US7087754B2 (en) Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists
US6787541B1 (en) Thieno-and furopyrimidine derivatives as A2A-receptor antagonists
US7141575B2 (en) Triazolo[4,5-d]pyrimidine derivatives and their use as purinergic receptor antagonists
US7598256B2 (en) Pyrrolo [2,3-d] pyrimidine and their use as purinergic receptor antagonists
US7452894B2 (en) Purine derivatives as purinergic receptor antagonists

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION